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Thesis Organization 
 
This thesis is organized as a scientific paper. It contains seven chapters 
preceded by an abstract in English and Portuguese. 
 
The First Chapter consists of an introduction to the molecular mechanisms 
implicated in the skeletal muscle atrophy. How is the skeletal muscle organized? 
What is muscle hypertrophy and atrophy? Which are the degradative mechanisms 
implicated during muscle atrophy? Which are the molecular regulators of this 
catabolic process? All these questions are approached in this chapter. Furthermore, 
there is also a detailed introduction on miRNAs. Their origins, their biogenesis, their 
mechanism of action and their role in muscle cells and adult muscle. 
 
In the Second Chapter the major aims of the thesis are presented. 
 
A detailed description of the methods used in this thesis is presented in the 
Third Chapter.  
 
In the Fourth and Fifth Chapter, the results obtained are presented. The 
fourth chapter consist on the identification and functional characterization of the 
miRNAs altered during the atrophic conditions. The fifth chapter describes the 
identification and functional validation of the target genes of the altered miRNAs. 
 
The Sixth Chapter comprises a general discussion and main conclusions of 
this thesis. 
 
In the Seventh chapter, the future perspectives of this work are presented.
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Abstract 
 
Skeletal muscle atrophy is a condition associated to loss of muscle mass in many diseases. 
Atrophy is a characteristic response to starvation, aging and disuse conditions (such as 
immobilization, denervation or unloading) but it also occurs as a complication in several chronic 
diseases such as cancer, diabetes, sepsis, AIDS, renal and heart failure and others. Independently of 
the cause, the main feature of muscle wasting is the enhancement of protein degradation that 
overcomes protein synthesis.  
Skeletal muscle atrophy is a transcriptionally regulated process (Lecker et al., 2004; Sandri 
et al., 2004a; Stitt et al., 2004). FoxOs are critical transcription factors involved in the regulation of 
critical rate-limiting enzymes belonging to the two most important degradative pathways: the 
ubiquititn/proteasome (Gomes et al., 2001; Sandri et al., 2004a) and the autophagy/lysosome 
(Mammucari et al., 2007; Zhao et al., 2007). Also NF-kB is involved in transcriptional regulation 
during muscle wasting (Cai et al., 2004; Hunter and Kandarian, 2004). Furthermore, a restricted 
group of genes, called atrophy-related genes or atrogenes, are commonly up- or down-regulated to 
all the atrophic conditions (Lecker et al., 2004). These findings suggest the presence of a shared 
molecular mechanism that controls muscle atrophy. Among the atrogenes there are genes involved 
in several fundamental biological processes that may require an additional regulation to fine-tune 
their action during muscle wasting. This action might be accomplished by a new class of regulatory 
molecules, the miRNAs. miRNAs are predicted to regulate several genes from the same pathway. 
Their role in adult skeletal muscle is largely unknown. 
miRNAs are small non-coding RNAs with approximately 22 nucleotides that regulate post-
transcriptionally gene expression. They are highly conserved among species and they are predicted 
to regulate the expression of approximately 60% of protein coding genes. Conventionally, miRNAs 
are known to regulate gene expression by binding to the 3’-Untranslated Regions (3’UTRs) of the 
mRNAs and, therefore, blocking translation or inducing mRNA degradation. Each miRNA has the 
potential to target hundreds of different mRNAs. On the other hand each mRNA can be targeted by 
different miRNAs creating in this way complex regulatory networks. One of the hallmarks of 
miRNAs is their specificity. In fact, several miRNAs are involved in developmental and 
physiological processes that require tissue- and stage-specific expression. The tight regulation of 
miRNAs expression is crucial and alterations are correlated with pathological conditions.  
The essential role of these regulators in skeletal muscle was clearly demonstrated in several 
animal models in which the miRNA pathway was blocked leading to a compromised myogenic 
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development (Kwon et al., 2005; O'Rourke et al., 2007; Sokol and Ambros, 2005). Furthermore, 
several miRNA show a muscle-specific expression and are called myomiRs. This group is 
composed by miRNA-1, miRNA-133, miRNA-206, miRNA-208a, miRNA-208b and miRNA-499. 
Muscle specific miRNAs are involved in several processes of the muscle physiology including 
myogenesis, fiber type establishment and muscle regeneration. Besides myomiRs, other miRNAs 
were shown to be involved in the regulation of these processes. The involvement of several 
miRNAs in the regulation of several aspect of muscle biology creates a complex regulatory network 
increasing the complexity of muscle biology. Moreover miRNA deregulation is associated with 
muscle disease (De, V et al., 2010; Eisenberg et al., 2007; McCarthy and Esser, 2007a; Williams et 
al., 2009; Yuasa et al., 2008a). However, regardless of the growing evidences on miRNAs function 
few studies have addressed their biological role in vivo. In this thesis, we studied the role that 
miRNAs play in skeletal muscle atrophy. We have used an in vivo approach supported by 
bioinformatic analyses to identify some of the mechanisms controlled by miRNAs. 
In the first part of the thesis we have established the miRNA expression signature of several 
atrophic conditions by microarray analysis. According to our results, each atrophic condition has a 
specific miRNA expression profile. Only middle-to-late atrophic conditions showed a significant 
alteration of the miRNAs expression levels. Although no common miRNA was found between the 
different conditions, two highly up-regulated miRNAs were found in denervation, miRNA-206 and 
miRNA-21. Thus, we decided to address their biological role in vivo. Our studies showed, for the 
first time, that in vivo over-expression of these two miRNAs leads to an atrophic phenotype, while 
inhibition of these miRNAs induced hypertrophy.  
In the second part of this thesis, we performed mRNA expression profile by using the same 
samples used for miRNA profile. A bioinformatic approach based on gene expression data allowed 
us to identify genes that were both predicted targets of the miRNAs and down-regulated in the 
mRNA expression arrays. This approach allowed the identification of a set of target genes that were 
directly down regulated by the miRNAs. In particular, we decided to study YY1, eIF4E3 and 
PDCD10 because they were predicted targets of both miRNAs. Indeed, luciferase experiments 
together with over-expression experiments confirmed that YY1 is a target gene of miRNA-21 and 
eIF4E3 and PDCD10 are targets of both miRNA-206 and miRNA-21. Although the role of these 
genes during skeletal muscle atrophy is still not clear, they are clearly down-regulated during 
denervation and the function of this down-regulation is currently under study. 
Our results indicate that the atrophic process, apart from the transcriptional regulation, is 
also under a miRNA fine tuning. Furthermore, our data point to miRNA-206 and miRNA-21 as 
important modulators of the atrophic process suggesting that they are potential therapeutic targets.  
 XVII 
Resumo 
 
A atrofia do músculo esquelético é uma condição associada à perda de massa muscular que 
ocorre em várias doenças. Esta atrofia é uma resposta característica ao jejum, envelhecimento e a 
condições de desuso ( como imobilização, desenervação  e falta de carga no músculo) mas também 
ocorre como complicação associada a diversas doenças crónicas como cancro, diabetes, sepsia, 
SIDA e falha renal e cardíaca entre outras. Independentemente da causa, a maior característica da 
atrofia muscular é um aumento da degradação proteica em relação à síntese proteica. 
A atrofia do músculo esquelético é um processo regulado a nível da transcrição  transcrição  
(Lecker et al., 2004; Sandri et al., 2004a; Stitt et al., 2004). Os factores de transcrição da família 
FoxO são fundamentais para a regulação de enzimas limitantes que pertencem aos dois mecanismos 
catabólicos mais importantes do músculo: o sistema ubiquitina/proteassoma proteassoma (Gomes et 
al., 2001; Sandri et al., 2004a) e o sistema autofagia/lisossoma (Mammucari et al., 2007; Zhao et al., 
2007). O factor de transcrição NF-kB também está envolvido na regulação que ocorre durante o 
processo de atrofia muscular (Cai et al., 2004; Hunter and Kandarian, 2004). Para além disso, um 
grupo restrito de genes, chamados “atrogenes” ou genes relacionados com a atrofia, encontram-se 
frequentemente sobre- ou sub-expressos em todas as condições de atrofia. Estas evidências sugerem 
que existem mecanismos moleculares partilhados que controlam a atrofia muscular. Entre os 
“atrogenes” encontram-se genes envolvidos em diversos processos biológicos fundamentais que 
podem requerer um nível adicional de ajustamento durante a perda de massa muscular. Este 
ajustamento pode ser conseguido através de uma nova classe de moléculas reguladoras chamadas 
miRNAs. Os miRNAs são hipoteticamente capazes de regular vários genes da mesma via de 
sinalização. O seu papel no músculo adulto é amplamente desconhecido. 
Os miRNAs são pequenos RNAs não codificantes com aproximadamente 22 nucleotídeos 
que regulam a expressão de genes. São altamente conservados entre espécies e é previsto que sejam 
capazes de regular a expressão de aproximadamente 60% dos genes codificantes. 
Convencionalmente, os miRNAs regulam  a expressão génica ligando-se à região 3’-UTR (região 
não traduzida) dos RNAs mensageiros (mRNA), e posteriormente bloqueando a sua tradução ou 
induzindo a sua degradação. Cada miRNA tem o potencial de regular centenas mRNAs. Por seu 
lado, cada mRNA pode ser regulado por centenas de miRNAs diferentes, criando-se deste modo 
redes reguladoras complexas. Uma das principais características dos miRNAs é a sua 
especificidade. De facto, diversos miRNAs estão envolvidos em processos fisiológicos  e ligados ao 
desenvolvimento, e requerem, por isso, uma expressão que é específica para determinado tecido e 
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fase de desenvolvimento. Uma apertada regulação  da expressão dos miRNAs é essencial e 
alterações na sua expressão estão associadas a situações patológicas. 
O papel essencial que estas moléculas reguladoras têm no músculo esquelético foi 
claramente demonstrado em diversos modelos animais nos quais a via dos miRNAS foi bloqueada, 
comprometendo o desenvolvimento miogénico. (Kwon et al., 2005; O'Rourke et al., 2007; Sokol 
and Ambros, 2005). Para além destas evidências, existe um grupo de miRNAs específicos do 
músculo – são chamados myomiRs. Este grupo é composto pelos miRNA-1, miRNA-133, miRNA-
206, miRNA-208a, miRNA-208b e miRNA-499. Estes myomiRs estão envolvidos em diversos 
processos da fisiologia muscular, incluindo miogénese, estabelecimento do tipo de fibra e 
regeneração muscular. Na regulação destes processos estão envolvidos outros miRNAs para alem 
dos myomiRs. O envolvimento de diversos miRNAs na regulação de vários aspectos da biologia do 
músculo cria uma rede regulatória, aumentando deste modo a complexidade da biologia do 
músculo. Para além disso a desregulação da expressão de miRNAs está associada a doenças 
musculares (De, V et al., 2010; Eisenberg et al., 2007; McCarthy and Esser, 2007a; Williams et al., 
2009; Yuasa et al., 2008a). Independentemente do aumento do numero de evidências relacionadas 
com a função dos miRNAS, poucos estudos abordaram o seu papel biológico in vivo. Nesta tese, 
nós estudamos o papel dos miRNAs no processo de atrofia do músculo esquelético. Foi utilizada 
uma aproximação in vivo, que se baseou em análises bioinformáticas, para identificar alguns dos 
mecanismos controlados pelos miRNAs. 
Na primeira parte desta tese, nós estabelecemos o perfil de expressão de miRNAs em 
diversas condições de atrofia, usando para isso análise de micro-arrays. De acordo com os nosso 
resultados, cada condição atrófica possui um perfil de expressão de miRNAs específico. Apenas 
condições atróficas a médio-longo termo apresentam uma significativa alteração nos níveis de 
expressão dos miRNAs. Apesar de não ter sido encontrado nenhum miRNA comum a todas as 
condições de atrofia, identificamos dois miRNAs, miRNA-206 e miRNA-21, fortemente 
aumentados após desenervação. Decidimos por isso estudar o seu papel biológico in vivo. Os nossos 
estudos demonstraram, pela primeira vez, que a sobre-expressão destes miRNAs induzem um 
fenótipo atrófico enquanto a inibição in vivo induz um fenótipo hipertrófico. 
Na segunda parte desta tese, estabelecemos o perfil de expressão de mRNAs das mesmas 
amostras que tinham sido usadas para estabelecer o perfil de expressão de miRNAs. Uma 
aproximação bioinformática baseada nos dados de expressão génica permitiu-nos identificar os 
genes que eram simultaneamente alvos previstos dos miRNAs e que se encontravam sub-expressos 
nos arrays de expressão de mRNA. Esta metodologia permitiu-nos identificar um grupo de genes 
alvo cuja expressão é regulada negativamente pelos miRNAS. Em particular, decidimos estudar 
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YY1, eIF4E3 e PDCD10 porque estes três genes são previsivelmente regulados pelos dois miRNAs. 
De facto, experiências de luciferase juntamente com experiências de sobre-expressão confirmaram 
que YY1 é um alvo do miRNA-21 e que eIF4E e PDCD10 são alvos do miRNA-206 e miRNA-21. 
Apesar do papel destes genes durante o processo de atrofia muscular não ser conhecido, sabemos 
que estão sub-expressos durante a desenervação. A relevância da diminuição na expressão de YY1, 
eIF4E3 e PDCD10  durante a desenervação está presentemente a ser investigada. 
Os nosso resultados indicam que o processo atrófico, para além da regulação a nível da 
transcrição, é também modulado por miRNAs. Para além disso os nossos dados apontam para o 
miRNA-206 e  miRNA-21 como importantes moduladores do processo atrófico, sugerindo que 
estes miRNAs podem ser potenciais alvos terapêuticos. 
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1.1- Skeletal Muscle: the main player 
 
To walk or to run, to sit or to lie down, to listen or to look and even to breath, are all one 
contraction away from achieving their goals. This is the major function of muscles – to contract, to 
generate force, to produce movement. However, this does not mean that locomotion is the only 
muscle function. Skeletal muscles are highly specialized in producing energy and subsequently 
generating heat. They do so not only as a consequence of exercise, but also independently, and this 
constitutes a great adaptive advantage of several species throughout the animal kingdom. Most 
importantly, skeletal muscle plays an essential role in the maintenance of body’s energy 
homeostasis.  In periods of fasting, through catabolic processes, muscles are capable of releasing 
amino acids (alanine and glutamine) into the blood that are then used by the liver to maintain the 
glucose levels (gluconeogenesis). The main focus of this thesis are the molecular mechanisms 
implicated in the catabolic processes that ultimately lead to skeletal muscle atrophy. 
 
1.1.1- Skeletal Muscle Architecture 
 
Skeletal muscle is a highly organized tissue. According 
to the task they perform, they present different size, shape and 
properties. However their basic structure is the same. Skeletal 
muscles are surrounded by the epimysium, a coat of 
connective tissue that separates different muscles. Each 
muscle is divided into bundles or fascicles of fibers which are 
also coated by connective tissue – the perimysium. Finally the 
endomysium envelops each fiber (Fig 1). 
In the intramuscular region a highly vascularized 
system of arterioles and venules allows the supply of oxygen 
and substrates to produce energy. This system penetrates deep 
into the perimysium to form a dense capilar network that 
maintains a constant nutrient environment in the vicinity of the 
fiber. Additionally, in the intramuscular region we can also 
find the nerve branches that innervate the muscles. These 
nerves, composed of motoneurons, ramify into the 
perimysium. Each motoneuron establishes contact with a 
Fig 1: Schematic representation of the 
skeletal muscle architecture. Skeletal 
muscle is composed of fascicles of 
muscle fibers. Each fiber is composed of 
myofibrils.  
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single fiber through the neuromuscular junction.  
Skeletal muscle fibers are multinucleated cylindrical cells, in which the nuclei are located in 
the periphery underneath the plasma membrane – also called sarcolemma. Representing only 1% of 
the nuclei present in the muscle and almost undistinguishable are the satellite cells – the stem cells 
of the muscle. These are normally quiescent cells in adult muscle, but are able to proliferate in 
response to injury and give rise to regenerated muscle and to more satellite cells (Morgan and 
Partridge, 2003).  
Apart from the nuclei another organelle of great importance present in the cytoplasm are the 
mitochondria. Skeletal muscle contains two populations of mitochondria, the subsarcolemmal and 
the intermyofibrillar mitochondria. Apart from their localization they also possess different 
biochemical properties but their basic function is to supply the energetic demands of the fiber. 
Apparently they seem to be differentially affected by disease and exercise
 
training (Koves et al., 
2005). 
With the aid of electron microscopy it was shown that muscle fibers possess a tubular 
system. It is composed of T-Tubules that are required for the conduction of impulses to the interior 
of the fiber. Another tubular structure is the sarcoplasmic reticulum (SR) that is responsible for the 
Ca2+ handling during contraction/relaxation.   
The striated appearance of the muscle is due to the organization of the myofibril, the units 
responsible for the contraction. These myofibrils are disposed in parallel arrangement and run the 
entire length of the fiber. Myofibrils consist of bundles of myofilaments. These filaments are mainly 
composed of actin and myosin organized in thin and thick filaments, respectively. The 
myofilaments are arranged in functional 
units called sarcomeres. As we can see 
from Fig 2 each sarcomere is delimited 
by the Z-disk. This structure is 
composed mainly of -actinin, desmin, 
vimentin and, together, with nebulin 
provides positional support for the actin 
filaments. The I-band (light band), 
which is mainly composed of actin 
filaments, surrounds the Z-disk. These 
actin filaments expand to a dark 
anisotropic band called A-band. This A-
band is also composed of myosin thick 
Fig 2: Sarcomere Structure. Schematic representation and electron 
microscopy image of the sarcomere.  
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filaments and is interrupted in the middle by a darker band, the M-band, only composed of myosin 
filaments. Spanning from the Z-disk to the M-band there is a filament of titin (connectin) which 
serves not only as structural support but also for the assembly of the contractile machinery.  
  
1.1.2- Skeletal muscle fiber type 
 
Although the basic structure of the muscle fiber is the same, the proteic composition varies, 
giving different properties to the muscles. Skeletal muscle fibers are classified having in 
consideration their metabolic, biochemical and structural properties. In this way skeletal muscle 
fibers can be classified as type I (oxidative/slow) or type II fibers (glycolytic/fast). They are usually 
identified according to the myosin heavy chain (MyH) isoform they preferentially express, since 
myosins are the main determinant of the contractile properties. Type I fibers express mainly MyH-7 
and have a slow velocity of shortening. They are rich in mitochondria and mainly use oxidative 
metabolism for energy production. This provides a stable and long-lasting supply of ATP, thus 
rendering these fibers fatigue-resistant. Type II fibers on the other hand can be subdivided into three 
subtypes: IIa, IIx, and IIb according to the MyH isoform they express (MyH-2, MyH-1 and MyH-14 
respectively). They have a lower mitochondrial content and their metabolic properties are graded, 
being the IIb the fastest, most glycolitic and thus most susceptible to fatigue and the IIa the slowest 
and most oxidative. Since in most cases both fiber types coexist in one muscle, the type of 
contraction (slow or fast) results from the percentage of different fiber types present in the muscle. 
Muscles containing mainly type I fibers are slow muscles highly vascularized, containing high 
levels of myoglobin, in opposition to muscles containing mainly type II fibers. 
 
Although being a post-mitotic tissue, adult skeletal muscle has a great capability to adapt to 
a wide variety of stimuli. The amount and pattern of muscle activity together with stimuli received 
during pathological conditions may lead to alterations in fiber size and fiber type and consequently 
alterations in its properties 
 
1.2- Skeletal Muscle Hypertrophy and Atrophy 
 
Skeletal muscle is the most abundant tissue in the human body accounting for ≈50% of the 
total body mass. It is not only the major site of metabolic activity but it is also the largest protein 
reservoir, serving as a source of amino acids to be utilized for energy production during periods of 
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food deprivation (Nader et al., 2005). Accordingly, amino acids generated from muscle protein 
breakdown are utilized by the liver to produce glucose. Muscle is a dynamic tissue that 
continuously adapts its size not only to the nutritional status but also to a variety of external stimuli, 
including mechanical load, neural input, hormones/growth factors and stress. In normal conditions 
the balance between protein synthesis and protein degradation dictates the maintenance of skeletal 
muscle mass. Whenever this balance is shifted we can have one of the two situations: muscle 
hypertrophy or muscle atrophy. 
 
1.2.1- Skeletal Muscle Hypertrophy 
 
Skeletal muscle hypertrophy is characterized by an increase in the muscle mass and in the 
cross section area of the fibers. Two types of muscular hypertrophy can occur: sarcoplastic 
hypertrophy or myofibrilar hypertrophy. While the first one is associated to an increase of the 
sarcoplasmic fluid without any increase in muscle force, the second implies an increase in the 
contractile components of the fiber with increase in muscle strength. Generally, muscle hypertrophy 
is associated to strength training, however it can also be the consequence of genetic conditions, as it 
will be discussed later. In any case, there is an increase in protein synthesis. 
Simultaneously to the increase in fiber size there is also incorporation of new myonuclei in 
the fibers to maintain the proportion between cytoplasm and nuclei. This myonuclei derive from the 
activation of satellite cells – the stem cells of the muscle. (Zammit, 2008). Satellite cells play a 
major role during embryonic and pos-embryonic period, contributing for muscle growth. In adult 
muscle they become quiescent and therefore have a minor role in muscle growth. However there are 
some studies that state the importance of satellite cells during muscle hypertrophy. In fact, muscle 
hypertrophy, induced by loading or IGF-1, was partially or totally prevented by muscle irradiation, 
thus eliminating all satellite cells (Adams, 2006) (Barton-Davis et al., 1999). In the same way, 
depletion of satellite cells by knocking out Pax7, a transcription factor required for satellite cell 
differentiation, severely blunted postnatal muscle growth (Oustanina et al., 2004). However a recent 
study completely contradicts these arguments and present evidences that adult muscle growth is 
completely independent of satellite cells. The authors develop a genetic mouse model to 
conditionally ablate satellite cells in adult muscles. Basically they have generated a mouse model in 
which the diphtheria toxin A (DTA) gene is under the control of the Pax7-CreER. After tamoxifen 
injection the Pax7 expressing cells start to produce DTA leading to an ablation of almost 90% of the 
satellite cells. When submitted to synergistic ablation, a model of hypertrophy, Pax7 depleted 
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muscle underwent hypertrophy. The authors further showed that although satellite cells are not 
required for muscle hypertrophy, they are requested for the formation of new fibers and for muscle 
regeneration (McCarthy et al., 2011). Therefore, it is now believed that muscle hypertrophy results 
mainly from an increase in protein synthesis rather than an activation of satellite cells. 
 At the molecular level, Insulin Growth Factor-1 (IGF-1) was shown to be one of the most 
important growth factor implicated in muscle hypertrophy. Although it is mainly produced by the 
liver, there are some muscle specific isoforms (Hameed et al., 2004), such IGF1Ea that was shown 
to promote proliferation and differentiation of satellite cells (Adi et al., 2002; Allen and Boxhorn, 
1989; Doumit et al., 1996). During overload-induced muscle hypertrophy the expression of this 
growth factor was increased suggesting a role in muscle growth (DeVol et al., 1990). This data was 
confirmed by muscle-specific transgenic mice that showed muscle hypertrophy, increased 
regeneration and increased muscle strength (Coleman et al., 1995; Musaro et al., 2001).  
The binding of IGF-1 or insulin to its receptor leads to a cascade of events that culminate in 
the activation of AKT. This serine/threonine kinase is a critical component of the anabolic pathways 
and is activated by various stimuli, including growth factors, mechanical stimuli, and insulin. There 
are 3 AKT isoforms, being AKT1 and AKT2 the ones with highest expression in skeletal muscle 
(Yang et al., 2004). Several lines of evidence support the idea that AKT is essential to muscle 
growth. In fact, mice that lack AKT1 are smaller than their littermates (Yang et al., 2004). 
Accordingly, over-expression of a heart-specific active form of AKT1 results in a hypertrophic 
phenotype (Matsui et al., 2002; Shioi et al., 2002). The same is observed in skeletal muscle with a 
constitutively or inducible active form of Akt (Blaauw et al., 2009; Lai et al., 2004). On the other 
hand the over-expression of 2 upstream phosphatases, PTEN and SHIP2, that prevent the docking 
of AKT to the plasma membrane, inhibits muscle growth (Bodine et al., 2001c; Goberdhan et al., 
1999; Huang et al., 1999) confirming the essential role of AKT in muscle hypertrophy. 
Several molecules, downstream of Akt, were shown to be involved in cell size regulation. 
Both IGF-1 and nutritional stimuli leads to the phosphorilation (through AKT) and activation of 
mTOR (mammalian target of rapamycin), a kinase that is selectively inhibited by rapamycin. It was 
shown that in hypertrophic conditions, both AKT and mTOR are phosphorilated, and this 
hypertrophy could be blocked by rapamycin (Bodine et al., 2001c; Pallafacchina et al., 2002; 
Rommel et al., 2001). In fact rapamycin was able to block the effects of AKT in muscle growth in 
the inducible AKT transgenic mice (Izumiya et al., 2008). The activation of mTOR leads to an 
increase in protein synthesis by two different mechanisms: the activation of p70S6 kinase, a known 
positive regulator of protein translation, and the inhibition of 4E-BP1, a negative regulator of the 
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protein initiation factor eIF-4E (Hara et al., 1997; Proud, 2004). Ohanna et al (Ohanna et al., 2005) 
showed that p70S6 kinase is required for muscle fibers to achieve normal size. 
 Finally, activation of AKT phosphorylates and inhibits the activity of GSK3  (Glycogen 
synthase kinase 3 beta) (Cross et al., 1995) leading to hypertrophy. It was demonstrated that a 
dominant negative, kinase dead form of GSK3 induces dramatic hypertrophy in skeletal myotubes 
(Hardt and Sadoshima, 2002; Rommel et al., 2001). Since GSK3 blocks protein translation 
initiated by the eIF2B protein (Hardt and Sadoshima, 2002), it’s possible that GSK3 stimulates 
protein synthesis independently of the mTOR pathway. 
But AKT is not always required in order to have an hypertrophic phenotype. In fact, 
Rafaello et al (Raffaello et al., 2010) showed that JunB, a transcription factor markedly down-
regulated in muscle of several atrophic conditions, is sufficient to promote muscle growth 
independently of mTOR and AKT. Furthermore, JunB over-expression reduced denervation-
induced muscle atrophy by inhibiting MAFbx/Atrogin-1 and Murf-1. This inhibition was the result 
of a physical interaction between JunB and FoxO3 that prevented the binding of FoxO3 to the 
promoter region of MAFbx/Atrogin-1 and Murf-1. Finally, the authors have shown that JunB over-
expression leads to a reduction in the myostatin levels, therefore releasing muscle growth from the 
inhibitory action of myostatin. 
 As discussed briefly, another important player in skeletal muscle hypertrophy is myostatin, a 
negative regulator of muscle growth that is secreted mainly by the muscle. Myostatin is a member 
of the transforming growth family-  (TGF- ), and at the molecular level, binds to the activin 
receptor IIB (ActRIIB), a type II TGF-  receptor, which, in turn, activates activin receptor-like 
kinase 4 (ALK4) or ALK5, both type I serine/threonine kinase receptors. The downstream targets of 
this pathway are still to be elucidated. Mutations in the myostatin gene were shown to be 
responsible for the hypertrophic phenotype in cattle (Charlier et al., 1995) and in humans (Schuelke 
et al., 2004). Furthermore, a similar phenotype was observed in knock-out mice (McPherron et al., 
1997). Surprisingly this increase of mass, observed in myostatin null mice, was not accompanied by 
an increase of force (Amthor et al., 2007). Similarly, the treatment of adult mice with anti-myostatin 
antibody led to an increase of muscle mass of approximately 12% (Whittemore et al., 2003a). This 
hypertrophic phenotype was the result not only of hypertrophy but also hyperplasia, increase in the 
number of the muscle fibers, suggesting an activation of muscle satellite cells. In fact myostatin 
influence the expression of myogenic transcription factors such as Pax7, MyoD and myogenin, 
inhibiting satellite cell activation and differentiation (McFarlane et al., 2006; McFarlane et al., 
2008). Given the capacity to activate satellite cells and to improved muscle regeneration blockage 
of myostatin soon became an attractive therapeutic target. In fact several studies used different 
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strategies to inhibit myostatin in order to revert the phenotype of muscle associated pathologies. 
The identification of a Myostatin pro-peptide that has a inhibitory role on the biological activity of 
myostatin was the starting point for this therapeutic approach (Bogdanovich et al., 2005; Thies et 
al., 2001). Soon after, another approach was used. The administration of intra-peritoneal injections 
of blocking antibodies for three months in Mdx-/- mouse resulted in an increase in body weight, 
muscle mass, muscle size and absolute muscle strength (Bogdanovich et al., 2002; Whittemore et 
al., 2003b). This approach was also used in amyotrophic lateral sclerosis (SLA) (Holzbaur et al., 
2006). Later on, the use of DNA vaccines (Tang et al., 2007) and retrovirus-based RNAi system 
were also used efficiently in order to down-regulate the myostatin expression levels (Yang et al., 
2008). 
Regardless of the cause, physiological or genetic, skeletal muscle hypertrophy is always 
associated with an increase in protein synthesis. But, what happens when protein synthesis is 
overtaken by protein degradation? 
 
1.2.2- Skeletal Muscle Atrophy 
 
Skeletal muscle atrophy is a condition associated to loss of muscle mass without any genetic 
cause, in contrast to dystrophy. It is characterized by an overall decrease in protein content, fiber 
diameter, force production, and fatigue resistance. It is a characteristic response to starvation, aging 
and disuse conditions (such as immobilization, denervation or unloading) but it also occurs as a 
complication in several chronic diseases such as cancer, diabetes, sepsis, AIDS, renal and heart 
failure and others. In all this situations protein synthesis is overtaken by protein degradation. 
Sarcopenia, the loss of muscle mass in the elderly, is predicted to occur in 5-10% of over-
60-year old population. Apart from the loss of lean mass, it is characterized by the loss of the 
neuromuscular junctions, and a reduction of type II fibers that ultimately leads to an increase of 
frailty. On the other hand, cachexia is a wasting syndrome occurring as a complication associated to 
chronic diseases or it’s treatments. It is estimated to occur in 55% of all cancer patients. It is a 
multifactorial syndrome accompanied by loss of fat and muscle mass. In cachexia the chronic 
lesions produce cytokines, such as TNF-  (tumor necrosis factor-alpha), TWEAK (TNF-like weak 
promoter of apoptosis), IL-6, and others, that will affect systemically the whole body. Cachexia 
may also result from the direct effect of the treatments used in these conditions. Most importantly, 
cachexia is often associated with a poor prognostic. 
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Severe muscle wasting leads to death. This was clearly seen during the II World War by 
Jewish physicians and also before the advent of antiretroviral therapy for AIDS patients. But also 
mild atrophy has consequences as it was shown to suppress the immune system and to increase 
cancer mortality by decreasing the response and tolerance to therapy (Glass and Roubenoff, 2010). 
Different types of atrophy have distinct causes, and the molecular mechanisms implicated are also 
distinct and only recently started to be clarified.  
Two independent pioneering studies (Bodine et al., 2001a; Gomes et al., 2001) toke 
advantage of gene expression profiling to identify important players in muscle wasting. These 
authors compared, by gene expression analysis, muscles from normal animals with muscles from 
different atrophic models: denervation, cachexia, diabetes and renal failure. They have identified a 
group of genes that were up- or down-regulated in all atrophic models studied, suggesting a 
common transcriptional program implicated in muscle atrophy. The authors have called this genes 
atrogenes or atrophy-related genes and among these, we could find proteins implicated in protein 
degradation, ATP production, extracellular matrix and proteins involved in transcription and 
translation control.  
A close analysis of the atrogenes, revealed the presence of two groups of genes belonging to 
the two major degradative pathways of the muscle: the ubiquitin/proteasome and the 
autophagy/lysosome pathway. 
 
1.2.2.1- The Ubiquitin/Proteasome system  
 
The ubiquitin-proteasome is one of the major mechanisms involved in protein breakdown 
during muscle atrophy. It is a highly selective process that requires a tight regulation. Although the 
main function is to control protein turnover and to eliminate abnormal proteins, it also plays an 
important role in signal transduction, class I antigen presentation, cell cycle regulation, and 
transcription control (Glickman and Ciechanover, 2002). Not surprisingly, deregulation of this 
pathway has been implicated in cancer and in several inherited diseases. 
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1.2.2.1.1- The Proteasome 
 
The proteasome is a large multicatalytic protease that 
mediates protein degradation. It is composed of two multimeric 
complexes: the 20S core particle and the 19S regulatory particle 
(Fig 3). The 20S core particle is a barrel-shaped structure 
arranged as a stack of four rings, two  and two , each of them 
composed of 7 subunits. The general structure is thus , 
being that the catalytic sites are located in the  rings. In fact, 
among the 7 residues that compose the -rings three have 
catalytic properties, 1, 2, and 5, which mediate caspase-like, 
tryptic-like or chimotryptic-like activity, respectively. On each 
extremity of the 20S proteasome is attached a regulatory 19S 
particle. It is composed of at least 19 units, being that 9 form the lid while 10 constitute the  base. 
At the base, and in close contact with the -ring of the 20S proteasome we can find 6 ATPases, 
responsible for generating energy for the degradative process. While some of these ATPAses are 
responsible for the opening of an orifice in the -ring of the 20S proteasome to allow substrate 
entry, others mediate the recognition of the substrate-linked poly-ubiquitin chain. The other non-
ATPase subunits of the base are also reported to bind to the poly-ubiquitin chains and even to E3-
ligases. The function of the lid subunits is less clear. It was shown that it is required for the 
unfolding of ubiquitin-tagged proteins (Glickman et al., 1998) and also for the de-ubiquitination of 
the proteins, an essential process for recycling ubiquitin (reviewed in (Glickman and Ciechanover, 
2002; Navon and Ciechanover, 2009; Pickart and Cohen, 2004). 
Two other alternative proteasome regulatory complexes were identified, the11S (also called 
PA28) and the PA200. These two complexes are highly conserved and they can be found from 
worms to humans. While the 11S is a homo- or heteromeric complex composed of 7 subunits, the 
PA200 is a single chain protein of 200 KDa. Structural studies revealed that a central channel was 
formed in the 20S proteasome upon binding to the 11S regulatory complex, suggesting a diffusion 
model in which the proteins pass from the open regulatory unit into the 20S core proteasome. In 
contrast to what happens with the 19S regulatory unit, it was shown that the association of the 11S 
particle to the 20S core proteasome is ATP-independent and is responsible for the degradation of 
peptides and non ubiquitinated proteins. Although the biochemical properties of these complexes 
are now clear, little is known about their biological functions. It is however known that 11S 
regulatory complex is mainly expressed in the immune system and it is up-regulated after IFN-  
Fig 3: Proteasome Structure. 
Composed of two multimeric 
particles: the 20S core particle and the 
19S regulatory article 
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treatment (Stratford et al., 2006). On the other hand, PA200 was shown to be located within the 
nucleus and it was proposed to be involved in DNA repair. (Reviewed in Rechsteiner and Hill, 
2005). In skeletal muscle there is little information on these alternative regulatory units of the 
proteasome. However it is known that chronic contractile activity in skeletal muscle induces an 
impressive increase in the protein levels of the PA28 and PA200 complex (Ordway et al., 2000) and 
that several types of skeletal muscle wasting induces an increase expression of the PA200 complex 
(Lecker et al., 2004), suggesting that in fact they do play a role in skeletal muscle and that further 
studies are required to clarify their function. 
 
1.2.2.1.2- Ubiquitin and the ubiquitin conjugating cascade 
 
Ubiquitin is a highly conserved 76-amino-acid polypeptide that is ubiquitously expressed in 
all eukaryote cells. No clear function has been attributed to free ubiquitin. It is found linked to 
substrate proteins through an isopeptide bond that is established between the carboxyl group of the 
final amino acid of ubiquitin and the -amino group found in one or more lysine residues of the 
cellular protein. Ubiquitin itself contains seven lysines, and each of these can be further conjugated 
by the carboxyl terminus of another ubiquitin to form a polyubiquitin chain. The way ubiquitin 
became linked to the proteins will determine their fate. Proteins can remain monoubiquitinated or 
additional ubiquitin moieties can be attached forming poly-ubiquitin chains. While 
monoubiquitination of proteins are thought to have a role in their localization and in their 
degradation via lysosome, the role of polyubiquitination depends on the lysine involved in the chain 
formation. Lysine 48 is the most studied and important in muscle wasting since it is responsible for 
directing the targeted proteins for degradation through the multimeric proteasome.  
Protein ubiquitination is a multistep process in which ubiquitin has to be initially activated, 
in an ATP-dependent way (Fig 4). In this process an E1-activating enzyme forms a thiol-ester bond 
with the carboxy-terminal glycine of the ubiquitin. Activated ubiquitin is then transferred to the E2-
conjugating enzyme. This E2-ubiquitin complex binds to E3 ubiquitin ligases which are specifically 
coupled with the substrate protein. These E3 ubiquitin ligases are responsible for transferring the 
ubiquitin to the target protein (Reviewed in (Weissman, 2001). In eukaryotic cells there is only one 
E1-activating enzyme that provides activated ubiquitin to a family of several E2-conjugating 
enzymes. Typically each of these E2 interacts with several E3-ligases. But it is in the large number 
of E3 ligases that reside the specificity of this reaction. In fact there are several types of ubiquitin 
ligases: those that bind directly to the substrate and those that require the formation of a protein 
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complex, those who function as scaffold to bring E2 and the substrate together and those that 
receive the activated ubiquitin from the E2 and then transfer it to the substrate. Although they are a 
heterogeneous group of proteins they can be classified in two major groups: HECT-domain and 
Ring Finger-domain. The HECT-domain contains a COOH-terminal domain to which the activated 
ubiquitin is transferred from the E2, and a variable NH2-domain that specifically recognize and 
binds the substrate. The Ring Finger-domain family of E3 can be further divided in two distinct 
groups: those monomers or homomeric, in which the same protein contains the Ring Finger and the 
substrate recognition site, and those multisubunit proteins in which the Ring Finger is only 
responsible for the binding to the E2 and for the recruitment of the other proteins to the complex. 
(Reviewed in Glickman and Ciechanover, 2002). 
Another group of proteins important in the regulation of this system are the deubiquitinating 
(DUB) enzymes. There are almost 70 different DUB enzymes in the human genome with several 
functions being documented (Reviewed in Wing, 2003). First they are essential as processors of the 
ubiquitin gene products. In the genome, ubiquitin is encoded as fusion proteins, with either 
additional copies of ubiquitin arranged in tandem or as a fusion with either the L40 or S27a 
ribosomal subunits. DUBs are therefore responsible for processing the ubiquitin gene products into 
mature ubiquitin. Secondly, DUBs have an important role as editing enzymes in situations in which 
protein ubiquitination has to be reverted. This can happen when ubiquitinated proteins are to be 
rescued from proteasomal degradation or in cases in which the signaling function of ubiquitin has 
been accomplished. Finally, DUBs play a crucial role in recycling the ubiquitin from the 
ubiquitinated proteins that are degraded in the proteasome. This process of ubiquitin recycling is 
helped by other proteins that, although not being DUBs, possess deubiquitinating activity under 
Fig 4: Ubiquitination Machinery. Free ubiquitin (Ub) is activated by a E1-activating enzyme and transferred to an E2-
conjugating enzyme. These E2 associate with an E3-ligase that, directly or indirectly, will transfer the ubiquitin to the 
target substrate (Weissman, 2001). 
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certain situations. This is the case of RPN11 from the lid of the 19S proteasome that only when 
integrated in the proteasome has this capacity. 
During the last years, the ubiquitin/proteasome pathway has been implicated in several 
human pathologies from neurodegenerative disorders to cancer. Therefore a better understanding of 
each of these different components of the pathway, in each particular system, will help the finding 
of active molecules that can be used as therapeutic approach. 
 
1.2.2.1.3- The Ubiquitin-Proteasome System in skeletal muscle 
 
In skeletal muscle, the accumulation of ubiquitinated proteins in an ATP-dependent way was 
initially shown by (Wing et al., 1995), during denervation and starvation and it was latter confirmed 
in other muscle wasting-associated conditions: cancer cachexia (Baracos et al., 1995), and sepsis 
(Tiao et al., 1996; Tiao et al., 1997). Additional studies have demonstrated increased rates of 
ubiquitination in extracts prepared from atrophying muscles (Combaret et al., 2004; Kee et al., 
2003; Solomon et al., 1998).  
Gene expression analysis of atrophic human samples revealed an increased transcription of 
ubiquitin and proteasome related genes. In fact, sepsis, was sufficient to induce an increase in the 
mRNA levels of Ubiquitin and HC3, a component of the 20S proteasome, in the human rectus 
abdominis muscle (Tiao et al., 1997) Also head trauma patients, 8 days after the incident, show a 
clear activation of the ubiquitin/proteasome system, as shown by the increased levels of ubiquitin, 
HC2, a component of the 20S proteasome and of an E2 conjugating enzyme (Mansoor et al., 1996).  
But, it was clearly from studies in murine models of atrophy that the major advances in 
understanding these conditions were achieved. A comparative study analysing different types of 
skeletal muscle atrophy identified several proteasome and ubiquitin related genes that were part of a 
common program of transcriptional adaptation to muscle atrophy (Lecker et al., 2004). Not 
surprisingly, the two most induced genes, in all the atrophic conditions, were two muscle specific 
E3-ligases, MAFbx/atrogin-1and Murf-1. These two genes had already been shown to be up-
regulated during three atrophic conditions – denervation, immobilization and unweighting (Bodine 
et al., 2001a). The authors of this study went further, generating the respective knock-out mouse 
models of these two genes in order to understand their biological role. Under basal conditions both 
of these animals were normal when compared to WT. However, when submitted to atrophic stimuli, 
such as denervation, MAFbx and Murf-1 knock out animals were spared from atrophy, by 50 and 
30 % respectively. But, what is it known about these two genes?  
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MAFbx, also known as Atrogin-1, is a E3-ligase that contains a F-box domain. This means 
that MAFbx/Atrogin-1 belongs to the family of E3-ligases that function as a SCF complex (for 
Skp1, Cullin, F-box) (Gomes et al., 2001; Jackson and Eldridge, 2002). In these complexes the F-
box protein interacts with the substrates, while Cul1-Roc1 components associate with the E2 Ub-
conjugating enzymes. Skp1 is an adaptor protein that brings together the F-box protein and the 
Cul1-Roc1-E2 complex. Murf-1, on the other hand, contains a canonical N-terminal RING domain 
characteristic of RING-containing E3 ligases (Borden and Freemont, 1996) which are required for 
ubiquitin-ligase activity (Kamura et al., 1999). 
The role these two proteins play in muscle atrophy is unquestionable. However, and despite 
all the effort, little is known about their true targets. The first approach took advantage of the yeast-
2-hybrid assay in order to identify the binding partners of MAFbx/Atrogin-1(Li et al., 2004). One of 
the proteins that came out from this study was -Actinin-2. Co-immunoprecipitation experiments 
confirmed that these two proteins in fact interact. However, the protein levels of -Actinin-2 did not 
change upon MAFbx/Atrogin-1 over-expression suggesting that it is not a target of ubiquitination. 
Since -Actinin-2, like MAFbx/Atrogin-1, co-localize in the Z-disk of cardiomyocytes, the authors 
looked for proteins that also localize in the Z-disk and could interact with -Actinin-2. They found 
out that Calcineurin-A, which play an important role in coordinating myocyte gene expression 
program and that determines cell size, could also interact with MAFbx/Atrogin-1 and that in fact 
was ubiquitinated and degraded in a MAFbx/Atrogin-1 dependent way. Three other proteins were 
shown to be direct targets of mAFbx/Atrogin-1 dependent ubiquitination. One of these proteins was 
MyoD, a key myogenic transcription factor involved in muscle differentiation and muscle repair. In 
fact, over-expression of MAFbx/Atrogin-1 results in polyubiquitination of MyoD and in inhibition 
of MyoD-induced myotube differentiation (Lagirand-Cantaloube et al., 2009). Also myogenin, 
another myogenic transcription factor, was shown to be polyubiquitinated by MAFbx/Atrogin-1 and 
degraded during dexamethasone-induced myotube atrophy (Jogo et al., 2009).The last of the known 
ubiquitination target of MAFbx/Atrogin-1 is eIF3-f (elongation initiation factor3 subunit 5). eIF3-f 
has an important role in translation initiation (Hinnebusch, 2006).  The over-expression of this 
initiation factor was shown to induce hypertrophy, both in myotubes and in vivo, and to prevent 
starvation-induced atrophy in myotubes. Furthermore, repression of eIF3-f in myotubes induces 
atrophy. Using yeast two-hybrib assay MAFbx/Atrogin-1 was shown to directly interact with eIF3-f 
leading to its ubiquitination and degradation (Lagirand-Cantaloube et al., 2008). Considering these 
evidences, the first steps to understand how MAFbx/Atrogin-1 actually induces atrophy were done. 
Also Murf-1 has some known targets, and the majority of them are structural proteins. One 
of the first to be identified was titin, a giant protein responsible for the elasticity of the muscle. 
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Although being a structural protein, it also contains several domains that anticipate an important 
role in signal transduction. According to Centner et al (Centner et al., 2001), Murf-1 interacts with 
the repeats A168/A169 adjacent to the titin kinase domain and therefore might modulate the kinase 
activity of titin. Also myosin heavy chain (MyH) isoforms are targeted by Murf-1 and -3.  In fact, 
the generation of a double knock-out mouse model of Murf-1 and Murf-3 lead to a myopathy with 
MyH accumulation (Fielitz et al., 2007). These accumulating MyH were smaller than normal MyH 
suggesting a process of partial degradation. The authors further show, in vitro and in vivo, that 
Murf-1 and Murf-3 directly interact and ubiquitinate different MyH isoforms. Additionally, MuRF1 
degrades myosin-binding protein C and myosin light chain-1 (MLC1) and MLC2 during 
denervation and fasting conditions (Cohen et al., 2009). In order to obtain these in vivo results, the 
authors have generated a knock-in mouse model in which the Ring-finger of Murf-1 had been 
deleted. Curiously, these animals were spared from denervation-induced atrophy suggesting that 
deletion of this portion of the protein is similar to the loss of the entire proteins. Altogether these 
results suggest that Murf-1 interacts and ubiquitinate preferentially structural proteins. Contesting 
this idea, Hirner S et al, (Hirner et al., 2008), show that MuRF1 is predicted to interact with several 
proteins associated with glucose production and glycogen metabolism. Yeast two-hybrid assay has 
demonstrated the interaction of MuRF-1 with PDH, PDK2, PDK4, PKM2 (all participating in 
glycolysis) and with phosphorylase β (PYGM) and glycogenin (both regulating glycogen 
metabolism). In the light of these data, it is plausible that these two proteins, MAFbx/Atrogin-1 and 
Murf-1, up-regulated during several atrophic conditions, can regulate distinct aspects of the atrophic 
process.  
Considering the relevance of the ubiquitin/proteasome system in skeletal muscle atrophy, it 
is appealing to think that its inhibition can protect from loss of muscle mass. In this line of thought, 
several proteasome inhibitors were tested in order to see whether they were effective attenuating 
muscle atrophy. Early studies in which atrophic muscle were collected and incubated ex vivo with N 
-acetylleucyl-leucyl-norleucinal (LLN), or with CBZ-leucyl-leucyl-leucinal (MG132) showed a  
50% reduction in the overall rate of proteolysis (Tawa, Jr. et al., 1997). This study anticipates the 
potential role of proteasome inhibitors in attenuate the consequences of muscle wasting. Combaret 
et al (Combaret et al., 1999) used Pentoxifylline (PTX), which is a xanthine derivative widely used 
in humans, in order to prevent muscle wasting induced in Yoshida sarcoma-bearing rats. 
Apparently, daily administration of PTX blocked the ubiquitin pathway by suppressing the 
enhanced expression of ubiquitin, the 14-kDa ubiquitin conjugating enzyme E2, and the C2 20S 
proteasome subunit in muscle from cancer rats. Also Torbafylline (HWA 448) was shown to spare 
rat skeletal muscles from wasting induced by cancer or sepsis (Combaret et al., 2002). Another 
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proteasome inhibitor, Velcade, also known as PS-341 and bortezomib, when administrated in vivo, 
lead to a 50% reduction in atrophy associated with denervation (Beehler et al., 2006). Also the 
administration of MG132 (1 mg/kg/48 h) in vivo, during hindlimb unloading (HU), partially 
prevents muscle atrophy.  
Although effective, the inhibition of the proteasome only partially prevents muscle atrophy, 
suggesting that another mechanism might be involved in loss of muscle mass during catabolic 
conditions.  
1.2.2.2- The Autophagy/Lysosome Pathway 
 
Another mechanism implicated in skeletal muscle atrophy is the Autophagy/Lysossome 
pathway. It is mainly implicated in the lysosomal degradation of long-lived proteins and damaged 
or supernumerary organelles. Degradation by this mechanism occurs normally at basal levels for the 
routine turnover of cytoplasmatic components, and it plays an important role during development, 
differentiation and tissue remodeling. On the other hand, alterations in the autophagic flux are also 
implicated in several diseases, from neurodegenerative to cancer, passing by neuromuscular. 
Autophagy is a ubiquitous and well conserved process from yeast to mammals. Due to its 
characteristics can be divided into three different types (Fig 5): macroautophagy, microautophagy 
and chaperone-mediated autophagy (CMA). Macroautophagy implicates the formation of a C-
shaped double-membrane vacuole (phagophore) that wraps cytoplasm and organelles to be 
Fig 5: Types of autophagy: Macroautophagy, Microautophagy and Chaperone-Mediated Autophagy. During 
macroautophagy occurs the formation of a double-membrane vesicle called autophagosome that engulfs the 
cytoplasmatic components to be degraded. The autophagosome then fuses with the lysosome where the degradation 
occurs, forming in this way the autophagolysosome. During microautophagy, on the other hand, the components to be 
degraded are engulfed directly by an invagination of the lysosome membrane. Chaperone-mediated autophagy is a 
selective process in which the proteins to be degraded a peptide motif that is recognized by the chaperones. These 
proteins are then transported by LAMP-2A to the interior of the lysosome (Ding, 2010). 
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degraded. This vacuole then fuses with the lysosomal membrane and the autophagic body enters the 
lysosome were the components are degraded and recycled (reviewed in (Yang et al., 2005). On the 
other hand, during microautophagy the cytoplasmatic material is incorporated in the lysosome 
through a direct invagination of the lysosomal membrane forming an internal vacuolar vesicle 
where the degradation occurs. CMA is different from these two types of autophagy because it does 
not imply the formation of vesicular traffic and also because is a much more selective autophagic 
process. In fact, only cytosolic proteins with particular peptide motifs are recognized by the 
complex system of molecular chaperones and co-chaperones. These proteins are then unfolded and 
translocate across the lysosomal membrane helped by a group of lysosomal proteins. The most 
important of which is LAMP-2A that is required for binding the targeted proteins to the lysosomal 
membrane and also for its translocation into the lumen of the lysosome. In this introduction we will 
focus mainly in macroautophagy that will be called autophagy for the sake of simplicity. 
Apart from the CMA, autophagy was initially thought to be mainly a non selective process 
in which bulk cytoplasm was randomly sequestered into the cytosolic autophagosomes. However, 
there are evidences that autophagy can selectively eliminate damaged organelles such as 
mitochondrias, endoplasmatic reticulum and peroxissomes (Eskelinen, 2008). Furthermore, recent 
studies have shown that LC3, one of the key molecules in the formation of the autophagosome, may 
act as a membrane receptor and interact with p62 or NBR1 (multi-functional adaptor proteins that 
bind to poly-ubiquitinated proteins) to promote the selective elimination of poly-ubiquitinated 
proteins/aggregates (Glick et al., 2010).  
Autophagy is a process normally induced during nutrient-poor condition and it is 
responsible for the degradation of superfluous material, in order to provide amino-acids for adaptive 
protein synthesis. The molecular steps of this process are well studied in yeast and are conserved in 
mammals, and will be discussed below. 
 
1.2.2.2.1- Autophagic machinery  
 
One of the open questions related to autophagy is the origin of the membranes that forms the 
autophagosome. What is known is that a double-layer membrane starts surrounding the 
cytoplasmatic cargo until it completely engulfs it, forming in this way the autophagosome. These 
autophagosomes then fuse with the lysosome allowing the degradation of its content by the 
lysosomal proteases. Nutrients are then recycled back to the cytosol through lysosomal permeases. 
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The autophagosome starts to 
form at the phagophore assembly site/ 
pre-autophagosome structure (PAS) 
and it is orchestrated by a tightly 
regulated machinery comprising two 
highly conserved ubiquitin-like 
conjugation systems: the Atg12-Atg5 
and the Atg8-
phosphatidylethanolamine (PE) system 
(Fig 6). Both systems are inter-
connected since if one is defective the 
other cannot target proteins to the PAS. 
In the Atg12-Atg5 conjugation 
system, Atg12 behaves like ubiquitin. 
It is initially activated, in an ATP-dependent way, by Atg7 that functions as an E1-activating 
enzyme. It does so by creating a thioester bond between the C-terminal glycine of Atg12 and a 
cysteine residue in Atg7. Atg12 is then transferred to another cysteine residue in Atg10, forming a 
new thioester bond and releasing Atg7. Atg10 functions as an E2-conjugation enzyme and 
potentiates the covalent linkage of Atg12 to Atg5. Conjugated Atg12-Atg5 complexes binds to 
Atg16 and this multimeric complex is required for the elongation of the expanding pre-
autophagosomal membrane. The formation of this complex is thought to induce the curvature of the 
autophagosomal membrane through asymmetric recruitment of Atg8. 
Atg8 is also an ubiquitin-like molecule, and it is present in early isolation membranes, 
autophagosome and autophagic bodies. It is initially proteolytically cleaved by Atg4, exposing a 
glycine residue that will allow it’s binding to Atg7. This activated Atg8 is then transferred to Atg3, 
an E2-like enzyme that will mediate the conjugation of Atg8 with phosphatidylethanolamine (PE), 
an abundant membrane phospholipid. This Atg8 lipidation can be reverted by Atg4, which cleaves 
lipid-protein linkage, and this allows cycles of conjugation/deconjugation important for the normal 
progression of autophagy. There are at least 4 mammalian Atg8 homologs, MAP1LC3 (LC3), 
GATE16 (Golgi Associated ATPase Enhancer 16KDa), Gabarap (Gabba Receptor-Associated 
Proteins) and Atg8L. Among them the most abundant in autophagosome membrane is LC3. It can 
be detected in two different forms: LC3-I and LC3-II.  While the first correspond to the free 
cytosolic form, the second correspond to the membrane bound, lipidated form. The proportion 
Fig 6: Two ubiquitin-like conjugation systems are involved in 
autophagosome formation. Atg8 and Atg12 are ubiquitin-like 
proteins that are activated by the E1-like enzyme Atg7. Atg8 and 
Atg12 are then transferred to the E2-like enzymes Atg3 and Atg10, 
respectively. While Atg8 becomes conjugated to 
phosphatidylethanolamine (PE), Atg12 binds to Atg5. Atg8-PE is 
integrated in the forming autophagosome. The complex Atg12-Atg5 
binds Atg16 and this allows the multimerization of the complex 
(Klionsky, 2005). 
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between LC3-I and LC3-II reflects the abundance of autophagosome and is one of the best methods 
to assay autophagy levels and flux. 
The autophagosome formation is regulated by several mechanisms. The complex 
Atg1/Atg13/Atg17 is required for the initial formation of the phagophore, possibly, by recruiting 
Atg9, a transmembrane protein that is thought to be involved in the recruitment of lipids to the 
growing membrane. The phosphorylation status of Atg13, which is regulated by TOR (Target of 
rapamycin), influences the binding to Atg1 and the formation of the above mentioned complex. In 
this way, growth factor and the nutrient status of the cell, through TOR, are capable of controlling 
autophagy. Another protein implicated in autophagosome elongation is the class-III PI3 kinase 
Vps34. This protein uses phosphatidylinositol (PI) as substrate to generate phosphatidyl inositol 
triphosphate (PI3P) that is essential to the process of phagophore elongation. Furthermore, the 
interaction of Vps34 with Atg6 (Beclin-1 in mammals) increases significantly its catalytic activity 
to generate PI3P (Funderburk et al., 2010; Furuya et al., 2005). In mammals, other regulatory 
proteins that complex with Beclin-1/Vps34 have been identified, such as the stimulatory Ambra-1, 
Atg14L and UVRAG (ultraviolet irradiation resistance associated gene) (an homologue of Vps38, 
that is part of yeast Vps34 complex II) or the inhibitory Rubicon (RUN domain and cystein-rich 
domain containing, BECN1-interacting) and Bcl-2 (Itakura et al., 2008; Liang et al., 2006; Maiuri et 
al., 2007; Matsunaga et al., 2009; Pattingre et al., 2005; Sun et al., 2008a; Zhong et al., 2009). 
Ultimately, mature autophagosome fuses with the lysosomal compartment forming the 
autophagolysosome. This maturation step is essential for the autophagic flux and any blockage will 
result in the accumulation of autophagosomes. There are several proteins that seem to be involved 
in the regulation of this essential process. Rubicon and UVRAG alternatively interact with the 
complex Beclin-1/Vps34 and while the first down-regulate the endocytic trafficking and the 
maturation of the autophagosome the latter has the opposite effect.  
 
1.2.2.2.2- Autophagy Regulation 
 
The autophagic response occurs as a consequence of diverse external and/or internal stimuli. 
Therefore the signaling pathways implicated are also diverse. One of the most important conditions 
associated with increase autophagy is nutrient depletion. In mammals, the main signaling pathway 
implicated in this condition is the mTOR pathway. 
mTOR, the mammalian Target of Rapamycin, is a serine/threonine kinase capable of 
sensing growth factors, nutrient signals and energetic status of the cell. Growth factor regulates 
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mTOR through insulin/insulin-like growth factor 1 (IGF1) - PtdIns3K - PKB (protein kinase B)/ 
AKT pathway. In the presence of extracellular growth factors, this signalling pathway activates 
mTOR and consequently inhibits autophagy (Inoki et al., 2002; Manning et al., 2002). Whenever 
growth factors are removed from the medium, even in the presence of nutrients the cells activate 
autophagy (Lum et al., 2005) in order to maintain energy homeostasy. On the other hand, amino 
acid starvation, or nutrient deprivation, is known to inhibit mTOR and in this way induce 
autophagy. Rapamycin, an inhibitor of mTOR, is able to induce autophagy even in the presence of 
nutrients suggesting that mTOR has a negative regulatory role in autophagy (Noda and Ohsumi, 
1998). Finally, mTOR senses the energetic status of the cell through AMPK. When the ATP/AMP 
ratio decreases, for instances under glucose deprivation or if mitochondria are dysfunctional, 
AMPK is activated, inhibiting mTOR and thus inducing autophagy (Corradetti et al., 2004; Shaw et 
al., 2004), that will increase the ATP production via recycling of nutrients. 
mTOR can inhibit autophagy by two different mechanisms: by controlling transcription and 
translation acting on 4E-BP1 and p70S6 kinase, and by directly or indirectly interact with Atg 
proteins, such as Atg13, in the autophagosome formation, as it was already described before.  
Although much is already known about the regulation of autophagy, the cross-talk between 
different pathways requires further studies. 
 
1.2.2.2.2- Autophagy in skeletal muscle  
 
Early biochemical studies, by zonal 
centrifugation, in skeletal muscle of starved rats revealed 
the existence of two populations of lysosome-like 
particles: one, less representative, originated from 
macrophages and connective tissue and another, much 
more representative, originated from muscle fibers. The 
authors further stated that although evidences had been 
provided for the existence of a lysosomal system they 
could not explain “why morphological studies have 
repeatedly failed to observe lysosomes in normal muscles 
cells” (Canonico and Bird, 1970). Two years later the 
first evidences for the presence of autophagosomes in 
skeletal muscle were reported. Electron microscopy 
Fig 7: Autophagic vacuoles engulfing glycogen.  
Diaphragm of rats, 3h after birth. Scale mark 0,5 
m (Schiaffino and Hanzlikova, 1972a). 
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studies, in neonatal skeletal muscle, revealed the presence of double layer vacuoles filled with 
glycogen (Fig 7) suggesting a functional role of the lysosomal system in mobilizing glycogen 
(Schiaffino and Hanzlikova, 1972a). However, the role autophagy plays in skeletal muscle was 
difficult to prove and extremely controversial (Furuno et al., 1990; Schiaffino and Hanzlikova, 
1972b) mainly due to technical limitations that relied in enzymatic assays and in the use of 
unspecific pharmacological inhibitors.  
In the last years, several tools have been developed that allow a better study of the 
autophagic flux in vivo and in particular in skeletal muscle. Apart from the technical advances in the 
imaging techniques, the generation of a transgenic animals in which the LC3 gene (Atg8 in yeast), 
involved in the autophagosome formation, was fused with the GFP gene, allowed the in vivo 
visualization of the autophagosomes (Mizushima et al., 2004). Analyzing the effect of starvation-
induced autophagy in vivo, it was observed that fast skeletal muscle has a higher induction of 
autophagosome formation than slow skeletal muscle. Furthermore, GFP positive dots 
(autophagosomes) in skeletal muscle are much smaller than those of other tissues such as liver, 
pancreas or even heart, providing a possible explanation for the previous difficulty in observing 
autophagy related structures in skeletal muscle. Using a similar approach, (Mammucari et al., 2007) 
showed that autophagosome formation is implicated in muscle atrophy induced by FoxO3, one of 
the most important transcription factor implicated in muscle atrophy. In fact co-electroporation of 
the tibialis anterior muscle with LC3-GFP and with constitutively active FoxO3 (c.a.Foxo3) 
increased the number of GFP positive foci, representing autophagosomes. Furthermore the authors 
provided evidences that FoxO3 is directly regulating the expression levels of LC3 by binding to its 
promoter region.  
The role of autophagy in muscle wasting was further confirmed by a genetic model of 
Amyotrophic Lateral Sclerosis (ALS). In this transgenic model the expression of SOD1
G93A
, the 
mutated form of the protein, is known to induce an increase in ROS levels that results in muscle 
atrophy with consequent muscle weakness. In this model, muscle atrophy was partially reduced 
when the autophagic flux was blocked by the over-expression of shRNAs against LC3, thus 
preventing autophagosome formation (Dobrowolny et al., 2008). Furthermore, the contribution of 
autophagy in the loss of muscle mass that occurs during ageing, also called sarcopenia, was recently 
demonstrated (Wenz et al., 2009; Wohlgemuth et al., 2010). These reports showed an increase in 
the expression levels of several components of the autophagic machinery during ageing, suggesting 
that in the elderly there is a higher requirement of this system to degrade and recycle damage 
components of the fibers. The authors went further on showing that PGC1a, a key regulator of 
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mitochondrial biogenesis, was sufficient to ameliorate loss of muscle mass and to decrease the age-
induced autophagy.  
These studies clearly demonstrated that autophagy is a process implicated in muscle 
wasting. Additionally, autophagosomes are characteristic of a class of muscle disorders called 
Autophagic Vacuolar Myopathies. Altogether, these evidences might suggest that autophagy is 
detrimental for muscle physiology. However it is also possible that autophagy is a required 
mechanism to increase cell survival and to eliminate damaged organelles. The fact that several 
adquired or genetic muscle disorders present abnormal mitochondrias and aggregated proteins 
might suggest that autophagic flux is impaired instead of exacerbated. Therefore, in order to address 
the basal role of autophagy in skeletal muscle, (Masiero et al., 2009; Masiero and Sandri, 2010), 
generated muscle specific knock-out mice for Atg7, rendering them unable to form the 
autophagosome. The authors observed that instead of preventing muscle loss, these mice had 
increased muscle atrophy and presented several features of myopathy, such as accumulation of 
protein aggregates, abnormal mitochondrias and concentric membranous structures. A similar 
phenotype was observed in muscle-specific Atg5 knock-out mice, another genetic model of 
blockage of the autophagy (Raben et al., 2008). Altogether these results suggest that autophagy is 
required at basal levels for normal muscle physiology and that its blockage is detrimental and leads 
to muscle degeneration. 
In agreement with these results, (Grumati et al., 2010) showed that in skeletal muscles of 
collagen VI–knockout (Col6a1-/-) mice, an animal model of Bethlem myopathy and Ullrich 
congenital muscular dystrophy, autophagy flux is impaired. Furthermore, forced activation of 
autophagy by genetic, dietary and pharmacological approaches restored myofiber survival and 
ameliorated the dystrophic phenotype of Col6a1-/-mice. Therefore, autophagy seems to be an 
essential mechanism that is activated under stress conditions, such muscle atrophy or genetic 
disorders. Defective activation or blockage of autophagy is detrimental since it leads to the 
accumulation of aggregated proteins and damaged organelles. 
 
Another important point to consider is the regulation of autophagy in skeletal muscle since it 
is particular when compared with other tissues such as liver or pancreas. While most tissues show a 
transient activation of autophagy, in skeletal muscle there is a persistent generation of 
autophagosomes (Mizushima et al., 2004) that requires transcriptional regulation. This suggests that 
in skeletal muscle there might be different pathways that govern short-term and long-term induced 
autophagy. In spite of the little amount of information regarding this topic, some inhibitors and 
activators of autophagy were already identified. The first of which was Runx1, a DNA-binding 
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protein, that it is highly up-regulated in denervation, a condition of induced autophagy although to a 
less extent than fasting. Wang X et al (Wang et al., 2005), generated a knock-out model of Runx1 
and have demonstrated that it is essential to prevent disused myofibers from undergoing autophagy, 
myofibrillar disorganization, and severe muscle wasting. Although the mechanism of action is not 
clear a recent study in hepatic cells showed that Runx1 interacts with FoxO3 promoting the FoxO3 
recruitment to the Bim promoter (Wildey and Howe, 2009). Another regulator of autophagy in 
skeletal muscle is Jumpy, a PI3P phosphatase associated with sporadic cases of centronuclear 
myopathy. It was shown that in C2C12 myoblasts, reduction of Jumpy by siRNA lead to an 
induction of autophagosome formation and increased rate of proteolysis (Vergne et al., 2009). The 
authors went further demonstrating that Jumpy co-localizes transiently with the autophagosome and 
proposed a model in which the balance between the PI3P production (regulated by VPS34) and the 
PI3P hydrolysis (regulated by Jumpy) determines the induction and baseline levels of autophagy. 
But the most potent autophagy inhibitor in skeletal muscle is the kinase AKT. Acute activation of 
Akt in adult mice or in muscle cell cultures completely inhibits autophagosome formation and 
lysosomal-dependent protein degradation during fasting (Mammucari et al., 2007; Mammucari et 
al., 2008; Zhao et al., 2007) However the role of mTOR, a downstream target of AKT, in opposition 
to other tissues, is much less important. In fact, biochemical studies have determined that 
rapamycin-mediated mTOR inhibition only barely (10%) increases protein breakdown in 
differentiated myotubes (in opposition to the 50% protein breakdown induced by AKT inhibition) 
(Zhao et al., 2007), and it is not sufficient to induce autophagosome formation in vivo (Mammucari 
et al., 2007; Sartori et al., 2009; Zhao et al., 2007). Moreover, deletion of S6K1, a downstream 
target of mTOR, and of S6K2 does not affect the autophagic flux in cultured myotubes (Mieulet et 
al., 2007). Therefore the starvation induced autophagy resulting from inactivation of the IGF1-Akt 
pathway does not seem to be dependent of mTOR in contrary to what happens in other tissues in 
which mTOR is the main inhibitor of autophagy. 
 
As it was already described, skeletal muscle atrophy can result from several conditions, 
pathological or not. All these conditions lead to a decrease in protein synthesis and an increase in 
protein degradation. Protein degradation results from the activation of the two main degradative 
systems in the muscle: the ubiquitin/proteasome system and the autophagy/lysosome system. But 
which are the molecular pathways that activate these mechanisms?  
 
Chapter 1 - Introduction 
 25 
1.2.2.3- The main orchestrators of skeletal muscle atrophy 
 
The molecular pathways 
involved in muscle atrophy only 
recently started to be unraveled. 
One of the most important 
pathway is the IGF-1/Akt/FoxO 
(Fig 8). Briefly, this pathway is 
activated by Insulin or Insulin-
like Growth Factor (IGF-1) that 
binds to their receptors. This 
leads to the autophosphorilation 
of these receptors and generates 
the docking sites for Insulin 
Receptor Substrate (IRS) that 
becomes phosphorilated by the 
receptor. Phosphorilated IRS 
recruits and activates 
phosphatidylinositol-3-kinase 
(PI3K) which phosphorylates 
membrane phospholipids, 
generating phosphoinositide-3,4,5-triphosphate (PIP3). In turn, PIP3 acts as a docking site for two 
kinases, phosphoinositide-dependent kinase 1 (PDK1) and Akt that leads to their activation. 
Activated Akt inhibits protein degradation by phosphorylating the transcription factors of the FoxO 
family, and thus maintaining them in the cytoplasm. Simultaneously, activated Akt stimulates 
protein synthesis via the mammalian target of rapamycin (mTOR) and glycogen synthase kinase 3  
(GSK3 ). Whenever the IGF-1/Akt pathway becomes shutdown, such as in atrophic conditions, 
FoxO transcription factors are no longer phosphorylated by Akt and enter the nuclei where they can 
transcribe the atrogenes and activate an atrophic program (Sandri et al., 2004b). There are several 
evidences stating the relevance of this pathway in skeletal muscle atrophy. To start with, inhibition 
of PI3K or over-expression of a dominant-negative Akt reduces the size of C2C12 myotubes 
(Rommel et al., 2001). Furthermore, the activation of Akt during denervation partially prevents 
atrophy (Bodine et al., 2001a; Pallafacchina et al., 2002). And this is consistent with the fact that 
Fig 8: IGF-1/Akt Pathway and FoxO in Muscle Atrophy and 
Hypertrophy (Sandri et al., 2004a). 
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muscles from mice lacking Akt1 and Akt2 are smaller than their WT littermates (Peng et al, 2003). 
Additionally in vitro administration of insulin or IGF-1 was sufficient to blunt the atrophic response 
to dexamethasone, a glucocorticoid known to induce muscle atrophy (Sacheck et al 2004). 
Moreover, fasting and glucocorticoids induce the expression of FoxO factors both in the liver and in 
the muscle (Furuyaa et al, 2003; Imae et al 2003). Not surprisingly, FoxO1 was found significantly 
increased in several conditions of muscle atrophy (Lecker et al., 2004). Altogether these data 
indicate that during muscle atrophy this pathway is regulated both at the transcriptional and pos-
translational level in order to orchestrate a complex atrophic program. 
As it was shown, FoxO family of transcriptional factors are key elements in the atrophic 
process. They belong to the Forkhead family of proteins that are present in all eukaryotes, and they 
are characterized by the presence of a conserved DNA binding domain called Forkhead Box 
(Calnan and Brunet, 2008). In invertebrates, FoxO subfamily is composed of four members: FoxO1 
(FKHR), FoxO3 (FKHRL1), FoxO4 (AFX) and FoxO6. While the first 3 are ubiquitously 
expressed, FoxO6 is expressed mainly in the brain (Jacobs et al., 2003). While playing different 
roles in different tissues, in the skeletal muscle FoxO1 and FoxO3 are mainly involved in the 
atrophic process (Brunet et al., 1999; Sacheck et al., 2004; Sandri et al., 2004a; Stitt et al., 2004). In 
fact, muscles from transgenic mice over-expressing FoxO1 are smaller than WT controls (Kamei et 
al., 2004) and knockdown of FoxO expression by RNAi is able to block the upregulation of 
atrogin1/MAFbx expression during atrophy  (Liu et al., 2007; Sandri et al., 2004a), indicating that 
FoxO is sufficient to promote muscle loss. 
Another important pathway during skeletal muscle atrophy is the NF-kB pathway. This 
transcription factor play major roles as mediators of inflammation and immunity, and in the muscle 
appear to mediate the effect of several cytokines, such as TNF-  during muscle wasting and 
cachexia. In the inactive state NF-κB is sequestered in the cytoplasm by a family of inhibitory 
proteins called IκB. In response to TNFa, the IκB kinase (IKK) complex phosphorylates IκB 
resulting in its ubiquitination and proteasomal degradation. This leads to nuclear translocation of 
NF-κB and activation of NF-κB-mediated gene transcription. Muscle-specific over-expression of 
IKKß in transgenic mice leads to severe muscle wasting, that is mediated, at least in part, by the 
ubiquitin-ligase MuRF1 but not by atrogin-1/MAFbx (Cai et al., 2004). On the contrary, muscle-
specific inhibition of NF-κB by transgenic expression of a constitutively active IκB mutant partially 
prevents denervation induced atrophy. Likewise, lack of p105/p50 NF-kB gene, in knock-out mice, 
abolished muscle atrophy induced by hindlimb unloading (Hunter and Kandarian, 2004). The exact 
mechanism by which NF-kB becomes activated is still unknown. However, it is known that NF-κB 
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is transiently activated after an acute bout of physical exercise, although it is not known whether 
this has any effect on activity-dependent gene regulation (Ho et al., 2005; Ji et al., 2004).  
As it was already seen, myostatin is a member of the TGFß family, expressed and secreted 
predominantly by the skeletal muscle that functions as a negative regulator of muscle growth. It was 
also showed that lack of myostatin induces muscle growth. So it was hypothesized that it could also 
play a role in muscle atrophy. However the results are conflicting. The systemic over-expression of 
myostatin, through injection of Chinese hamster ovary cells engineered to express myostatin, was 
found to induce profound muscle and fat loss, analogous to that seen in human cachexia syndromes 
(Zimmers et al., 2002). However the generation of muscle specific myostatin transgenic animals 
showed that this atrophy was mild and only present in males (Reisz-Porszasz et al., 2003). The 
same mild atrophy was also observed when myostatin was electroporated into adult T.A. muscles 
(Durieux et al., 2007). In order to clarify this issue, Sartori et al (Sartori et al., 2009) used a similar 
approach.  The TGF-  pathway was activated by electroporating muscles with c.a.ALK5 or 
c.a.ALK4, the two receptors of this pathway, leading to a reduction of 20% in the cross section area 
of the muscles. This atrophy was dependent on the activation of the SMADs 2 and 3, two 
transcription factors downstream of the TGF-  pathway. This indicates that activation of the 
myostatin pathway has a role in muscle atrophy and that its inhibition might be beneficial to prevent 
muscle loss. 
 
 
Until now, it was shown that skeletal muscle atrophy is a process that requires the activation 
of two degradative processes: the ubiquitin/proteasome and the autophagy/lysosome system. The 
activation of these two systems is tightly regulated at the transcriptional level, but also at the post-
translational level. But a new class of master regulators have emerged in the recent years that can 
regulate entire pathways. They operate at the post-transcriptional level and their role in skeletal 
muscle atrophy is barely unknown. They are called miRNAs. 
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1.3- miRNAs: from their origins to their functions in muscle atrophy 
 
miRNAs are small non-coding RNAs with approximately 22 nucleotides that can regulate 
post-transcriptionally gene expression. They are highly conserved among species and they are 
present in animals, plants, and virus. Currently there are more than 1000 human miRNAs and 
almost 700 murine miRNAs. They are predicted to regulate the expression of approximately 60% of 
protein coding genes. Conventionally, miRNAs are known to regulate gene expression by binding 
to the 3’-Untranslated Regions (3’UTRs) of the mRNA, and in this way block translation or induce 
mRNA degradation. Each miRNA has the potential to target hundreds of different mRNAs, and on 
the other hand each mRNA can be targeted by different miRNAs creating in this way complex 
regulatory networks. One of the hallmarks of miRNAs is their specificity. In fact, several miRNAs 
are involved in developmental and physiological processes that require tissue- and stage-specific 
expression. The tight regulation of miRNAs expression is crucial and alterations are correlated with 
pathological conditions.  
In 1969, Roy J. Britten and Eric H. Davidson, wrote a theory about the organization of the 
genome of higher organisms. They based their theory in some observations: “There exists a 
significant class of genomic sequences which are transcribed in the nuclei of higher cell types but 
appear to be absent from cytoplasmic RNA's”, “This genome differs strikingly from the bacterial 
genome due to the presence of large fractions of repetitive nucleotide sequences which are scattered 
throughout the genome. Furthermore, these repetitive sequences are transcribed in differentiated 
cells according to cell type-specific patterns.” Their theory can be summarized by the statement 
“Batteries of producer genes are regulated by activator RNA molecules synthesized on integrator 
genes.” These were, perhaps, the foundations for the appearance of the miRNAs (Britten and 
Davidson, 1969). 
But it was only in 1993 that Lee et al (Lee et al., 1993) have discovered in C. elegans the 
first miRNA, lin-4. It was seen that lin-4 disrupt the timing of post-embryonic development in C. 
elegans by repressing the expression of lin-14, which encodes a nuclear protein (Lee et al., 1993). 
The negative regulation of lin-14 by lin-4 requires partial complementarity between lin-4 and the 
3’UTR of lin-14 mRNA (Ha et al., 1996; Olsen and Ambros, 1999). 
Seven years later a second miRNA, let-7, was discovered, again in nematodes (Reinhart et 
al., 2000). let-7 functions in a manner similar to lin-4, repressing the expression of the lin-41 and 
hbl-1 mRNAs by binding to their 3’UTRs (Lin et al., 2003; Reinhart et al., 2000; Vella et al., 2004). 
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The dawn of miRNAs was followed by large scale screenings that established miRNAs as a 
new and large class of ribo-regulators (Lagos-Quintana et al., 2001; Lau et al., 2001; Lee and 
Ambros, 2001). 
 
1.3.1- Genomic distribution and transcription regulation 
 
Human and murine 
miRNAs are distributed along the 
entire respective genomes except in 
the Y chromosome. miRNA 
Transcriptional Units (TUs) can be 
scattered individually along the 
chromosomes or they can be 
arranged in clusters. Two or more 
miRNA located in the same 
chromosome at close distance of 
each other (usually it is considered 
between 3Kb and 10 Kb) are 
defined as clusters. It is predicted that approximately 50% of the known miRNAs are clustered. 
These miRNAs clusters are often transcribed into polycistronic primary transcripts, and the 
miRNAs belonging to one cluster are often related to each other. However there are also clusters in 
which the members belong to different miRNAs families and this might be important for the 
regulation of a specific target gene or several target genes of the same pathway. (reviewed in (Davis 
and Hata, 2009; Kim and Nam, 2006; Olena and Patton, 2010; Zhang et al., 2009). 
Initially miRNAs were thought to be mainly intergenic. However a closer analysis showed 
that almost 70 % of the known miRNAs were located in defined TUs. The vast majority of these 
miRNAs located in TUs are located in introns of protein coding genes, although they can also be 
located in introns of non-coding RNAs. Some miRNAs may also be located in exons of non-coding 
genes while only a few have a mixed localization depending on the splice variant transcribed in the 
tissue (Fig 9). 
One question that we can pose regards the transcriptional regulation of these miRNAs. 
Initially, several reports indicated that miRNAs and the host genes had similar profiles suggesting 
that the regulatory mechanism were the same (Baskerville and Bartel, 2005; Combaret et al., 2004; 
Fig 9:Genomics organization and structure of miRNAs genes. (Kim 
and Nam, 2006) 
Chapter 1 - Introduction 
 30 
Lagos-Quintana et al., 2001; Lau et al., 2001; Rodriguez et al., 2004). However there are other 
recent studies in which the expression profiles of miRNA and the host gene are independent 
indicating that these miRNAs are under the regulation of their own promoter (Fujita et al., 2008). In 
fact it is now believed that 25-33% of intronic miRNAs are transcribed form independent promoters 
(Corcoran et al., 2009; Ozsolak et al., 2008). 
The analysis of miRNAs regulatory regions revealed that they are, in everything, similar to 
the ones of protein coding genes. The relative frequency of CpG islands, TATA box, TFIIB 
recognition, initiator elements, and histone modifications clearly suggests that these promoters, like 
the ones from mRNA, are regulated by transcription factors, enhancers and silencing elements. This 
is essential for the time-, developmental- and tissue-specific expression pattern of miRNAs.  
(reviewed in (Davis and Hata, 2009; Krol et al., 2010). Repression of miRNAs to ensure their 
tissue-specificity has also been reported. In fact miRNA-124, a miRNA abundant in the brain, is 
negatively regulated by the REST factor, which is highly expressed in precursor neuronal cells and 
in non neuronal cells. During development the REST factor is silenced allowing the expression of 
miRNA-124 in the post-mitotic neuronal cells. Simultaneously, it is now thought that miRNAs are 
particularly involved in the regulation of transcription factors (Shalgi et al., 2007). This, creates 
double feedback loops in which the miRNA regulates the expression of a transcription factor which 
modulates the expression of the miRNA itself, contributing for the fine tuning of the miRNA 
expression levels. 
 
1.3.2- Overview of miRNAs Biogenesis 
 
miRNAs are transcribed into long transcripts mainly by RNA polymerase II, although there 
are also evidences implicating RNA polymerase III in the transcription of some miRNAs (Borchert 
et al., 2006). Most of them are polyadenylated in its 3’end and capped at its 5’extremity, like 
mRNAs. In the canonical pathway (Fig 10) these primary-miRNAs (pri-miRNAs) folds into a stem 
loop structure that will be further processed by two RNAse III endonuclease, Drosha and Dicer. In 
the nucleus, the hairpin structure is cleaved from the flanking regions originating the precursor-
miRNA (pre-miRNA) that is ≈70 nucleotide long. This first processing step is catalyzed by Drosha 
that is helped by a cofactor, DGCR8 (DiGeorge syndrome critical region gene 8) (Pasha in 
Drosophila). This complex is called the Microprocessor. DGCR8 contains two dsRNA-binding 
domains that directly interact with the stem-loop and with the flanking region, serving as a 
molecular anchor to Drosha that carries out the cleavage reaction. The cleavage produces highly 
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exact extremities and is highly 
regulated. The production of pre-
miRNAs not always requires the 
participation of the microprocessor 
complex. In fact, a rare alternative 
pathway has been identified initially 
in fly and nematodes, but also 
present in mammals (Berezikov et 
al., 2007; Okamura et al., 2007; 
Ruby et al., 2007). This pathway 
uses the splicing machinery to 
liberate introns that mimic the 
features of pre-miRNAs. These 
structures are called mirtrons. After 
being spliced they enter the normal 
miRNA processing pathway.  
Pre-miRNAs are then 
exported to the cytoplasm by 
Exportin-5 in a Ran-GTP dependent 
way, where they will be further 
processed. In the cytoplasm the 
terminal loop of the pre-miRNA is 
cleaved originating a mature dsRNA 
of approximately 22 nucleotides of 
length. This step is carried out by 
Dicer. The PAZ domain of Dicer 
binds to the 3’overhangs of the pre-
miRNAs and this binding determines 
the cleavage site since that Dicer’s 
catalytic sites are located precisely two helical turns away from the PAZ domain (bound to the pre-
miRNA). In this step, Dicer is assisted by the Tar RNA Binding Protein – TRBP (know as 
Loquacious in Drosophila), another dsRNA binding protein. At the end of this last processing step 
Argonaute 2 is recruited to the complex Dicer/TRBP leading to the unwinding of the duplex. At this 
stage one of the strands, the mature miRNA, is preferentially incorporated into the complex that 
Fig 10: miRNA Biogenesis. (Krol et al., 2010) 
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will repress target gene expression – the RNA-Induced Silencing Complex (RISC). The choice of 
the mature strand is based on the thermodynamic stability of the two ends of the duplex. The 
complementary strand (miRNA*) in most cases is degraded. However there are growing evidences 
that both strands can be incorporated into the RISC complex in a functional way (Guo and Lu, 
2010). 
The key proteins of the RISC complex are the Argonautes (AGO). These proteins contain 
three highly conserved domains, PAZ, MID and PIWI domains, that interact with the miRNAs. In 
mammals there are four AGO that function in miRNA repression (Ago1 to Ago4). Different AGO 
proteins seems to have different specificity to the miRNA or siRNA pathway. Another crucial 
factor for miRNA-repression is the GW182 protein. This protein interact directly with AGO 
proteins and are thought to be the effectors of AGO. There are other proteins interacting with RISC 
to modulate miRNA function. This is the case of Fragile X Mental Retardation Protein (FMRP), 
which binds RNA molecules and might modulate translation. Also RNA Helicase RCK/p54, which 
is a p-body component, is thought to be essential to induce repression. Finally TRIM32 was 
recently seen to bind the RISC components enhancing in this way its activity. However further 
studies are required for a better understanding of the proteins that modulate this complex process of 
miRNA-mediated repression (Carthew and Sontheimer, 2009; Fabian et al., 2010; Krol et al., 2010).  
 
1.3.3- Prediction of miRNAs Targets 
 
One of the most challenging fields in the study of miRNAs is the identification of the target 
genes they regulate. The study of the molecular mechanism implicated in target recognition, 
together with computational approaches were soon translated into basic principles used in the 
development of bioinformatic tools that could predict miRNAs targets.  
The majority of animal miRNAs displays only modest base-pairing to their targets in 
contrast to what happens in plants, where the base pairing is perfect. Historically, miRNAs are 
known to regulate the 3’UTR of the target genes. This was experimentally demonstrated with the 
first miRNAs identified and it was also assumed as an in silico convenience that was further 
confirmed experimentally. But the use of these predictive algorithms has left underestimated the 
possibility that miRNAs might regulate other regions, such as the 5’UTR or even the coding region 
of the mRNAs. In fact, experiments involving artificial and natural mRNAs have shown that their 
5’UTR can be targeted by miRNAs (Lytle et al., 2007). Recent reports have also started to address 
the possibility that miRNAs can target the Open Reading Frame (ORF) of certain genes. 
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Accordingly, three independent studies have identify three miRNAs that functionally target the 
coding region of DNMT3B (Duursma et al., 2008), p16 
INK4A
 (Lal et al., 2008) and several zinc 
finger family members (Huang et al., 2010). Moreover, several computational analysis either in 
Drosophila either in Vertebrates genomes revealed that miRNA complementarities in conserved 
coding regions are more common than predicted (Forman et al., 2008; Stark et al., 2007; Tay et al., 
2008). Even more surprising is the fact that miRNAs seems to have the capacity to activate the 
translation of certain mRNAs by binding to their 5’UTR as it was demonstrated by Orom et al and 
Henke et al (Henke et al., 2008; Orom et al., 2008). These recent facts suggest that animal miRNAs 
might function in a very similar way to Plants miRNAs with no significant mechanistic differences 
in target recognition. 
But which are the principles currently assumed for target recognition? The interaction 
between miRNA and mRNA are through base pairing - most of the times imperfect base pairing. 
The most important region of the miRNA is the so called “seed” region. According to the seed 
“rule”, the interaction between miRNA and mRNA requires a contiguous and perfect (or nearly 
perfect) Watson-Crick base pairing of the 5’ nucleotides 2-8 of the miRNA. Although this seems to 
be a rather general and consensual rule, there are some exceptions in which mismatches or even 
bulged nucleotides have been identified in the seed region. Another observation is that the presence 
of an A in the 1
st
 nucleotide and a A or U in the position 9 seams to improve miRNA activity 
although it’s not required. Another characteristic of the miRNA/mRNA interaction is the presence 
of mismatches and bulged nucleotides in the position 10-12. As for the 3’ extremity of the miRNA, 
the complementarity is quite relaxed although it stabilizes the interaction mainly when the seed 
matching is not perfect.  
Another point to take into consideration when discussing the miRNA/mRNA interaction is 
the presence of multiple sites in the same 3’UTR. In fact this seems to lead to a more efficient 
mRNA repression. Some algorithms also take into account the conservation between related species 
of the miRNA-binding site. Finally one must consider that mRNAs have a secondary structure that 
might block miRNAs binding.(reviewed in (Brodersen and Voinnet, 2009; Du and Zamore, 2005; 
Fabian et al., 2010).  
 Giving different weight to each of these parameters, several algorithms were developed to 
predict miRNAs targets. The most known and robust ones are: TargetScan, PicTar, Miranda and 
PITA. 
 TargetScan was the first to be developed (Lewis et al., 2003). It takes into consideration the 
conservation between species and for this aligns the sequences of the 3’UTR of zebrafish, mouse, 
rat and human. This procedure reduces the probability of finding false positives. This algorithm 
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requires a perfect complementarity between the seed region of the miRNA and the binding site. 
Finally, it takes advantage of the RNAFold from the Vienna package (Hofacker, 2003) in order to 
introduce a thermodynamic parameter and to further narrow down the list of predicted targets. This 
algorithm was redefined in 2005 (Lewis et al., 2005) in order to further increase the fidelity of the 
predictions. In this direction, the authors have decreased the complementarity of the seed region to 
6 nucleotides. They now require the presence of an A in the first position (5’) of the miRNA 
binding site. The relative position of the miRNA binding site in the interior of the 3’UTR is also 
taken into account. Altogether, this modifications lead to the development of a very stringent 
algorithm in order to avoid false positives. 
 Also PicTar (Krek et al., 2005) uses the 3’UTR regions from multiple species as initial data. 
However, it is not as stringent as TargetScan since it does not take into consideration the relative 
position of the binding site inside the 3’UTR. Then it looks for the binding site between miRNAs 
and 3’UTR, but also here is less stringent since it also considers imperfect bindings. Finally it takes 
into account the binding free energy for each possible interaction that comes out from the previous 
analysis.  
MiRanda (Enright et al., 2003) is a program that does not take into consideration the 
conservation between species of the target genes. It was develop taking into account the importance 
of the binding between the seed and target mRNA, but it does not require a perfect binding. Also 
this algorithm takes into account the thermodynamic stability of the miRNA-mRNA duplex, 
according to the Vienna package. An updated version (John et al., 2006) increases the stringency of 
this algorithms mainly by requesting a almost complete complementarity (allowing only a G:U 
instable binding). Simultaneously, this updated version takes into account the number of binding 
sites for the same miRNAs in the 3’UTR of the gene. 
PITA (Probability of Interaction by Target Accessibility) takes into consideration the 
accessibility of the target site in order to predict the interactions miRNA-RNA (Kertesz et al., 
2007). To accomplish this, it considers only mRNAs with perfect complementarity in the 6-8 
nucleotides of the seed region of the miRNA, allowing only one mismatch. The final classification 
of the miRNA/mRNA interaction indicates the energetic cost to release the mRNA from the binding 
with the miRNA.  To calculate this, it takes from the free energy of the mRNA, the energy 
implicated in the formation of the duplex miRNA-mRNA. This algorithm does not take into 
consideration the conservation between species.  
Although the principles used for target recognition are quite well established and accepted, 
and considering that different algorithms have different sensibilities, validation of the predicted 
targets is always required. 
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1.3.4- Mechanisms of mRNA posttranscriptional repression by miRNAs 
 
Mature miRNAs are loaded into the RISC complex and together this complex is able to bind 
the target mRNA and regulate the expression of the target gene. However the mechanisms that 
miRNAs use to regulate gene expression are still very controversial and poorly understood. It is 
widely accepted that the degree of complementarity between miRNA and mRNA dictate the 
regulatory mechanism implicated in gene silencing. Accordingly, perfect complementarity induces 
Ago-catalyzed cleavage of the mRNA, while bulges and mismatches are believed to block 
translation of the mRNA into protein. But, is this a universal rule that functions for all 
miRNAs/mRNAs?  The advances made in the last decade in understanding the molecular 
mechanisms involved in miRNA-induced silencing are not conclusive. On the contrary, they have 
generated a series of hypothesis on how miRNAs influence mRNA translation/stability.  
 
1.3.4.1- Post-transcriptional Repression by miRNAs 
 
The initial observations concerning miRNAs functioning revealed that protein level of the 
target gene was decreased while mRNA levels remained unchanged, suggesting the involvement of 
a translational repression mechanism. Translation of mRNA is a highly complex process that 
involve multiple protein factors and that can be divided in three stages: initiation, elongation and 
termination. During translation, proteins interacting with the poly-A tail (such as PABPC) bind to 
proteins interacting with the 5’cap of the mRNA (such as eIF4E and the eIF4G complex) giving rise 
to a circular mRNA that is protected from degradation and it’s translated. So how do miRNAs 
repress translation? Does it occur at the initiation stage or at the elongation stage? Several in vitro 
and in vivo studies were preformed giving rise to several hypotheses that still require further 
confirmation. 
One of the first theories that came out suggested that the nascent polypeptide chain might be 
degraded co-translationally, and this hypothesis was supported by the fact that miRNAs and target 
mRNAs were associated with polysomes without any de novo protein being detectable (Nottrott et 
al., 2006). An alternative model proposed to explain these facts was the ribosome drop-off model in 
which the ribosomes engaged in the translation of miRNA-associated mRNAs were prone to 
dissociate prematurely (Petersen et al., 2006). This model was further supported by the fact that 
miRNA-associated mRNAs tend to dissociate faster from the polysomes than unrepressed mRNAs 
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after treatment with a translational inhibitor. All these two theories suggested that miRNA block 
translation at a post-initiation step. 
However, several studies have suggested that miRISC complex represses mRNA translation 
at the initiation step. For example, studies using mRNAs translated in a cap independent manner 
(such as using an Internal Ribosome Entry Site - IRES) failed to be repressed by miRNAs 
(Humphreys et al., 2005; Pillai et al., 2005). Always supporting a cap-dependent mechanism, it was 
seen that, in cell extracts, an artificial mRNA containing a m
7
Appp-cap structure fail to be repressed 
by miRNAs while the normal m
7
Gppp-capped mRNAs were silenced (Mathonnet et al., 2007; 
Wakiyama et al., 2007). Soon several competing models came out trying to explain how miRNAs 
could induce translational repression at the initiation stage. In the first model, miRISC is proposed 
to compete with eIF4E for the binding of the mRNA 5’ cap. It was speculated that Ago2, GW182 or 
another downstream factor could compete directly with eIF4E for cap binding. Based on the fact 
that several repressed mRNAs are deadenylated, a second model was proposed in which miRISC, 
through GW182 protein, stimulates the deadenylation of the mRNA tail. However there are also 
reports indicating that nonpolyadenylated mRNAs can be targeted by miRNAs. Finally, miRISC 
might be implicated in the recruitment of eIF6, a factor that prevents the premature association of 
the 60S ribosomal subunit with the 40S pre-initiation complex, to the mRNA, preventing in this 
way the assembly of translationally competent ribosomes at the start codon. Currently, and taking 
into account the available data, it is more accepted that translational repression occurs at the 
initiation step. (reviewed in Carthew and Sontheimer, 2009; Fabian et al., 2010; Huntzinger and 
Izaurralde, 2011). 
 
1.3.4.2- Degradation of the target mRNAs 
 
Although the initial studies reported a block in translation, soon the evidences for target 
mRNA cleavage started to appear. Microarray experiments after over-expression of specific 
miRNA showed a massive down-regulation of the predicted targets (Farh et al., 2005; Guo et al., 
2010; Lim et al., 2005; Selbach et al., 2008). Furthermore, depletion of miRNAs from the cells 
(Baek et al., 2008; Krutzfeldt et al., 2005; Selbach et al., 2008) or even depletion of essential 
components of the miRNA pathway lead to an increase abundance of the predicted mRNA targets 
(Eulalio et al., 2007; Eulalio et al., 2009; Giraldez et al., 2006; Rehwinkel et al., 2005), indicating 
that miRNAs also regulate mRNA stability and degradation. 
Chapter 1 - Introduction 
 37 
It is widely accepted that fully complementary targets leads to endonucleolytic cleavage. But 
what happens to partially complementary targets? It is believed that in these cases mRNAs 
degradation is not due to AGO2-mediated cleavage but rather due to deadenylation, decapping and 
exonucleolytic digestion of the mRNAs. In this mRNA decay pathway, mRNAs are primarily 
deadenylated by the Caf1-Ccr4-Not1 deadenylase complex in a process that requires the protein 
GW182. Subsequently mRNAs are decapped by the DCP2 enzyme, and finally degraded by the 5’-
to-3’ exonuclease XRN1. Depletion of AGO2, GW182 or depletion of the deadenylation complex 
lead to the stabilization of the miRNAs targets indicating that miRNA-bound to AGO2 in a 
complex with GW182 might recruit deadenylases to induce mRNA degradation. One question that 
remains open is whether mRNA degradation is a consequence of translational blockage or whether 
mRNA deadenylation renders mRNA silenced for translation.  
 
Despite the evidences supporting the several modes of action of miRNA mediated mRNA 
repression, it remains controversial which is the prevailing mechanism. There are several recent 
studies indicating that target degradation is the main mode of regulation. Using transfection or 
depletion of a specific miRNAs allowed Selbach et al. and Baek et al. to study the effects at the 
level of protein and mRNA in simultaneous. The authors have concluded that the main mechanism 
was miRNA induced mRNA degradation and only rarely block of translation (Baek et al., 2008; 
Selbach et al., 2008). Another study showed that, in HEK-293T cells transfected with miRNA-124, 
mRNA degradation accounted for 75% of the changes observed at the protein level. These authors 
have co-immunoprecipitated mRNAs bound to AGOs and identified 600 transcripts that were 
differentially bound after the expression of miRNA-124, but analyzing the translational rates they 
couldn’t find evidences for translational blockage (Hendrickson et al., 2009). But the same doubt 
remains – is translational repression the cause of these degradation? Regardless, it is now well 
accepted that mRNA degradation is an important and well documented mechanism trough which 
miRNAs exert their functions. (reviewed in Carthew and Sontheimer, 2009; Fabian et al., 2010; 
Huntzinger and Izaurralde, 2011; Pillai et al., 2007). 
 
1.3.4.3- P-Bodies and the compartmentalization of miRNA-mediated repression 
 
Repressed mRNAs can be found in discrete cytoplasmatic foci known as P-bodies, GW-
bodies or stress granules (Fig 11). These foci are enriched in factors involved in mRNA decay 
mechanism and translational repression. They contain deadenylases, decapping enzymes and the 
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exonuclease Xrn1 involved in mRNA decay. 
They lack ribosomes and translation initiation 
factors and this is consistent with the idea that p-
bodies contain repressed mRNAs. As expected, p-
bodies also contain components of the miRNAs 
pathway such as AGO2 and GW182 proteins. 
Several evidences showed that a functional 
miRNA pathway is required for p-bodies formation. However, disruption of these cytoplasmatic 
structures, by silencing certain components, does not interfere with the functioning of the miRNA 
pathway.  
One interesting observation is that mRNAs located in the p-body are not necessarily 
committed to degradation. In fact under certain conditions mRNAs can exit the p-body and re-enter 
the translational process, indicating that p-bodies can function as a temporary storage for repressed 
mRNAs (reviewed in (Fabian et al., 2010; Pillai et al., 2007). Although little is known about this 
mechanism, it is appealing to think that cells can have a ready-to-use stock of mRNAs that can be 
immediately translated upon request and that miRNAs can contribute to this repression state. 
 
1.3.5- Functions of miRNAs 
 
During the last two decades a large amount of information has been gathered concerning 
miRNAs biology. Taking into consideration the large amount of genes that can be regulated by 
miRNAs it is reasonable to think that they play a major role in several biological processes. In fact, 
they modulate crucial aspects of cell metabolism and identity. They can induce cell death, but they 
can also increase cell viability. They are responsible for important regulatory events on 
development and organogenesis. They can interfere with temporal and spatial determination. They 
are involved in fine-tuning delicate processes such as neuronal synaptic plasticity and heart 
functioning. They take part on the response to viral infections. And obviously…as everything that is 
important in basic physiological mechanisms, they are also important in disease. Consistent ly it has 
been reported that miRNAs are deregulated in oncogenesis, in heart failure, in hepatitis, in diabetes, 
in autoimmunity, in neurodegeneration and in mental disorders. And if they are deregulated in 
disease they are a potential therapeutical target or at least can be used as a prognostic factor. And 
this has been intensively studied in the last few years. Furthermore, loss and gain of function 
experiments have started to unravel the striking functions of miRNAs in numerous facets of muscle 
Fig 11: P-bodies in Drosophila cells. P-bodies are 
cytoplasmatic foci where proteins involved in mRNA 
degradation and translational repression co-localize. Co-
localization of the decapping protein DCP1 with GW182 
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biology. But what is known about the role of miRNAs in the model that we study, the skeletal 
muscle?  
 
1.3.5.1- miRNAs in skeletal muscle 
 
Skeletal muscle, together with the cardiac muscle, is enriched of a subset of miRNAs called 
myomiRs (Fig 12). The first group of myomiRs identified was miRNA-1, miRNA-133 and 
miRNA-206 (Sempere et al., 2004). These miRNAs are encoded in bicistronic miRNAs genes 
located in different chromosomes. miRNA-1-1 and miRNA-133a-2 are clustered on mouse 
chromosome 2, miRNA-1-2 and miRNA-133a-1 are clustered on mouse chromosome 18 and 
miRNA-206 and miRNA-133b are located in mouse chromosome 1. While the cluster containing 
miRNA-1-2/miRNA-133a-1 is located in the intron of a protein coding gene – Mib1, a E3 ubiquitin 
ligase ubiquitously expressed, the other two clusters are derived from non-coding regions of the 
genome. miRNA-1-1 and miRNA-1-2 share the same nucleotide sequence, while miRNA-206 only 
differs from them in 4 nucleotides. miRNA-133a-1, miRNA-133a-2 and miRNA-133b have almost 
the same sequence. This suggests that these three miRNAs might have a common ancestral origin, 
and that they might regulate similar target genes. As for their expression profiles, the cluster 
containing miRNA-206 is expressed almost exclusively in the skeletal muscle, while the other two 
cluster are expressed both in skeletal and cardiac muscle. 
Fig 12: Genomic organization of the muscle-specific miRNAs and their sequence homologies. Genomic 
localization of the muscle-specific miRNAs, their host genes and tissues where they are mainly expressed. Comparison 
of the miRNAs sequences (from 5’ to 3’).  Matching color indicates sequence homology while black nucleotides 
represent differences.(Chen et al., 2009a)  
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Another family of myomiRs is composed by miRNA-208a, miRNA-208b and miRNA-499. 
The first two miRNAs are located on chromosome 14 and are both encoded by an intron of their 
host genes, Myh6 and Myh7 respectively. Several evidences indicate that their expression and the 
expression of their myosin host genes share common regulatory elements. Likewise, miRNA-499, 
another myomiRs, is also located in the intron of a myosin gene – Myh7b, and is also co-expressed 
with its host gene. Considering that the first two miRNAs are very similar among them and that 
miRNA-499 contains the exactly same seed region it is expected that these three miRNAs regulate 
the expression of common target genes. It is interesting to see that myosin genes not only encode 
for the major contractile proteins of the muscle but also encode miRNAs that have major functions 
in regulating muscle gene expression. 
 
1.3.5.2- miRNAs and the differentiation of muscle cells 
 
The differentiation of muscle cells is a highly regulated process in which transcription 
factors such as MyoD, Myogenin, Myf5, MRF4, MEF2 and SRF are key players. The sequential 
activation of these factors blocks the proliferative potential of myoblasts inducing their 
differentiation into multinucleated myotubes. This is a complex process that is tightly regulated at 
the transcriptional level. Recently it was shown that an additional post-transcriptional level of 
regulation was also implied, being miRNAs the new players in this fine tuning.  
Using C2C12 muscle cells transfected with the first myomiRs identified, miRNA-1, 
miRNA-133 and miRNA-206, allowed the study of these miRNAs in vitro (Chen et al., 2006a; Kim 
et al., 2006). While miRNA-1 and miRNA-206 induced myogenesis, miRNA-133 promoted 
myoblast proliferation. The fact that miRNA-1 and miRNA-133 have opposing effect on C2C12 
differentiation was quite unexpected since they are originated from the same polycistronic transcript 
but it is easily understood when we take in consideration some of the validated targets. In fact 
miRNA-1 was shown to target Histone Deacetylase 4 (HDAC4), a transcription repressor of muscle 
differentiation that blocks MEF2 activity. Additionally, miR-1 also represses the translation of 
Hand2, a transcription factor that promotes ventricular cardiomyocytes expansion during 
embryogenesis (Zhao et al., 2005). On the other hand, miRNA-133 was shown to repress SRF, an 
essential regulator of muscle differentiation (Chen et al., 2006b). Furthermore, miRNA-133 was 
also shown to repress the translation of the polypyrimidine tract-binding protein (nPTB), an 
essential factor involved in alternative splicing that influences the muscle differentiation program 
(Boutz et al., 2007). Also uncoupling protein 2 (UCP2), an important regulator of energy 
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expenditure and thermogenesis in various organisms, was shown to be repressed at the translation 
level by miRNA-133 during C2C12 differentiation (Chen et al., 2009b). Altogether, these results 
may explain the opposite effects of these two miRNAs.  
 The role of miRNA-206 in muscle differentiation was also studied in detailed. Initial reports 
(Anderson et al., 2006; Kim et al., 2006; Rao et al., 2006) identified p180subunit (Pola1) of DNA 
polymerase alpha and the Gap junction protein connexin43 (Cx43) as being functional targets of 
miRNA-206. The first is essential for DNA synthesis and therefore its down-regulation by miRNA-
206 is believed to contribute to exit from cell cycle proliferation during myotube differentiation. 
Gap junctions, on the other hand, are hypothesized to be required in embryonic skeletal muscle to 
allow passage of signaling molecules and metabolites and for the coordinated maturation of 
contractile capabilities. Cx43 is known to be down-regulated at the late stages of myoblast 
differentiation, and this down-regulation is now believed to occur as a consequence of the miRNA-
206 modulation (Anderson et al., 2006). Also stating the important role of miRNA-206 in C2C12 
differentiation, Rosenberg et al (Rosenberg et al., 2006) showed that this miRNA targets follistatin-
like 1 (Fstl1) and Utrophin (Utrn). Although the role of Fstl1 remains elusive, it is known that 
repression of Utrn is an essential step during differentiation, since it’s replaced by Dystrophin in the 
Dystrophin Associated Glycoprotein Complex.  
 Considering the role miRNAs play during myogenic differentiation, it is not surprising that 
myogenic transcription factors are involved in their regulation. In fact it’s known that the induction 
of miRNA-206 is affected in part for the binding of MyoD to its promoter region (Rosenberg et al., 
2006). Chip-on-Chip analyses also showed that MyoD and Myogenin can bind to the up-stream 
regions of miRNA-1, miRNA-133 and miRNA-206 inducing their expression (Rao et al., 2006). 
Also SRF, together with MyoD and Mef2, is able to bind to the promoter region of miRNA-1 as it 
was seen in the heart (Zhao et al., 2005). Therefore, miRNA expression levels are regulated by 
myogenic transcription factors, and, to fine tune this process, some miRNAs can modulate the 
levels of transcription factors.  
 Apart from the myomiRs, other miRNAs are also implicated in muscle differentiation. This 
is the case of miRNA-181, a broadly expressed miRNA. miRNA-181 expression levels dramatically 
increases in the TA muscle after cardiotoxin-induced injury and in C2C12 cells during 
differentiation (Naguibneva et al., 2006). C2C12 cells depleted of miRNA-181 had compromised 
differentiation mainly due to a decrease expression of MyoD and myogenin. Bioinformatics 
analysis of the possible targets of miRNA-181, together with in vitro experiments revealed that 
homeobox protein Hox-A11, a MyoD repressor, is in fact a target of miRNA-181. Taken together, 
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the results of this study showed that miRNA-181 is required for the differentiation process mainly 
due to its capacity to regulate a Hox-A11, a repressor of the differentiation process.  
 Another miRNA involved in the differentiation process is miRNA-214. This miRNA was 
shown to be expressed during early segmentation stages in zebrafish somites (Flynt et al., 2007), 
and to be involved in cardiac hypertrophy (Watanabe et al., 2008). A detailed study in C2C12 cells 
showed that this miRNA promotes cell differentiation, mainly by facilitating the cells from exiting 
cell cycle. This miRNA does so by targeting N-Ras, a proto-oncogen that is known to target muscle 
differentiation (Liu et al., 2010). An independent study showed that the transcription of this miRNA 
is repressed by Polycomb Group proteins (PcG). During muscle cell differentiation this repression 
is relieved mainly by the binding of MyoD and myogenin inducing an up-regulation of miRNA-
214. This miRNA, through a negative feed-back loop, represses the levels of Ezh2, a catalytic 
component of the PcG complex, ensuring the maintenance of a differentiation program (Juan et al., 
2009).  
 Different members of the TGF-  pathway were shown to inhibit myogenesis mainly by 
suppressing the expression of MRFs. This is the case of myostatin and also SMAD3. The SMAD 
inhibitors of the pathway, such as SMAD7, on the other hand are enhancers of myogenesis since 
they interact with MyoD and block the signals from myostatin. Recently miRNA-24 has been 
shown to modulate TGF-  inhibition of myogenesis. Sun et al (Sun et al., 2008b) showed that 
SMAD3 is able to bind to the promoter region of miRNA-24 and to repress its expression. 
Furthermore it was shown that over-expression of miRNA-24 was sufficient to induce myogenesis 
and that it was able to rescue the TGF-  inhibition of differentiation. The authors proposed a 
mechanism in which miRNA-24, under the regulation of TGF- , controls the expression levels of 
early and late genes of the differentiation process.  
 An additional miRNA involved in muscle myogenesis is the miRNA-125b (Ge et al., 2011). 
The levels of this miRNA decline considerably during C2C12 differentiation and during muscle 
regeneration induced by BaCl2. Introduction of this miRNA in C2C12 cells dampened myoblast 
differentiation, as shown by the decrease in the differentiation index (number of MHC positive 
cells) and in the fusion index (percentage of nuclei in myocytes with at least two nuclei). The 
authors went further showing that miRNA-125b is able to regulate the expression of IGF-II, a 
critical inducer of skeletal muscle myogenesis, and that the expression of miRNA-125b is under the 
control of mTOR, although in a kinase independent-way. 
 Skeletal muscles are quite responsive to mechanical stress. It is known that mechanical 
forces are transduced by surface receptors into intracellular signals. In fact, an important factor that 
is known to delay C2C12 differentiation is cyclic stretch (Kook et al., 2008). In vitro studies 
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revealed that cyclic stretch decreases the levels of myogenin and stimulates proliferation of C2C12 
cells and recently it was shown to influence the levels of miRNAs in differentiating cells. One of 
this miRNAs is miRNA-146a (Kuang et al., 2009). Its expression levels were increased after 48-h 
of cyclic stretch (5% elongation/10cycles/min) in differentiating C2C12 cells. Furthermore the 
authors showed that cyclic stretch induced the proliferative state of C2C12 cells. To elucidate the 
functional role of the up-regulation of this miRNA the authors showed that NUMB is a target of 
miRNA-146a. NUMB is a key negative regulator of the Notch pathway, an important pathway for 
muscle development. It is known that Notch pathway allows the expansion of progenitor cells by 
repressing the differentiation program. It is then possible that cyclic stretch, trough the regulation of 
specific miRNAs, can alter the proliferative/differentiation potential of C2C12 cells. 
 Also miRNA-221 and miRNA-222 seem to be implicated in the differentiation process. 
Cardinali et al (Cardinali et al., 2009) showed that these two miRNAs are down-regulated during 
differentiation and that ectopic expression of these two miRNAs lead to a decreased exit from cell 
cycle and decreased myogenin expression. Among the predicted targets for these miRNAs one 
could find the cell cycle inhibitor p27. Since it had been shown that p27 interferes with myoblast 
fusion and expression of myosin, and considering that its expression levels were reduced during 
differentiation the authors confirmed that it was a true target by luciferase assay. This implicates 
miRNAs in the regulation of cell cycle during the differentiation process. 
 Apart from the known regulatory mechanisms implicating transcription factors, a new layer 
of complexity has been added to the process of muscle cell differentiation. The discovery of 
miRNAs that fine tune protein dosages anticipates an important role of these tiny molecules during 
muscle development and regeneration.  
 
1.3.5.3- Role of miRNAs in adult skeletal muscle 
 
One of the first evidences that miRNAs might play a crucial role in adult skeletal muscle 
came from a study in sheep (Clop et al., 2006). The aim of the study consisted in identifying the 
gene responsible for the hypertrophic phenotype of the Texel sheep. The authors found a point 
mutation in the 3’UTR of the myostatin gene that creates a new binding site for the miRNA-1 and 
miRNA-206. In these breed of animals, myostatin, a negative regulator of muscle growth, is down-
regulated by these two muscle-specific miRNAs inducing an exacerbated muscle growth.  
Another important evidence highlighting the essential role that miRNAs play in muscle 
came from loss-of-function experiments. In this case, O’Rourke et al (O'Rourke et al., 2007) 
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generated a muscle specific conditional knock-out of Dicer, the RNAse III enzyme required for 
miRNA maturation. In these mice, the expression of Cre recombinase was under the control of 
MyoD regulatory elements, and therefore started to be expressed from embryonic day 9.5. All Dicer 
skeletal muscle mutants died just after birth. They showed severe defects in skeletal muscle 
embryonic development that was mainly translated in muscle hypoplasia with hypertrophy of the 
few remaining fibers. This hypoplasia was attributed to an increase apoptosis rather than a defect in 
myofibers formation. These results are similar to the ones obtained by (Kwon et al., 2005; Sokol 
and Ambros, 2005) in which the knock-down of the muscle specific miRNA-1 in Drosophila caused 
arrest in embryogenesis with disorganized muscle development and aberrant expression of muscle-
specific genes. Altogether these results anticipate a fundamental role of miRNAs in different 
aspects of skeletal muscle biology.  
 
1.3.5.3.1- Role of miRNAs in fiber type switch 
 
As discussed previously, skeletal muscle is composed of fibers with different structural and 
metabolic properties. The expression of different MHC isoforms, together with the activity of 
mitochondrial enzymes dictates the classification of muscle fiber in Type I, IIa, IIx and IIb. Several 
lines of evidences suggest that these properties can be changed by miRNAs. 
In early studies, (McCarthy and Esser, 2007a) analyzing the expression levels of muscle-
specific miRNAs in both plantaris, a fast muscle, and soleus, a slow muscle, realized that miRNA-
206 was 7 fold increased in the soleus muscle compared to plantaris. Taken in consideration this 
fact, the authors proposed that miRNA-206 might be fiber type-I specific, and this was further 
supported by the fact that functional overload, a condition known to induce a fast-to slow switch, 
induced an increase in the expression levels of miRNA-206. Although no mechanistic explanation 
was proposed, the authors hypothesized that miRNA-206 might be repressing the fast phenotype of 
muscle fibers. 
More recently, van Rooij et al (van et al., 2007; van et al., 2009), showed that three 
miRNAs, miRNA-208a, miRNA-208b and miRNA-499, encoded in the introns of muscle myosin 
genes are involved in a network that is able to regulate MHC expression levels itself and 
hypothetically influence fiber type. As discussed previously, these myomiRs, encoded by Myh6 ( -
MHC), Myh7 ( -MHC), and Myh7b respectively, seem to be co-regulated with their host genes. 
Using knock-out and transgenic mice for miRNA-208a, the authors showed that the expression of 
the slow -MHC was influenced by this miRNA. Furthermore they showed that this regulation 
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involved the thyroid hormone receptor (TR), since miRNA-208a targets thyroid hormone receptor 
associated protein 1 (THRAP1), a modulator of the TR involved in the recruitment of RNA 
Polimerase II and general initiation factors. Furthermore, double knock-out animals for both 
miRNA-208b and miRNA-499 showed a substantial reduction in type I myofibers in soleus muscle. 
Conversely, forced expression of miRNA-499 in the soleus muscle induced a complete conversion 
of all fast myofibers into type I fibers. Altogether these results suggest that myosin genes, through 
the expression of miRNAs, can influence a myriad of other functions in muscle fibers. In fact 
miRNA-208 and miRNA-499 were shown to directly down-regulate the expression of Sox6, Pur , 
Sp3 and HP1 , four known repressors of the slow phenotype of muscle fibers (Bell et al., 2010; 
McCarthy et al., 2009; van et al., 2009).  
But miRNAs can also regulate essential factors for the metabolic properties of the fibers. 
This is the case of PGC1- , an important transcriptional co-activator involved in adaptive 
thermogenesis, fatty acid oxidation, gluconeogenesis, and mitochondrial biogenesis. It was shown 
by Aoi et al (Aoi et al., 2010) that miRNA-696 can block the translation of PGC1- . The 
expression levels of this miRNA, which is markedly affected by both exercise and immobilization 
in opposing ways, is inversely correlated with the protein levels of PGC1- . Furthermore, the over-
expression of this miRNA in myoblasts leads to a decrease in mitochondria biogenesis and fatty 
acid oxidation confirming the role this miRNA play in the fiber type switch observed during 
exercise/immobilization. 
 
1.3.5.3.2- Role of miRNAs in muscle regeneration 
 
Skeletal muscle regeneration is a complex process in which muscle satellite cells became 
activated, proliferate, migrate to the injured area and differentiate into new myofibers or fuse to 
injured fibers. Although the precise molecular mechanisms are not well defined, it is now known 
that miRNAs play a role in these processes. In fact Nakasa et al (Nakasa et al., 2010) showed that 
local injection of a mixture of double strand miRNAs (miRNA-1, miRNA-133 and miRNA206) 
into a lacerated muscle accelerate muscle regeneration and prevents fibrosis. Although no targets 
were identified, this effect was associated to an increased expression of myogenic factors such as 
MyoD, myogenin and Pax7. To clearly demonstrate the role of miRNA-206 on muscle 
regeneration, Yuasa et al (Yuasa et al., 2008a) preformed in situ hybridization on cardiotoxin-
injected muscles. They observed a marked increase in the staining for miRNA-206 in newly formed 
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myofibers with centralized nuclei but not on intact pre-degenerated fibers. These results suggest that 
miRNA-206, together with miRNA-1 and miRNA-133, do have a role in the regenerative process.  
Confirming the involvement of miRNAs in regeneration and differentiation of satellite cells 
Crist et al (Crist et al., 2009) showed that miRNA-27b is able to directly down-regulate Pax3, an 
essential transcription factor that has to be down-regulated in order to allow satellite cell to 
differentiate. In vivo over-expression of a miR-27b in Pax3-positive cells in the embryo lead to 
down-regulation of Pax3, resulting in interference with progenitor cell migration and in premature 
differentiation. Furthermore, injection of inhibitors of miRNA-27b in the injury site resulted in 
altered levels of Pax3 and in defective regeneration, reflecting the key role miRNA-27b plays in this 
process.  
As it was seen before, miRNA-181 is up-regulated during differentiation of C2C12 cells. 
Likewise, its expression levels are increased during the regenerative process induced by cardiotoxin 
injection. Consistently, Hox-A11, one of the know target of miRNA-181, is down-regulated during 
this process. Another miRNAs that seems to affect muscle regeneration is miRNA-125b (Ge et al., 
2011). In vivo experiments revealed that the expression of this miRNA is decreased during BaCl2-
induced muscle regeneration. Co-injection of this miRNA negatively affects this process while co-
injection of antagomir against miRNA-125b promoted muscle regeneration. This data, together with 
the fact that miRNA-125b targets IGF-II, and with the fact that miRNA-125b inhibits myoblast 
differentiation, sustain a model in which miRNA-125b has to be repressed in order to allow muscle 
regeneration to occur.  
Although the exact role of miRNAs in the regenerative process is still poorly unknown, the 
fact they are deregulated anticipates a potential therapeutic application for conditions associated 
with defective regeneration such as dystrophies and sarcopenia. 
 
1.3.5.3.3- Role of miRNAs in sarcopenia 
 
Sarcopenia is defined as the slow but progressive loss of muscle mass with advancing age 
and is characterized by a deterioration of muscle quantity and quality leading to a gradual slowing 
of movement and a decline in strength. The role of miRNAs during this process only now starts to 
be unraveled. The first approach used by Drummond et al (Drummond et al., 2008) consisted in 
analyzing by Taqman RT-PCR the expression levels of three muscle specific myomiRs, miRNA-1, 
miRNA-133 and miRNA-206, in human samples. According to their data the expression of the pri-
miRNA-1 and pri-miRNA-133 increased significantly although no change was observed in the 
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mature miRNAs. To further investigate the role of miRNAs during sarcopenia, the same authors, 
profiled miRNA expression patterns in aging human skeletal muscle using a miRNA array. Among 
the 18 differentially expressed miRNAs the Let-7 family members Let-7b and Let-7e were the most 
up-regulated. Among the possible targets of these miRNAs the authors found three cell cycle 
regulators, CDK6, CDC25A and CDC34, to be down-regulated at the mRNA level. Although a 
direct validation was not performed the authors propose that Let-7 expression may be an indicator 
of impaired cell cycle function possibly contributing to reduced muscle cell renewal and 
regeneration in older human muscles (Drummond et al., 2010).  
 
1.3.5.3.4- Role of miRNAs in muscle hypertrophy and atrophy 
 
As discussed before, the role that miRNAs play in muscle hypertrophy was clearly 
demonstrated by the point mutation in the 3’UTR of the myostatin gene found in the hypertrophic 
Texel sheep. But other studies that followed confirmed the role of miRNAs in the control of muscle 
mass.  
McCarthy and Esser (McCarthy and Esser, 2007a) studied functional overload (FO) of the 
plantaris muscle, a condition that leads to an increase of 45% in muscle mass after 7 days. They 
showed an increased transcription of miRNA genes as indicated by the elevated levels of pri-
miRNA-1-2, pri-miRNA-133a2 and pri-miRNA-206. While the expression levels of the first two 
mature miRNAs were reduced by 50%, the mature miRNA-206 did not change after FO. Although 
the reasons for this discrepancy between pri-miRNA and mature miRNA were not found, these data 
clearly demonstrate that transcription of miRNAs is influenced by hypertrophic stimuli.   
But miRNAs can also negatively regulate hypertrophic stimuli. As it was already seen, one 
of the most important growth factor implicated in muscle hypertrophy is IGF-1. What Elia et al 
(Elia et al., 2009) showed is that there is a reciprocal regulation of miRNA-1 and IGF-1 either in 
cardiac or skeletal muscle. In fact, miRNA-1 is able to block the translation of IGF-1. On the other 
hand, down-regulation of IGF-1 leads to a decrease phosphorylation of AKT and Foxo3. 
Dephosphorylated Foxo3 enters the nucleus where it binds to two responsive elements in the 
regulatory region of miRNA-1 inducing its transcription. These evidences imply Foxo3, one of the 
most important transcription factor involved in skeletal muscle atrophy, in the regulation of miRNA 
transcription. But also Foxo3 itself can be targeted by miRNAs. This is the case of miRNA-155 
(Yamamoto et al., 2011) and miRNA-96 (Lin et al., 2010). While the first was down-regulated in a 
regulatory T-cell line, the second is up-regulated in human breast cancer to induce cell proliferation. 
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Both of them were shown to bind and modulate the 3’UTR of Foxo3, but their role in skeletal 
muscle atrophy is unknown. 
Skeletal muscle atrophy is a characteristic response to microgravity exposure caused by 
spaceflight. After 11 days of spaceflight the expression levels of miRNA-206 were significantly 
reduced whereas the expression levels of miRNA-1 and miRNA-133 showed a trend towards 
reduction (Allen et al., 2009). This decrease in the expression of miRNA-206 was accompanied by 
an increase expression of Atrogin-1 and myostatin, two genes involved in muscle atrophy. Whether 
miRNA-206 plays a direct or indirect role in the repression of these atrogenes is still unknown. 
Somehow contradictory results were obtained by Williams et al (Williams et al., 2009) studying the 
expression levels of miRNA-206 in denervation, another disuse condition. In this case miRNA-206 
was robustly increased in fast-twitch fibers, extensor digitorum longus (EDL), tibialis anterior (TA), 
and gastrocnemius/plantaris, after 10 days of denervation. The authors confirmed the results from 
McCarthy et al (McCarthy and Esser, 2007a) in which the expression of this miRNA was 
considerably over-expressed in slow muscle and denervation only modestly increased miRNA-206 
expression levels in this muscle. 
Increased protein degradation and reduced protein synthesis can also be the result of pro-
inflammatory cytokines. One of these cytokines that is known to play an important role during 
muscle wasting is TWEAK – TNF-like weak inducer of apoptosis (Dogra et al., 2007). Incubation 
of C2C12 myoblasts with this cytokine lead to a decrease in the expression levels of miRNA-1, 
miRNA-133, miRNA-23 and miRNA-206 and to an increase in the expression levels of miRNA-
146a and miRNA-455 (Panguluri et al., 2010). On the other hand, in vivo experiments showed that 
only miRNA-1 and miRNA -133 were significantly repressed in TWEAK transgenic mice.  
Although very preliminary, these studies confirm the role that miRNAs play in the control of 
muscle mass. A more broad approach to identify the most important miRNAs involved in these 
processes together with the identification and validation of their targets will help in identifying 
possible therapeutic targets.  
 
1.3.5.4- miRNAs in muscle pathology 
 
In the previous section we have addressed the role of miRNAs in several aspects of muscle 
physiology. However in the recent years some studies started to unravel their role in muscle 
pathology.  
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One of the first approaches, performed by Eisenberg et al (Eisenberg et al., 2007), consisted 
in analyzing by miRNA microarray the expression profiles of human samples from 10 different 
primary muscle disorders. Among these disorders one could find muscular dystrophies, 
inflammatory myopathies and congenital myopathies. They have identified 185 miRNAs that were 
deregulated in these 10 disorders among which 55 were commonly deregulated in more than 5 
disorders. Furthermore, they have found five miRNAs, miRNA-146b, miRNA155, miRNA-214, 
miRNA-221 and miRNA-222, common to all disorders suggesting the involvement of common 
regulatory mechanisms. The authors have further found a sub-group of 18 miRNAs that correctly 
predict and distinguish the various diseases from the normal muscle tissue.  
Among the muscular disorders the most studied one in terms of miRNAs is, with no doubts, 
the Duchene Muscular Dystrophy (DMD). This is an X-linked recessive disease caused by 
mutations in the dystrophin gene. Loss of dystrophin protein in DMD leads to membrane 
destabilization and subsequent activation of pathophysiological processes, resulting in 
inflammation, necrosis, and fibrosis. Studies in human samples as well as in DMD animal models, 
such as the mdx mouse model and the CXMDj dog model, revealed the presence of miRNAs with 
altered expression. In fact, McCarthy et al (McCarthy et al., 2007) showed that the diaphragm of 
mdx mice presented increased expression of miRNA-206, while the plantaris showed decreased 
expression of this myomiR. Also miRNA-133 was decreased in the soleus muscle of mdx mice. 
Although it is not clear the reason why different muscles behave differently, it is interesting to find 
the dramatic increase in miRNA-206 in the diaphragm since it is the muscle that better recapitulate 
the human disease in the mdx mice. Also Yuasa et al (Yuasa et al., 2008b) reported that miRNA-
206 is increased in T.A. muscle from mdx mice, while there was a slight decrease in the T.A. 
muscles of CXMDj dog. The proposed reason for this discrepancy comes from the fact that 
miRNA-206 is mainly expressed in newly formed fibers and in CXMDj dog muscles there is much 
more inflammatory infiltrate fibroblasts and degenerating fibers reducing in this way the quantity of 
miRNA-206 producing fibers. 
A wider approach was used by Greco et al (Greco et al., 2009). In order to identify miRNAs 
involved in the pathological pathways of DMD they compared the miRNA expression profile of 
adductor muscles derived either from mdx or wt mice. They have observed a striking increase in the 
expression levels of miRNA-31, miRNA-34c, miRNA-206, miRNA-222, miRNA-223, miRNA-
335, miRNA-449 and miRNA-494 while miRNA-1, miRNA-29c and miRNA-135a were 
significantly decreased in mdx muscles. To confirm the role of these miRNAs in the pathology, 
their expression levels were analyzed in muscle samples from DMD patients. The vast majority of 
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the analyzed miRNAs were deregulated in a similar manner in mdx mice and in DMD patients 
suggesting a conserved pathological mechanism.  
Another miRNA that was recently implicated in DMD is miRNA-222. Using a 
bioinformatics approach De Arcangelis et al (De, V et al., 2010) identified three miRNAs, miRNA-
24, miRNA-222 and miRNA-339 predicted to target 1-Syntrophin, a key component of the 
dystrophin-associated protein complex (DAPC) that is significantly reduced in mdx muscles at the 
protein level, suggesting a post-transcriptional regulation. Studies with the 3’UTR of 1-Syntrophin 
revealed that it was in fact modulated in mdx muscles. Furthermore, northern blot analysis revealed 
that miRNA-222 was up regulated up to 3 fold in gastrocnemius muscle of mdx mice. Interestingly 
the over-expression of this miRNA in C2C12 cells lead to a down-regulation of muscle specific 
miRNAs such as miRNA-1, miRNA-133 and miRNA-206, suggesting that miRNA-222 might have 
a role in the regulation of others miRNAs. 
 The role of miRNAs was also addressed in amyotrophic lateral sclerosis (ALS). This is a 
progressive neurodegenerative disease that results in loss of motor neurons, denervation of target 
muscles fibers, muscle atrophy and paralysis. To gain further insights in the molecular mechanisms 
implicated in the disease, Williams et al (Williams et al., 2009) compared the miRNA expression 
profiles of muscles from Wt mice and from G93A-SOD1 transgenic mice that express a low copy 
number of a mutant form of superoxide dismutase (SOD1) in which glycine-93 is replaced with 
alanine (G93A-SOD1), as seen in a subset of human ALS patients. The most up-regulated miRNA 
was miRNA-206, the muscle specific miRNA. To understand the role of this miRNA the authors 
have generated miRNA-206 specific knock-out mice. Despite the important role of this miRNA in 
muscle physiology homozygous for the deletion of miR-206 showed no obvious abnormalities. 
However when these mice were crossed with the G93A-SOD1 transgenic mice the resulting 
mutants showed an acceleration in the progression of the disease, suggesting that miRNA-206 is 
required to counteracts, although ultimately unsuccessfully, the pathogenesis of ALS. The authors 
focused on the neuromuscular junctions (NMJs), and they saw that miRNA-206 was required for 
the formation of new NMJs after injury. Furthermore they showed that miRNAs-206 inhibits the 
translation of HDAC4, a factor implicated in the control of neuromuscular gene expression. They 
further showed that the opposing effects of miRNA-206 and HDAC4 on NMJs innervation was 
indirectly mediated by FGFBP1, a secreted factor that interacts with FGF7/10/22 family members 
which are known regulators of synapse formation. 
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As we have seen, miRNAs are involved in different aspects of muscle biology. The 
identification of miRNAs deregulated in different conditions, together with a better understanding 
of their targets will help us understanding the molecular mechanisms implicated in the normal and 
diseased muscle, and ultimately will allow the development of new and specific therapeutic tools.
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 The major aim of this thesis was to address the biological role of miRNAs during the 
process of skeletal muscle atrophy. 
 Skeletal muscle atrophy is a condition associated to food deprivation, aging and disuse. It is 
also a complication of several chronic diseases, such as cancer diabetes, sepsis, AIDS, renal and 
heart failure among others. In all these situations protein synthesis is overtaken by protein 
degradation. This increased catabolism is achieved by the activation of two degradative pathways: 
the ubiquitin/proteasome and the autophagy/lysosome that are tightly regulated at the transcriptional 
level by specific molecular pathways.  
Recently a new regulatory mechanism, capable of regulating gene expression post-
transcriptionally, has been discovered. miRNAs, small RNA molecules with approximately 22 
nucleotides in length, bind to the 3’UTR of the target genes and either repress protein translation or 
induce mRNA degradation.  They are predicted to regulate almost 60% of protein coding genes. 
Several miRNAs can target the same 3’UTR and the same miRNA can target several mRNAs, thus 
creating a complex regulatory network. Their expression is tightly regulated by transcription factors 
and this contributes for their tissue and developmental specificity. Deregulation of their expression 
patterns is often associated with pathological conditions and it is now used as a prognostic tool. 
Given their tissue specificity, their therapeutical potential is now being studied.  
In skeletal muscle, the role of miRNAs only recently started to be approached. The existence 
of a group of myomiRs anticipates an active role of these regulatory molecules. Furthermore, the 
elimination of the miRNA pathway, in the muscle, leads to a lethal phenotype. It is now known, 
mainly by in vitro studies, that muscle specific miRNAs are involved in the process of muscle 
differentiation. In vivo studies revealed that miRNAs are also involved in fiber type switch, in 
muscle regeneration and in the normal functioning of the neuromuscular junction. Finally, the 
expression of miRNAs is altered in different muscle disorders. But nothing is known about the role 
of miRNAs during skeletal muscle atrophy, the major subject studied in our laboratory. 
Lecker et al (Lecker et al., 2004), showed that during different atrophic conditions a group 
of genes, called atrogenes, were commonly transcriptionally regulated, suggesting the existence of 
common regulatory mechanisms. Therefore, we have hypothesized that miRNAs could also be 
transcriptionally regulated during the atrophic process and that a common miRNA could govern 
atrophy. To address this hypothesis, we intended to characterize the miRNA signature in atrophying 
muscles. This would allow the identification of condition-specific miRNAs and, possibly, miRNAs 
common to all the atrophic conditions (AtromiRNA). We were also interested in studying the 
biological role of the most deregulated miRNAs. With loss and gain of function, we could 
understand if the miRNAs under study do have an active role in the atrophic program. This would 
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be one of the first in vivo approaches to the function of miRNAs in the skeletal muscle. 
Simultaneously, we were interested in understanding through which targets these miRNAs were 
modulating atrophy. To accomplish that, we were interested in developing innovative approaches 
that could facilitate the identification of the possible targets. We were also interested in study the 
biological role of the targets, in the particular context of muscle wasting. 
Given that muscle atrophy is a transcriptionally regulated process, and that miRNAs are 
transcriptionally regulated but simultaneously regulate transcription factors, the understanding of 
this new layer of regulation might open new doors to the understanding of the molecular 
mechanism governing atrophy. Additionally, and taking in consideration the advances made in the 
last decade in the miRNAs biology, it is not unrealistic to think on miRNAs as new potential 
therapeutic tools or targets. 
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3.1- Animal models and surgical procedures 
 
All experimental procedures were approved by the Ethics Committee of the University of 
Padova and authorized by the Italian Ministry of Health. Mice were housed in individual cages in 
an environmentally controlled room (23 °C, 12-h light-dark cycle) and provided food and water ad 
libitum. Adult male CD1 mice that were 2 or 3 month old were used.  
Three different models of skeletal muscle wasting were used: starvation, denervation and 
diabetes. For starvation experiments chow was removed in the morning and mice stayed with free 
access to water but with no food for a period of 24h or 48h and then they were sacrificed. In 
denervation experiments the sciatic nerve of one leg was cutted. The other leg was used as control. 
Mice were sacrificed after 3, 7 or 14 days. Diabetes-induced muscle wasting was accomplished by 
one single acute intraperitoneal (IP) injection of streptozotocin (Sigma S-0130). Briefly, STZ 
(180mg/Kg) was dissolved in freshly prepared sodium citrate buffer (pH 4.4) (Sigma S-4641), and 
administered as a single dose IP immediately after preparation. Concurrent controls received an 
equal volume of vehicle. Mice were sacrificed 7 days after IP injection. Total RNA was extracted 
from atrophic EDL muscles to access the expression levels of Atrogin-1, an atrophy-related 
ubiquitin ligase that is up-regulated during different models of muscle loss.  
Adult male CD1 mice (28-34g) were used in all over-expression, silencing and luciferase 
experiments. Tibialis Anterior (TA) muscles were 
electroporated as described previously (Fig 13) (Dona 
et al., 2003; Sandri et al., 2004a). Briefly, TA muscles 
were isolated through a small hind limb incision and 
plasmid DNA was injected along the muscle length. 
Plasmid DNA was diluted in a total volume of 40ul of 
0.9% NaCl (final concentration) solution. Electric 
pulses were then applied by two stainless steel spatula 
electrodes placed on each side of the isolated muscles 
belly (21 V/cm for five pulses at 200-ms intervals) 
with the Electro Square Porator (ECM 830, BTX). 
Electroporated muscles were collected 7, 10 or 14 
days later. No gross or microscopic evidence for 
necrosis or inflammation as a result of the electroporation procedure was noticed.  
Fig 13: In vivo electroporation allows the generation 
of transgenic muscles. A saline physiological solution 
containing the desired combination of DNA is injected 
in the exposed T.A. muscles. Five electrical pulses of 
21V are applied to the muscles to allow the entry of the 
DNA into the muscle fibers 
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The following constructs were electroporated or co-electroporated in T.A. muscles of at least 
three different animals:  
 pcDNA 6.2-GW/EmGFP-miR-Negative Control (Negative Control) – 20 g 
 pcDNA 6.2-GW/EmGFP-miR-miRNA-206 (miRNA-206) – 20 g 
 pcDNA 6.2-GW/EmGFP-miR-miRNA-21 (miRNA-21) – 20 g 
 miRNA-206 (10 g) + miRNA-21 (10 g) 
 pmiRZIP lentivector (ZIP NULL) – 10 g 
 pmiRZIP lentivector anti-miRNA-206 (ZIP-206) – 10 g 
 pmiRZIP lentivector anti-miRNA-21(ZIP-21) – 10 g 
 Zip-206 (10 g) + Zip-21 (10 g) 
 Zip-21 (10 g) + Zip-206 (10 g) 
 pMIR206-Luc (10 g ) + Renilla Null (5 g) 
 pMIR21-Luc (10 g ) + Renilla Null (5 g) 
 pMIR206-Luc (10 g ) + Renilla Null (5 g) + miRNA-206 (20 g) 
 pMIR21-Luc (10 g ) + Renilla Null (5 g) + miRNA-21 (20 g) 
 pMIR206-Luc (10 g ) + Renilla Null (5 g) + ZIP-206 (25 g)  
 pMIR21-Luc (10 g ) + Renilla Null (5 g) + ZIP-21 (25 g) 
 pMIR-YY1-3’UTR-Luc (10 g ) + Renilla Null (5 g) 
 pMIR-eIF4E3-3’UTR-Luc (10 g ) + Renilla Null (5 g) 
 pMIR-PDCD10-3’UTR-Luc (10 g ) + Renilla Null (5 g) 
 pMIR-PolK-3’UTR-Luc (10 g ) + Renilla Null (5 g) 
 pMIR-YY1-3’UTR-Luc (10 g ) + Renilla Null (5 g) + Negative control (20 g)  
 pMIR-YY1-3’UTR-Luc (10 g ) + Renilla Null (5 g) + miRNA-206 (20 g) 
 pMIR-YY1-3’UTR-Luc (10 g ) + Renilla Null (5 g) + miRNA-21 (20 g) 
 pMIR-YY1-3’UTR-Luc (10 g ) + Renilla Null (5 g) + miRNA-206 (10 g) + miRNA-21(10 g)  
 pMIR-eIF4E3-3’UTR-Luc (10 g ) + Renilla Null (5 g) + Negative control (20 g) 
 pMIR-eIF4E3-3’UTR-Luc (10 g ) + Renilla Null (5 g) + miRNA-206 (20 g) 
 pMIR-eIF4E3-3’UTR-Luc (10 g ) + Renilla Null (5 g) + miRNA-21 (20 g) 
 pMIR-eIF4E3-3’UTR-Luc (10 g ) + Renilla Null (5 g) + miRNA-206 (10 g) + miRNA-
21 (10 g) 
 pMIR-PDCD10-3’UTR-Luc (10 g ) + Renilla Null (5 g) + Negative control (20 g) 
 pMIR-PDCD10-3’UTR-Luc (10 g ) + Renilla Null (5 g) + miRNA-206 (20 g) 
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 pMIR-PDCD10-3’UTR-Luc (10 g ) + Renilla Null (5 g) + miRNA-21 (20 g) 
 pMIR-PDCD10-3’UTR-Luc (10 g ) + Renilla Null (5 g) + miRNA-206 (10 g) + miRNA-21 (10 
g) 
 pMIR-PolK-3’UTR-Luc (10 g ) + Renilla Null (5 g) + Negative control (20 g) 
 pMIR-PolK-3’UTR-Luc (10 g ) + Renilla Null (5 g) + miRNA-206 (20 g) 
 pMIR206-Luc (10 g ) + Renilla Null (5 g) + pcDNA3 (20 g) 
 pMIR206-Luc (10 g ) + Renilla Null (5 g) + FoxO3 TM (20 g) 
 pMIR206-Luc (10 g ) + Renilla Null (5 g) + Ikk  (20 g) 
 pMIR21-Luc (10 g ) + Renilla Null (5 g) + pcDNA3 (20 g) 
 pMIR21-Luc (10 g ) + Renilla Null (5 g) + FoxO3 TM (20 g) 
 pMIR21-Luc (10 g ) + Renilla Null (5 g) + Ikk  (20 g) 
 pcDNA3.1/V5-His-Empty (20 g)+ YFP-LC3 (10 g) 
 pcDNA3.1/V5-His-YY1 (20 g) + YFP-LC3 (10 g) 
 pcDNA3.1/V5-His-eIF4E3 (20 g) + YFP-LC3 (10 g) 
 pGL2-Murf-1 promoter (5,5Kb)-Luc (10 g) + Renilla Null (5 g) + Negative Control (20 
g) 
 pGL2-Murf-1 promoter (5,5Kb)-Luc (10 g) + Renilla Null (5 g) + miRNA-206 (20 g) 
 pGL2-Murf-1 promoter (5,5Kb)-Luc (10 g) + Renilla Null (5 g) + miRNA-206 (20 g) + 
miRNA-21 (20 g) 
 pGL3-Atrogin-1 promoter (3,5Kb)-Luc (10 g) + Renilla Null (5 g) + Negative Control (20 g) 
 pGL3-Atrogin-1 promoter (3,5Kb)-Luc (10 g) + Renilla Null (5 g) + miRNA-206 (20 g) 
 pGL3-Atrogin-1 promoter (3,5Kb)-Luc (10 g) + Renilla Null (5 g) + miRNA-206 (20 g) 
+ miRNA-21 (20 g) 
 
3.2- Cell Culture 
 
For in vitro experiments we used MEFs (Mouse embryonic fibroblasts) and C2C12 (Mouse 
myoblast) cells. Cells were maintained in culture with D-MEM (Dulbecco’s modified Eagle’s 
medium) (Invitrogen # 41966-029) containing 1% penicillin-streptomycin (Gibco # 15070) and 
10% FBS (Fetal bovine serum) (Gibco # 10106-169). C2C12 cells were maintained in proliferation 
and were not differentiated into myotubes. Transfection was performed using the Lipofectamine 
2000 reagent (Invitrogen # 11668-027) according to the manufacturer’s protocol. One day prior to 
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the transfection, the cells were plated onto 6-well plates at a density of 100000 cells per well. The 
next day, cells were transfected with a total of 4 g of plasmidic DNA per well if 6-well plate were 
being used or with 1.6 g of plasmidic DNA per well if 12-well plate were being used. The cells 
were cultured for 4 h in Optimem (Invitrogen # 31985-047) without serum or antibiotics. 
Afterwards, the medium was changed, and the cells were incubated in Optimem supplemented with 
FBS and penicillin-streptomycin. Cells were used 24 or 48 h according to the experiments. 
 
3.3- RNA and miRNA purification  
 
For the micro array experiments mRNA and miRNAs were isolated form frozen 
gastrocnemius muscles from animals placed under different atrophic conditions and controls. The 
isolation of miRNAs/mRNAs was achieved by an initial purification with Trizol (Invitrogen 
#15596-026) followed by a subsequent purification and fractionation with the Purelink miRNA-
Isolation Kit (Invitrogen #K1570-01). Briefly, frozen muscles were powdered in a mortal and were 
then homogenized in 1,5ml of trizol with the polytron. The aqueous phase (0,6 ml) was isolated 
according to the Trizol instructions and transferred to a new eppendorf. Ethanol 100% was added to 
arrive to a final concentration of 35% (0,32 ml). This solution was added to the first spin column 
from the Purelink miRNA Isolation Kit. After a centrifugation at 12000g for 1min at RT the flow 
through was kept, since it contains the miRNA fraction (RNA smaller than 200 nucleotides), as well 
as the first spin column that contains the mRNA fraction (RNA higher than 200 nucleotides). 
Ethanol 100% was added to the flow through in order to arrive to a final concentration of ethanol of 
70% (1,07 ml). This solution was added to a second spin column and centrifuged at 12000g for 1 
min at RT. The second column contains the miRNA fraction. Both spin columns were washed twice 
with washing buffer. miRNAs were eluted from the second column with 55 l of DNAse/RNAse 
free water while mRNA were eluted from the first column with 200 ul of DNAse/RNAse free 
water. In this way miRNA and mRNAs were extracted from the same sample. 
For the Real-Time PCR (RT-PCR) experiments total RNA was extracted from T.A., 
Gastrocnemius, EDL and Soleus muscle using the Trizol reagent according to the manufacturer’s 
instructions. The same protocol was used for RNA purification from cells. 
The quantification of the miRNA/mRNA was done in a NanoVue Plus (G&E Healthcare) 
and RNA integrity was assessed with the NanoRNA 6000 LabChip kit with a Agilent 2100 
Bioanalyzer (Agilent Technologies) according to the manufacturer’s instructions. 
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3.4- Micro Array of miRNAs  and mRNAs 
 
For the microarray of miRNAs the mirVana  miRNA Probe set platform (1564 V1, October 
2005)(Ambion) was used. This platform contains approximately 400 probes for human, murine and 
rat microRNAome present in the miRNA Registry (miRBase - Release 9). The probes were spotted 
on SCHOTT Nexterion
®
 Slide E slides by a robotic station Microgrid II Biorobotics present at the 
CRIBI - Padova University. Each miRNA probe was represented in quadruplicate in the array. The 
array also contains at least two different spike probes in order to normalize the labeling procedure. 
Micro arrays of miRNAs were done by competitive hybridization in which the miRNA population 
of the atrophic samples was compared to the miRNA population of a pool of control samples mixed 
in equal amounts. Dye swap was performed in order to avoid dye bias. At least three biological 
replicates were performed for each atrophic condition. To label the miRNAs we used the 
mirVana
TM
 miRNA Labeling Kit (Ambion #AM1562) and amine-reactive dyes (GE Healthcare) 
following the manufacturer’s instructions. Briefly, 2 g of purified miRNAs of each sample, 
together with 800 pg of spikes per sample, were poly-adenylated, purified, conjugated with Cy3 or 
Cy5 and purified for a second time. After this procedure, labeled miRNAs (and spikes) were 
incubated in the spotted slides for 21h at 42°C. Array acquisition was performed using a 
ScanArray
™
 Lite, (Perkin Elmer). In order to avoid false positives, a very stringent analysis was 
preformed. To achieve this, only the fluorescent values 40% above the background were utilized. 
Furthermore, only the values present in at least 65% of the microarray experiments were 
considered. Doing so, from the 384 probes present in the array only 159 were considered for further 
analysis. Some experiments were completely removed from the analysis since the results obtained 
with the inversion of the fluorophore were not consistent. In order to obtain a more up-dated 
information regarding the probes present in the array, miRNA probes were re-annotated using the 
miRbase database (http://microrna.sanger.ac.uk). At the end of this process from the 159 probes that 
passed the qualitative analysis only 118 matched murine miRNA. These miRNAs were analyzed 
using the software MacOSX MeV v4.2 (MultiExperiment Viewer) that allows the visualization, 
clusterization, classification and statistical analysis of the data .  
The mRNA microarray experiments were conducted at the CRIBI by Matteo Silvestrin and 
Cristiano de Pittà. For the microarray, the Operon Mouse Oligo Set, version 1.1 was used. This 
platform contains approximately 13500 probes for the mouse genome. The probes were designed 
based on almost 14000 UNIGENE clusters from M musculus, mainly at the 3’ terminal region. The 
probes were spotted on MICROMAX Glass Slides SuperChip I (PerkinElmer Life Science, Inc) 
using a robotic station   Microgrid II Biorobotics present at the CRIBI - Padova University. Total 
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RNA was labeled using the MessageAmp aRNA Kit (Ambion). Briefly, 1 g  of total RNA was 
amplified using a T7 RNA polymerase, followed by a retro-transcription using an ArrayScript and a 
oligo(dT15) primer. This double-strand cDNA was then used to synthesize the antisense mRNA 
using the MEGAscript IV, a T7 RNA Polimerase that incorporates the 5-(3-ammnioallyl)-UTP 
(aaUTP). This aaUTP was used in the labeling reaction since it contains a reactive ammine group 
that binds to the NHS ester group of the Cy3 or Cy5 fluorophore (GE Healthcare).  After labeled, 
these aRNAs were hybridized with the pre-spotted slides for 48h. Array acquisition was performed 
using a ScanArray
™
 Lite, (Perkin Elmer). Data was analyzed using the M.I.D.A.W Microarray Data 
Analysis Web Tool (Romualdi et al, 2005). This software allows background correction, global and 
local mean and variance normalization. The expression data was subsequently analyzed using the 
software MacOSX MeV v4.2 (MultiExperiment Viewer) that allows the visualization, 
clusterization, classification and statistical analysis of the data. In order to identify altered genetic 
pathways DAVID (Database for Annotation, Visualization and Integrated Discovery) database was 
used. 
 
3.5- Integration of the data obtained with the mRNA expression profile 
with those of the miRNA expression profile. 
 
In order to reduce the number of predicted targets, Matteo Silvestrin and Cristiano de Pittà 
from the CRIBI, developed a software that integrates the data from the mRNA micro-array and the 
data from the miRNA micro-array. Briefly, using the freely available predictive database (Miranda, 
TargetScan, Pictar and PITA), a list of all the predicted targets of the altered miRNAs was 
downloaded. The obtained list was crossed with the list of mRNAs whose expression was altered in 
the mRNA microarray. In order to cross this information the GeneMIR++ algorithm was used. This 
algorithm runs under the MatLab 7.4 (MathWorks) software and basically performs the statistical 
analysis of the biological conditions in which the expression levels of a certain mRNA is under the 
control of one or more miRNAs (Huang and Chow, 2007). This program consider only the miRNAs 
and the mRNAs that are expressed above the average expression level and gives back the highest 
probabilistic punctuation when the expression levels of the miRNAs and of the mRNAs are strongly 
inversely correlated and the lowest probabilistic punctuation when both miRNA and mRNA have 
the same expression pattern. In this way the huge list of predicted targets is reduced in a biological 
way since it includes the data from the mRNA expression analysis. 
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3.6- Validation of the microarray results  
 
miRNA expression profiles were validated using the TaqMan
® 
MicroRNA Assays (Applied 
Biosystems). According to the manufacturer’s instructions, each 15 μl RT reaction contained 5 ng 
of total RNA, 3.0 μl of 5× stem-loop RT primer, 1× RT buffer, 0.25 mM of dNTPs, 50 U 
MultiScribe™ reverse transcriptase and 3.8 U RNase inhibitor. Reaction mixes were incubated in a 
MJ Mini Personal Thermo Cycler (BioRad) for 30 min at 16°C, 30 min at 42°C, followed by 5 min 
at 85°C, and then held at 4°C. RT products were diluted three times with 45 l of H2O prior to 
setting up PCR reaction. For each sample RT-PCR was carried out in triplicates. Each 10 μl 
reaction mixture included 1 μl of diluted RT product, 5 μl of 2 × TaqMan® Universal PCR Master 
Mix and 0.5 μl of 20× TaqMan® MicroRNA Assay. The reaction was incubated in a 7900 HT Real-
Time PCR System (Applied Biosystems) in 96- well plates at 95°C for 10 min, followed by 40 
cycles of the following steps: 95°C for 15 sec and 60°C for 1 min. To evaluate differences in 
miRNA expression, we used a relative quantification method. The expression of the miRNA target 
was standardized by a non-regulated small non-coding RNA that works as reference. U6 small 
nuclear RNA (U6 snRNA) (Applied biosystems - Assay ID 001973) was used as endogenous 
control because the level of this small RNA remains constant in the different atrophic conditions. 
The miRNA studied were miRNA-21 (Applied biosystems - Assay ID 000397), miRNA-206 
(Applied biosystems - Assay ID 000510) and miRNA-133b (Applied biosystems - Assay ID 
002247). The relative expression ratio was calculated using the 2
-Δ ΔCt 
(RQ, relative quantification) 
method.  
Gene expression analysis was performed by RT-PCR. Complementary DNA was generated 
using Superscript III Reverse transcriptase (Invitrogen #18080044). Brifley, 400ng of total RNA 
was incubated at 65°C for 5 minutes together with 1 l Random primer hexamers (50 ng/μl random) 
and 1 l dNTPs (10 mM each). This mix was then incubated for 2 minutes on Ice to allow the 
primers to align to the RNA. After this incubation the following reagents were added: 4 l of First 
strand buffer 5x, 1 l of DTT 100mM, 1 l of RNase Out (Invitrogen #11777019) and 0,5 l of 
Superscript III Reverse Transcriptase. This mixture was then incubated in a MJ Mini Personal 
Thermo Cycler (BioRad) for 5 min at 25°C, 60 min at 50°C, followed by 15 min at 70°C, and then 
held at 4°C. At the end of the RT reaction, the volume of each sample was adjusted to 50 l with 
RNase free water. 1 μl of diluted cDNAs were amplified in 10 μl PCR reactions in an ABI Prism 
7900HT (Applied Biosystem) thermocycler in 96-well plates. The Power SYBR Green PCR Master 
Mix (Applied Biosystem #4367659) was used for the Real-Time PCR reaction. Briefly, 5 l of 
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SYBR Green was mixed with 0,2 l of gene specific primers (50 M each) and with 4 l of water. 
The PCR mix was then incubated in a 7900 HT Real-Time PCR System (Applied Biosystem) in 96- 
well plates at 95°C for 10 min, followed by 40 cycles of the following steps: 95°C for 15 sec and 
60°C for 1 min.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To evaluate differences in miRNA expression, a relative quantification method was chosen 
where the expression of the mRNA is standardized by a non-regulated gene used as reference. Two 
genes were used as a reference:  glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and pan-
Actin. The relative expression ratio was calculated using the 2
-Δ ΔCt 
(RQ, relative quantification) 
method. The oligonucleotide primers used are described in Table 1. 
 
3.7- Cross-sectional area measurements  
 
Cross-sectional area of electroporated fibers was measured as described previously (Sandri 
et al., 2004a) and compared with the surrounding non electroporated myofibers (control). The 
pictures of the electroporated muscles were taken at 20x magnification. Fiber cross-sectional area 
Primer Sequence 
Atrogin-1-Fw 5’-GCAAACACTGCCACATTCTCTC-3’ 
Atrogin-1-Rv 5’-CTTGAGGGGAAAGTGAGACG-3’ 
GAPDH-Fw 5’-CACCATCTTCCAGGAGCGAG-3’ 
GAPDH-Rv 5’-CCTTCTCCATGGTGGTGAAGAC-3’ 
Pan-Actin-Fw 5’-CTGGCTCCTAGCACCATGAAGAT-3’ 
Pan-Actin-Rv 5’- GGTGGACAGTGAGGCCAGGAT-3’ 
YY1-Fw 5’-TGAGAAAGCATCTGCACACC-3’ 
YY1-Rv 5’-CGCAAATTGAAGTCCAGTGA-3’ 
eIF4E3-Fw 5’-AACATCCCTCCTGTGACCAG -3’ 
eIF4E3-Rv 5’-TCCAATGGTCGCTAACAACA-3’ 
PDCD10-Fw 5’-GGGCACTTGAACACCAAAAG-3’ 
PDCD10-Rv 5’-CAGGCCACAGTTTTGAAGGT-3’ 
PolK-Fw 5’-AGATCCCAGACACACCCTTG-3’ 
PolK-Rv 5’-GTCACGTAGGGGAGGCATTA-3’ 
Table 1:  List of primers used in Real Time experiments 
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was measured using IMAGE software (Scion, Frederick, MD). All data are expressed as the mean ± 
SEM. Comparison were made by using the student’s t test, with p<0.05 being considered 
statistically significant. 
 
3.8- Luciferase assays 
 
 Luciferase measurements in muscles electroporated with reporter constructs were performed 
using the Dual-Luciferase Reporter Assay System (Promega # E1910) adapting the manufacturer’s 
instructions. Briefly, muscles were powdered in liquid nitrogen before the addition of the lysis 
buffer. This suspension was submited to repeated cycles of freazing/thawn after which they are 
centrifuged (Serrano et al., 2001). The supernatant was analyzed according to the manufacturer’s 
instructions. To control for transfection efficiency, firefly luciferase activity was divided by renilla 
luciferase activity. Results are expressed as means ± SD of at least three different animals. 
In cells, luciferase assay was performed according to the manufacturer’s instructions. 
 
3.9- Cloning and Plasmids 
 
Transfection and electroporation experiments were preformed with the following constructs. 
pmiRZIP lentivector (ZIP NULL), pmiRZIP lentivector anti-miRNA-206 (ZIP-206) and pmiRZIP 
lentivector anti-miRNA-21(ZIP-21) were acquired from System Bioscience. pMIR206-Luc and 
pMIR21-Luc were acquired from Signosis BioSignal. Renilla Null and Renilla TK were acquired 
from Promega (pRL-null # E2271, pRL-TK # ). FoxO3 TM was kindly provided by M.E. 
Greenberg, and Ikk was kindly provided by P. M. Cànoves. 
The mature sequences of miRNA-206 and miRNA-21 were cloned into the BLOCK-iT PolII 
miR RNAi Expression Vector Kit with EmGFP (Invitrogen #K4936-00). The oligos used are shown 
in Table 2. As negative control the pcDNA6.2-GW/EmGFP-miR-neg control was used. This vector 
forms an hairpin structure that is processed into mature miRNA that is predicted not to target any 
known vertebrate gene. 
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To clone the 3’UTR of the different analyzed genes the following strategy was taken. RNA 
from muscle was retro-transcribed into cDNA and the region of interest was amplified by PCR. The 
primers were design to contain SpeI or NotI restriction sites as shown in Table2. The PCR product 
was purified and cloned into the pCR2.1-TOPO Vector (Invitrogen #45-0641). Both pCR2.1-TOPO 
vector and the pMIR206-LUC were opened with the restriction enzymes DpeI+NotI. The insert was 
cloned into the pMIR-LUC. All Constructs were sequenced to confirm the insert and the absence of 
mutation.  
 
 
 
 
 
 
Name  Sequence 
miRNA-206 – Top 5’-TGCTGTGGAATGTAAGGAAGTGTGTGGGTTTTGGCCACTGACTGACCCACACACCC TACATTCA-3 
miRNA-206 – Bottom 5’-CCTGTGAATGTAGGGTGTGTGGGTCAGTCAGTGGCCAAAACCCACACACTTCCTTACATTCCAC-3 
miRNA-21 – Top 5’-TGCTGTAGCTTATCAGACTGATGTTGAGTTTTGGCCACTGACTGACTCAACATCTCTGATAAGCTA-3’ 
miRNA-21 – Bottom 5’-CCTGTAGCTTATCAGAGATGTTGAGTCAGTCAGTGGCCAAAACTCAACATCAGTCTGATAAGCTAC-3’ 
YY1-3’UTR-Fw 5’-GCCTCTTCAGGAGTGTGATTG-3’ 
YY1-3’UTR-Rv 5’-CAATTTCTGGGAGGCTCAAG-3’ 
eIF4E3-3’UTR-Fw 5’-TCTGCCATCGTATCACTTGC-3’ 
eIF4E3-3’UTR-Rv 5’-GCCTCTTACGCTCTGACCAC -3’ 
PDCD10-3’UTR-Fw 5’-ACTAGTCCAGGATGTTGAATGGGATT -3’ 
PDCD10-3’UTR-Rv 5’-GCGGCCGCAAGTAAAGAAATGTTTAACA-3’ 
PolK-3’UTR-Fw 5’-ACTAGTCCTTTAAGGAAGACAAGTGCAA-3’ 
PolK-3’UTR-Rv 5’-GCGGCCGCCAACAAAAATAAACTTCAGATGGAA-3’ 
YY1-CR-Fw 5’-GCCATGGCCTCGGGCGACACCCTCTAC-3’ 
YY1-CR-Rv 5’-CTGGTTGTTTTTGGCTTTAGCGTG-3’ 
eIF4E3-CR-Fw 5’-AACATGGCGCTGCCCCCGGCTGCC-3’ 
eIF4E3-CR-Rv 5’-GTGTTTTCCACGTCCACCTTCAAA-3’ 
Table 2: List of primers used for the cloning experiments 
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In order to confirm the specific binding of the respective miRNAs on the 3’UTR of eIF4E3, 
the binding sites for miRNA-206 and for miRNA-21 were mutated. The approach used consisted in 
mutate or delete 3 nucleotides of the seed region of each miRNA-binding site. Therefore the 
following mutants were created: eIF4E3 Mut206, eIF4E3 Del206, eIF4E3 Mut21 and eIF4E3 
Del21. For the mutagenesis of the eIF4E3-3’UTR-Luc vector the QuickChangeII site-directed 
Mutagenesis Kit (Stratagene #200524) was used. Briefly, 20ng of eIF4E3-3’UTR-Luc vector was 
used per reaction. A 50 l reaction contained 5 l of 10xReaction buffer, 250 ng of each primer, 1 
l of dNTP mix, 2.5 l of DMSO (5% final concentration) and 1 l of PFU ultra DNA polymerase. 
This mixture was then incubated in a MJ Mini Personal Thermo Cycler (BioRad) for 30 sec at 95°C 
to denature the vector followed by 20 cycles of 30 sec at 95°C, 1 min at 55°C, and 15 min at 68 °C 
and then held at 4°C. After this amplification step with the mutated primers, this reaction was 
digested for 2h with 1 l of DpnI enzyme in order to degrade the original template. After this step, 
4 l of this digested reaction mix was transformed into XL-Gold Ultracompetent bacterias 
(Stratagene #200314) according to the instruction manual. All the mutated constructs were 
sequenced to confirm the presence of the desired mutations and the absence of other unspecific 
Primer Sequence 
eIF4E3_mut-206_forw 5'-AAAGTCAGGGGCCTCCACTTGAAGCGCTAAACAGGAAGCCAAATTA-3' 
eIF4E3_mut-206_rev 5'-TAATTTGGCTTCCTGTTTAGCGCTTCAAGTGGAGGCCCCTGACTTT-3' 
eIF4E3_del-206_forw 5'-GGGCCTCCACTTGCGCTAAACAGGAAGC-3' 
eIF4E3_del-206_rev 5'-GCTTCCTGTTTAGCGCAAGTGGAGGCCC-3' 
eIF4E3_mut-21_forw 5’-GCCTAGCAAAACCCTTTTTCTGCTGCATTGTTGTGACACTTCCCTGCA-3' 
eIF4E3_mut-21_rev 5'-TGCAGGGAAGTGTCACAACAATGCAGCAGAAAAAGGGTTTTGCTAGGC-3' 
eIF4E3_del-21_forw 5'-TAGCAAAACCCTTTTTCTGAATTGTTGTGACACTTCCCTG-3' 
eIF4E3_del-21_rev 5'-CAGGGAAGTGTCACAACAATTCAGAAAAAGGGTTTTGCTA-3' 
Yy1_mut-1_forw 5'-GTGCATATTGTACACTTTTTGGGGATCTTATTAGTAATGCTGTGTGATTTTCTGGA-3' 
Yy1_mut-1_rev 5’-TCCAGAAAATCACACAGCATTACTAATAAGATCCCCAAAAAGTGTACAATATGCAC-3' 
Yy1_mut-2_forw 5'-GCTGTGTGATTTTCTGGAGGTTGATCGCTGTGCTTGCGGTAGATTTTCTTT-3' 
Yy1_mut-2_rev 5'-AAAGAAAATCTACCGCAAGCACAGCGATCAACCTCCAGAAAATCACACAGC-3' 
Yy1_del-1_forw 5'-CATATTGTACACTTTTTGGGGATATTAGTAATGCTGTGTGATTTTCT-3' 
Yy1_del-1_rev 5'-AGAAAATCACACAGCATTACTAATATCCCCAAAAAGTGTACAATATG-3' 
Yy1_del-2_forw 5'-GTGATTTTCTGGAGGTTGACTTTGCTTGCGGTAGATTT-3' 
Yy1_del-2_rev 5'-AAATCTACCGCAAGCAAAGTCAACCTCCAGAAAATCAC-3' 
Table 3: List of primers used for the mutagenesis experiments 
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mutations. The primers used for the mutagenesis are shown in Table 3. The same approach is 
currently being taken for the YY1-3’UTR-Luc vector. 
The coding regions of YY1 and of eIF4E3 were cloned into the pcDNA3.1/V5-His TOPO 
(Invitrogen #K4800-01). Briefly, the coding regions of these genes were PCR amplified from 
skeletal muscle cDNA using the primers shown in Table 2. PCR products were purified and cloned 
into the pcDNA3.1/V5-His TOPO Vector according to the manufacturer’s instructions. All 
Constructs were sequenced to confirm the insert and the absence of mutation. 
 
 3.10- Protein extraction and Western blotting 
 
Total proteins were extracted from MEFs or C2C12 by solubilization in lysis buffer 
containing 50 mM Tris, pH 7.5, 150 mM NaCl, 5 mM MgCl2, 10% glycerol, 1 mM DTT, 1 mM 
EDTA, 0.5% Triton X-100, Phosphatase inhibitor cocktail 2 (Sigma #P5726) and Phosphatase 
inhibitor cocktail 3 (Sigma #P0044) and Complete EDTA-free protease inhibitor mixture (Roche # 
11836145001). Protein concentration was quantified using the Bradford method (Bio-Rad Protein 
Assay - BioRad #500-0006).  
Total proteins were extracted from whole muscle or from 20 slices of 20 m of thickness by 
using the following lysis buffer: 50 mM Tris, pH 7.5, 150 mM NaCl, 5 mM MgCl2, 10% glycerol, 
2% SDS, 1% Trirton X-100, 1mM DTT, Phosphatase inhibitor cocktail 2 and Phosphatase inhibitor 
cocktail 3 and Complete EDTA-free protease inhibitor mixture. Protein concentration was 
quantified using the BCA method ( BCA Protein Assay Kit – Thermo Fisher Scientific #23227).  
50 µg of the whole-cell lysates was loaded and separated on 4–12% precast Bis–Tris 
NuPAGE gels (Invitrogen #NP0323). Proteins were transferred to Hybond-ECL Nitrocululose 
membrane (GE Healthcare #RPN303D) and stained with Ponceau S solution (Sigma-Aldrich) to 
verify the efficiency of the transfer. The blots were incubated in blocking buffer (TBS, 0.1% Tween 
20, and 5% nonfat milk) for 1 h at room temperature. Membranes were washed in washing buffer 
(TBS and 0.1% Tween 20) three times for 5 min each, probed with the primary antibody in TBS, 
0.1% Tween 20, and 2% nonfat milk overnight at 4°C, and then probed with the secondary antibody 
for 1 h in TBS, 0.1% Tween 20, and 2% nonfat milk. The antibody reaction was analyzed using the 
ECL method (SuperSignal West Pico Chemiluminescent substrate - Thermo Fisher Scientific 
#34080).  
The following antibodies from Santa Cruz Biotechnology were used: anti-YY1 (C-20) (# sc-
281) and anti-eIF4E3 (V-22) (sc-133542). 
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4.1- Overview of the miRNA expression profiles in different atrophic 
conditions. 
 
Gene expression analysis of muscles resulting from 
different atrophic conditions allowed the identification of a 
group of atrophy-related mRNAs that are transcriptionally 
regulated. To understand if these catabolic conditions also 
regulate miRNAs expression and if atrophy-related miRNAs 
exist, we carried out comparative miRNA expression profiles. 
Briefly, a pool of miRNAs obtained from control 
gastrocnemius muscles was hybridized, in a competitive way, 
with miRNAs obtained from gastrocnemius muscles of 
diabetic-, starved- and denervated-mice. This approach identified miRNAs specific of each 
catabolic condition and miRNAs that are shared in more than one condition.  
Fig 14: Do multiple types of skeletal 
muscle atrophy share common miRNAs?  
Fig 15: miRNA expression profile in different atrophic condition. Hierarchical clustering of 
atrophic samples compared to the respective controls. Ninety miRNAs were differently expressed 
between controls and atrophic gastrocnemius (n≥3). A color code represents the relative intensity of 
the expression signal when compared to the control samples, with red indicating higher expression 
levels and green indicating lower expression levels. 
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A platform that contains approximately 400 known miRNA (miRBase - Release 9) was used 
for the miRNA expression microarray. Importantly, starvation and denervation were analyzed at 
different time points to understand the kinetic of the miRNA response in these atrophic conditions. 
The miRNAs expression profiles obtained for each atrophic condition were hierarchically 
clustered using the Pearson correlation coefficient. Using this approach a significant association of 
the different atrophic conditions was obtained. According to the hierarchical clustering dendrogram 
(Fig 15.) the two different starvation time points grouped together. These two conditions were 
extremely complicated to analyze since the different biological replicates were very variable among 
them. Still, according to the obtained results there is no significant variation between the two 
conditions. Also denervation 
experiments grouped together, 
mainly at 7 and 14 days. Short term 
denervation, 3 days, gave a peculiar 
expression profile since the majority 
of the analyzed miRNAs were 
unaltered or were down-regulated 
when compared to the controls. A 
completely independent profile was 
obtained from the diabetic muscles 
(7 days after treatment with STZ) in 
which the vast majority of the 
studied miRNAs appeared up-
regulated. Altogether these results 
show that each atrophic condition 
has a particular miRNA expression 
profile. Furthermore, the results 
seem to indicate that the miRNA regulation is delayed compared to mRNA control. In fact mRNA 
changed their expression profile at earlier time points, immediately after the catabolic condition 
appears, while miRNA changes require a certain time. For instance, in denervated muscle the peak 
of mRNA changes happens at 3 day of denervation while the peak of miRNA alteration occurs at 14 
day of denervation. 
Fig 16: List of miRNAs that are significantly deregulated in atrophic 
conditions (p<0.05).  The expression value results from the average of the 
Ln (atrophic sample/control) and represented in a colorimetric scale. 
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A more detailed statistical analysis was performed 
to try to identify possible miRNAs that change their 
expression in all the atrophic conditions. This analysis was 
not conclusive as we can see from Fig 16 that represents 
the miRNAs commonly altered in all atrophic conditions. 
Although the expression of these miRNAs was 
deregulated, their expression pattern is not the same in all 
the studied conditions.  
Nevertheless, the analyses of each atrophic 
condition allowed the identification of the miRNAs that 
are persistently up- or down-regulated at different times 
and allow to determine whether these miRNAs are shared 
by another atrophic condition. Using this approach a group 
of 52 miRNAs were found to be deregulated in at least 3 
of the 6 conditions studied (Fig 17). According to this 
analyze most of the deregulated miRNAs are up-regulated 
in long lasting atrophic conditions. Indeed, there are 21 
miRNAs up-regulated after 7 days of denervation, 32 
miRNAs up-regulated after 14 days of denervation and 61 
miRNAs up-regulated after 7 days of STZ-induced 
diabetes. Among the up-regulated miRNAs two of them 
are particularly over-expressed during denervation. These 
are miRNA-21 and miRNA-206. Indeed, these two 
miRNAs are also up-regulated during STZ-induced 
diabetes and miRNA-206 is also induced after 48h of 
starvation. Also the Let-7 family is induced in 3 atrophic 
conditions, 14 days of denervation, diabetes and 48h of 
starvation. This is also the case of miRNA-181a that is 
induced in 7 days of denervation, diabetes and 48h of 
starvation.  
About the down-regulated miRNAs, the family of miRNA-30 is interesting since the 
expression of several members is reduced during denervation (7 and 14 days) and during starvation. 
Also miRNA-145 is strongly inhibited during these conditions. Conversely, miRNA-494 is peculiar 
since it is the only miRNAs down-regulated during STZ-induced diabetes. 
Fig 17: Schematic representation of the 
miRNAs differently expressed in at least 3 of 
the 6 atrophic conditions studied (p<0.05) 
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4.2- Validation of the microarray results. 
  
To obtain a more accurate quantification 
and to validate the results from the miRNA 
expression profile we decided to use TaqMan 
quantitative real time RT-PCR.  
The previous analyses have underlined 
that the two most and commonly up-regulated 
miRNAs were miRNA-21 and miRNA-206. In 
the microarray, miRNA-206 expression levels 
were increased in denervation, mainly after 7 
and 14 days from the cut of the sciatic nerve, 
diabetes and 48h of starvation. On the other 
hand, miRNA-21 was only up regulated in 
denervation, 7 and 14 days, and diabetes while it 
is down-regulated in starvation.  
When we monitored the expression of 
miRNA-206 in denervated muscles by 
quantitative RT-PCR we confirmed a 
progressive up-regulation of its expression that 
reaches its maximum of 20 fold induction at day 
14 after denervation (Fig 18). 48 hours of 
starvation led to a two-fold up-regulation of 
miRNA-206 expression levels while STZ-
induced diabetes didn’t significantly altered 
miRNA-206 expression levels.  
MiRNA-21 showed a different pattern of 
expression being up-regulated already at 3 days 
of denervation and then remaining constantly at 
this level during the other time points (Fig 19). 
Fig 18: miRNA-206 expression levels during different 
atrophic conditions quantified by TaqMan RT-PCR. (a)  
Quantification of miRNA-206 expression level during 
different time points of Denervation (n=3 for each time point). 
U6 was used to normalize the expression levels. (b) 
Quantification of miRNA-206 expression level after 48h of 
Starvation (n=3). SnoRNA202 was used to normalize the 
expression levels (c) Quantification of miRNA-206 expression 
level during Streptozotocin–induced diabetes (n=5). U6 was 
used to normalize the expression levels. Values represent 
mean ± STD. * p<0.05, **p<0.01 by T-Test. 
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Starvation on the other hand leads to a 50% 
decrease in the expression level of this 
miRNA while diabetes didn’t significantly 
change its expression level. Altogether, these 
results confirmed the data obtained in the 
microarray except for the diabetes condition.  
Considering these results we decided 
to focus on denervation since it is the 
atrophic condition that induces a more robust 
up-regulation of these two miRNAs. In order 
to better validate the functional meaning of 
this up-regulation we decided to use a 
luciferase assay. This approach reveals the 
activity of endogenous miRNAs. Briefly, we 
have used a vector that, in the 3’UTR of the 
Luciferase gene contains a binding site for 
the studied miRNA. In this way, an up-
regulation of the miRNA expression level 
leads to a reduction in the luciferase protein. 
These miRNA-Luc sensors were 
electroporated into TA muscles of adult mice 
and then animals were denervated. As shown 
in Fig 20, Luciferase activity of miRNA21 and 
miRNA 206 sensors is significantly reduced 
after 7 days of denervation. These findings 
support the results of the expression profiling 
and indicate an increase activity of both 
miRNAs during denervation.  
Fig 19: miRNA-21 expression levels during different atrophic 
conditions quantified by TaqMan RT-PCR. (a)  Quantification 
of miRNA-21 expression level during different time points of 
Denervation (n=3 for each time point). U6 was used to normalize 
the expression levels. (b) Quantification of miRNA-21 expression 
level after 48h of Starvation (n=3). SnoRNA202 was used to 
normalize the expression levels. (c) Quantification of miRNA-21 
expression level during Streptozotocin–induced diabetes (n=5). 
U6 was used to normalize the expression levels. Values represent 
mean ± STD. * p<0.05, **p<0.01 by T-Test. 
 
Chapter 4 – miRNA expression signature in different atrophic condition 
 
 78 
 
Fig 20: miRNA-206 and miRNA-21 are up-regulated during Denervation. (a) Schematic representation of the 
pMIR-LUC vector used to quantify the miRNA expression levels by luciferase assay. These vectors contain a 
CMV promoter, a firefly Luciferase Gene and a unique miRNA binding site at the 3’UTR region of the Luciferase 
gene . Whenever these miRNA is expressed, it binds to the perfectly complementary sequence resulting in 
repression of the luciferase gene expression. More than detecting the mature miRNAs levels this method measures 
miRNAs activity. (b) Quantification by Luciferase Assay of the miRNA-206 and miRNA-21 activity after 7 days 
of denervation. T.A. muscles were electroporated with 10ug of Luciferase sensor (206Luc or 21Luc) and with 5ug 
of Renilla Null (to normalize electroporation). One of the legs was denervated by severing the sciatic nerve. 
Luciferase levels were measured 7 days after denervation. (n≥4) Values represent mean ± STE. * p<0.05 by T-
Test. 
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These results confirm a functional induction of miRNA-21 and mRNA-206 in atrophying 
muscles. However, different muscles have different properties and therefore differently respond 
to catabolic signals. In order to understand whether the miRNA response after 15 days of 
denervation was similar between fast and slow muscles we evaluated the expression level of 
miRNAs in TA, a glycolitic muscle, and Soleus, an oxidative muscle. Importantly, the expression 
of miRNA-206 significantly increased in both TA and Soleus denervated muscles Fig 21. 
Interestingly, the basal levels of miRNA-206 in the Soleus was higher than in the TA. To what 
concerns miRNA-21, 15 days of denervation also induced its expression in both types of 
muscles. The basal expression of miRNA-21 was slightly lower in Soleus than in TA but the 
increase was more important in slow than fast muscle. Altogether these results suggest an 
involvement of miRNA-206 and miRNA-21 in muscle atrophy during denervation. 
  
Fig 21: Denervation leads to an up-regulation of miRNA-206 and miRNA-
21 both in fast and slow muscles. (a) Quantification of miRNA-206 expression 
level by TaqMan RT-PCR after 15 days of denervation in T.A and in Soleus 
muscle. (n=4). U6 was used to normalize the expression levels. (b) 
Quantification of miRNA-21 expression level by TaqMan RT-PCR after 15 
days of denervation in T.A and in Soleus muscle. (n=4). U6 was used to 
normalize the expression levels. Values represent mean ± STE. * p<0.05, 
**p<0.01 by T-Test. 
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4.3- miRNA-21 and miRNA-206 expression is independent of its host genes 
 
 A close analysis at the genomic localization of these miRNAs, revealed that miRNA-206 is 
a intergenic polycistronic miRNA encoded together with miRNA-133b, while miRNA-21 is located 
on the 10
th
 intron of the protein coding gene Vacuole Membrane Protein 1 (VMP1/TMEM49).  
Considering that miRNA-133b is embedded in the same genomic region of miRNA-206 and 
that shows the same muscle-specific pattern of expression of miRNA206, we monitored whether its 
expression changes in response atrophy. Fig 22 shows that miRNA-133b was significantly down–
regulated after 3 days of denervation, returning later on to basal level. During starvation and 
diabetes miRNA133b did not significantly 
change the level of expression. These 
results suggest that miRNA-206 is 
regulated independently of its polycistronic 
companion, miRNA-133b.  
Interestingly VMP1, is a protein 
implicated in the autophagic process since 
it is localized in the autophagossome and 
interacts with Beclin-1 (Vaccaro et al., 
2008). As discussed already, autophagy is 
Fig 22: miRNA-206 expression is independently regulated. 
(a), (b), (c) Expression levels of miRNA-133b, present in the 
same transcription unit than miRNA-206, during denervation, 
starvation and diabetes, respectively. U6 was used to 
normalize the expression levels. (n≥3) Values represent mean 
± STD. * p<0.05 by T-Test. 
 
Fig 23: miRNA-21 expression is independently regulated. 
Expression levels of Tmem49, the host gene of miRNA-21, during 
starvation (24h) or denervation (7 days). GAPDH  was used to 
normalize the expression levels of TMEM49. (n≥3) Values 
represent mean ± STD. * p<0.05 by T-Test. 
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one of the processes implicated in the protein degradation during skeletal muscle atrophy and 
consequently we decided to analyze the expression levels of this protein in denervation and 
starvation. Since the mRNA levels of VMP1 remain constant in all the atrophic conditions studied, 
we concluded that miRNA-21 is transcribed independently from its host gene confirming previous 
published data. (Fujita et al., 2008). 
 
4.4- miRNA-21 and miRNA-206 expression levels are affected by FoxO3 and 
NF-
Skeletal muscle atrophy is a tightly regulated process at the transcriptional level, being 
FoxO3 and NF- B two of the most important players. On the other hand miRNAs transcriptional 
regulation is a process poorly understood. Thus we decided to investigate whether FoxO3 and NF-
B transcriptional factors are also implicated in the up-regulation of these two miRNAs. Initially, 
the consensus binding sites for FoxO3, G/ATAAAT/CA., and for NF- B, GGGA/GNNT/CT/CCC, 
were searched in the 10 Kb region upstream pre-miRNA-21 and pre-miRNA-206. As documented 
in Fig 24 the putative promoter region of miRNA-206 contains 4 binding sites for FoxO and 1 for 
Fig 24: miRNA-21 and miRNA-206 
expression levels are affected by FoxO3 
and NF-Kb. (a) Schematic representation 
of the regulatory region of the miRNA-206 
and miRNA-21. The binding site for FoxO 
and Nf-Kb were searched in the 10Kb up-
stream each of these miRNAs. (b) 
FoxO3TM and IKKb increase the activity 
of miRNA-206. 10 g of the luciferase 
sensor for miRNA-206 (206Luc) were 
electroporated in T.A. muscle in the 
presence of 20 g of pcDNA3 (empty 
vector), FoxO3TM or IKKb expressing 
vector. A Renilla vector (5 g) was 
cotransfected to normalize for transfection 
efficiency. Fifteen days later, 
Luciferase/Renilla levels were measured. 
(n=8) Values represent mean ± STD. * 
p<0.05, ** p<0.01 by T-Test. (c) 
FoxO3TM and IKKb increase the activity 
of miRNA-21. 10 g of the luciferase 
sensor for miRNA-21 (21Luc) were 
electroporated in T.A. muscle in the 
presence of 20 g of pcDNA3 (empty 
vector), FoxO3TM or IKKb expressing 
vector. A Renilla vector (5 g) was 
cotransfected to normalize for 
electroporation efficiency. Fifteen days 
later, Luciferase/Renilla levels were 
measured. (n=4) Values represent mean ± 
STD. * p<0.05, ** p<0.01 by T-Test.  
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NF- B. On the other hand miRNA-21 contains 4 binding sites for FoxO and no predicted binding 
site for NF- B. 
To understand whether these transcription factors can affect miRNA expression TAs were 
electroporated either with c.a.FoxO3 or with IKK , an activator of NF- B (Cai et al., 2004), 
together with the Luciferase sensor for miRNA-206 or for miRNA-21. The presence of FoxO3 or 
NF- B significantly decreased the levels of luciferase sensor for both miRNA-206 and miRNA-21, 
consistent with an up-regulation of both miRNAs (Fig 24). However, these experiments can’t 
distinguish between a direct regulation of miRNAs by these transcription factors and an indirect 
effect consequent to muscle atrophy. To further investigate these two possibilities we have taken 
advantage of muscle specific FoxO1,3,4 KO animals that have been generated in the Sandri Lab. 
These mice show low levels of FoxO1, FoxO3 and FoxO4 proteins. We denervated these animals 
and the expression levels of these miRNAs were measured. Denervation led to a similar increase of 
Fig 25: FoxO is not responsible for the denervation-induced up-regulation of miRNA-21 and miRNA-206 (a) FoxO is 
not required for the up-regulation of miRNA-206 expression levels. TaqMan RT-PCR for miRNA-206 was performed on 
RNA extracted from T.A. muscles of WT and FoxO 1, 3 and 4 triple knock-out mice. Denervated muscles, 15 days after 
sciatic nerve severing, were compared to the contra-lateral muscles. (n=2) Values represent mean ± STD. * p<0.05, ** 
p<0.01 by T-Test. (b) FoxO is not required for the up-regulation of miRNA-21 expression levels. TaqMan RT-PCR for 
miRNA-21 was performed on RNA extracted from T.A. muscles of WT and FoxO 1, 3 and 4 triple knock-out mice. 
Denervated muscles, 15 days after sciatic nerve severing, were compared to the contra-lateral muscles. (n=2) Values 
represent mean ± STD. * p<0.05, ** p<0.01 by T-Test.  
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both miRNAs in Wt and KO animals (Fig 25), indicating that FoxOs are not necessary for the 
transcriptional regulation of these 2 miRNAs. The same analysis was impossible to do for NF-  
since we don’t have available the respective knockouts mice. 
 
4.5- miRNA-206 and miRNA-21 cooperate synergistically to induce skeletal 
muscle atrophy 
 
In order to address the biological role 
of miRNA-206 and miRNA-21 in adult 
skeletal muscle we have cloned the mature 
sequence of these miRNAs into a co-cistronic 
vector that also express the GFP under the 
control of the same CMV promoter (Fig 26). 
When used in vivo, GFP fluorescence allows 
the recognition of the electroporated fibers 
over-expressing the mature miRNA. The 
over-expression of these vectors in C2C12 
myoblasts lead to a significant up-regulation 
of the mature miRNAs, as detected by 
TaqMan RT-PCR (Fig 27) In order to deliver 
these vectors in vivo, we used the electroporation technique. This approach is designed to deliver 
DNA vectors specifically into adult skeletal muscle fiber, without transfecting other cell types 
present in the muscle, including the satellite cells, the muscle stem cell. To confirm that mature 
Fig 26: miRNA overexpressing vector. The pcDNA6.2-
GW/EmGFP-miR vector makes possible the over-expression 
of the pre-miRNAs. Under a CMV promoter, this co-cistronic 
vector allows the expression of the GFP together with the 
desired pre-miRNA. When electroporated in vivo, the presence 
of the GFP permits the identification of the electroporated 
fibers. 
Fig 27: Over-expressing vectors efficiently induce an in vitro up-regulation of the miRNAs levels (a), (b) Transfection 
of the miRNAs- over-expressing vectors into C2C12 myoblasts leads to an effective increase in the mature miRNAs levels. 
TaqMan RT-PCR for miRNA-206 (b) or for miRNA-21 (c) was performed on RNA extracted 48h after the transfection 
with the respective over-expressing vectors (4 g). U6 was used to normalize the expression levels of the miRNAs. (n=3) 
Values represent mean ± STD. * p<0.05, ** p<0.01 by T-Test. 
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miRNAs are expressed only in adult fibers we stained the transfected muscles with a -dystrophin 
antibody. Dystrophin is expressed only in adult myofiber and is localized immediately below the 
plasma membrane. As expected, GFP expression has been found only within dystrophin positive 
fibers (Fig 28 a,b) . Importantly, no mononucleated cells dystrophin negative were positive for GFP, 
indicating that only adult skeletal muscle fibers were electroporated. We then monitored the level of 
expression of mature miRNA in transfected muscles. Indeed, we found an up-regulation of 2-3 fold 
in these muscles. (Fig 28 c,d). 
 
 
Fig 28: Over-expressing vectors efficiently induce an in vivo up-regulation of the miRNAs levels (a), (b) Adult 
muscle fibers are efficiently electroporated with the miRNAs over-expressing vectors (20 g). GFP staining denotes the 
presence of the EmGFP-miRNA over-expressing vector for miRNA-206 (a) or miRNA-21 (b). In red, anti-dystrophin 
staining delineates the fiber boundaries. In blue, DAPI staining evidences the fiber nuclei. (c), (d) Electroporation of the 
miRNAs over-expressing vectors into adult T.A. muscles leads to an effective, but variable, increase in the mature 
miRNAs levels. TaqMan RT-PCR for miRNA-206 (c) or for miRNA-21 (d) was performed on RNA extracted from 
T.A. muscles, 10 days after electroporation with the respective over-expressing vectors (20 g). U6 was used to 
normalize the expression levels of the miRNAs. (n=2) Values represent mean ± STE. 
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To further prove that the over-expressed miRNA were also functional and able to suppress 
translation of target transcript in vivo we used the luciferase miRNA sensor (Fig 29). Muscles were 
electroporated with the specific sensor of each miRNA in the presence or absence of the miRNA 
vector. Over-expression of miRNA-206 or miRNA-21 dramatically reduced by 80% the luciferase 
of their specific sensors confirming that these vectors are able to produce functional miRNAs in 
vivo.  
Figure 29: In vivo electroporation of miRNA-206 and miRNA-21 efficiently increase the activity of these two 
miRNAs. Electroporation of the Luciferase sensor (10 g) for each miRNAs in the presence of the respective miRNAs 
(20 g) decrease the Luciferase levels, 7 days after electroporation. Renilla (5 g) was cotransfected to normalize for 
electroporation efficiency. (n=5) Values represent mean ± STE. * p<0.05, by T-Test. 
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Next we used these 
vectors to over-express these 
miRNA in normal muscle, in 
order to mimic the denervated 
muscles, and in denervated 
muscle to anticipate their 
expression. In fact, we have 
shown that the miRNA 
response to an atrophic stimulus 
is delayed when compared to the transcriptional response. In fact, atrogin-1 and Murf-1 mRNA 
reach the peak of their expression at 3 days of denervation and start to return to basal expression 
Fig 30: miRNA over-expression does not 
protect from denervation induced 
atrophy but rather it induces an atrophic 
phenotype. (a) Over-expression of miRNA-
206 during denervation induces a reduction 
in the C.S.A. of the fibers. Adult T.A. 
muscles were electroporated with the Neg. 
Control (20 g) or with the miRNA-206 
(20 g) over-expressing vector. 
Simultaneously, the right leg was 
denervated by severing the sciatic nerve. 
Cross-sectional area of transfected fibers, 
identified by the presence of GFP, was 
measured 10 days after electroporation. 
(n≥3 muscles) Values represent mean ± 
STE. ** p<0.01, by T-Test. (b) Over-
expression of miRNA-21 in denervated 
muscles induces a reduction in the C.S.A. of 
the fibers. Adult T.A. muscles were 
electroporated with the Neg. Control (20 g) 
or with the miRNA-21 (20 g)  over-
expressing vector. Simultaneously, the right 
leg was denervated by severing the sciatic 
nerve. Cross-sectional area of transfected 
fibers, identified by the presence of GFP, 
was measured 10 days after electroporation. 
(n≥3 muscles) Values represent mean ± 
STE. ** p<0.01, by T-Test. (c) Over-
expression of miRNA-206, at basal 
conditions, induces a reduction in the 
C.S.A. of the fibers and the presence of 
miRNA-21 potentiates this effect. Adult 
T.A. muscles were electroporated with the 
Neg. Control (20 g), miRNA-206 (20 g), 
miRNA-21 (20 g) or both miRNAs (20 g 
each). Cross-sectional area of transfected 
fibers, identified by the presence of GFP, 
was measured 10 days after electroporation. 
(n≥3 muscles) Values represent mean ± 
STE. * p<0.05, ** p<0.01, by T-Test. 
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immediately. Conversely, the expression of miRNA-206 is elevated at 7 days of denervation and 
reaches its peak at 14 days while miRNA 21 reach a plateau at 3 days of denervation that is 
maintained afterward. Therefore, we have hypothesized that these miRNAs might slow down the 
atrophic program by down regulating critical atrophy-related transcripts. In fact muscle loss occurs 
mainly during the first 7 days of denervation and then it is progressively reduced especially after 14 
days of denervation. To test this hypothesis we have electroporated miRNA expressing vectors in 
denervated and respective controlateral muscles and then we have monitored myofiber size. 
Interestingly, the expression of miRNA206 was sufficient to induce a 10% decrease of CSA when 
compared to controls (Fig 30 a, c). Moreover miRNA 206 over-expression did not protect from 
atrophy (Fig 30a). Denervated muscle fibers over-expressing miRNA-206 are 10% smaller than 
denervated controls. These findings suggest that miRNA-206 does not interfere with the atrophy 
program but instead is part of this process. When miRNA-21 was expressed in control innervated 
muscles, no major differences were observed when compared with negative controls. However, 
after denervation, miRNA21 expression enhanced muscle atrophy by 11% (Fig 30b). These results 
suggest that these 2 miRNAs don’t have a role in slowing down the atrophic process, but rather 
might contribute to potentiate the atrophic program.  
In order to understand whether they can have a synergistic action we expressed the two 
miRNAs separately or in combination in normal muscles (Fig 30c). When we measured the 
myofiber size we could confirm that miRNA-206 induced a significant reduction in the CSA while 
miRNA-21 didn’t show any effect on CSA. However, the co-expression of both miRNAs showed a 
synergistic effect, leading to a 20 % reduction in the CSA.  
 
4.6- miRNA-206 activates the promoter of Atrogin-1 
 
Given that these two miRNAs contributes to myofiber atrophy we monitored whether they 
were able to regulate the expression of Atrogin-1 and Murf-1, the two E3-ligases involved in 
protein breakdown. Thus, we transfected adult TA with the luciferase sensors that contain the 
promoter region of Atrogin-1 or MuRF1 in presence or absence of the miRNAs.  As shown in Fig 
31, only miRNA-206 was able to activate the Atrogin-1 promoter. Surprisingly, the co-expression 
of both miRNAs did not alter the activity of the promoter. On the other hand, the promoter of Murf-
1 was repressed by the presence of both miRNAs. Therefore, it is possible that miRNA-206 causes 
atrophy at least partially via activation of atrogin-1.  
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Fig 31: Effect of the over-expression of miRNAs on the promoter activity of 
atrogin1 and murf1. Electroporation of the promoter fused with the luciferase sensor 
(10 g) for atrogin1 and murf1 in the presence of miRNA206 (20 g) or miRNA-
206+miRNA-21(20 g each). Renilla (5 g) was co-electroporated to normalize for 
electroporation efficiency. 7 days after electroporation muscles were analyzed (n=4) 
Values represent mean ± STD. ** p<0.01, by T-Test. 
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4.7- Inhibition of miRNA-206 and miRNA-21 partially protects from 
denervation-induced atrophy. 
 
Since the over-expression of these miRNAs 
induces atrophy, we wondered whether their inhibition 
was protective against denervation-induced atrophy.  
The inhibition of miRNAs can be accomplished 
by the use of RNA molecules with different steric 
modifications. These molecules can be systemically 
delivered by intra-venous or sub-cutaneous injection, 
however the side effects of this systemic inhibtion are not 
well known. To avoid this problem we used a DNA 
vector, called miRZIP (Fig 32), that continuously 
produces the antisense RNA molecule for the miRNA of 
interest. Therefore, the produced anti-sense RNA 
molecules bind to the miRNA and act as sponge 
reducing the amount of free miRNA that can bind to the 
targets. This vector also expresses the GFP under a 
CMV promoter, therefore allowing the visualization of 
the electroporated fibers. To validate the function of 
these vectors we performed a luciferase assay in C2C12 muscle cell line. Briefly, a luciferase sensor 
for miRNA-21 or for miRNA-206 was transfected together with an empty miRZIP (Zip Null) vector 
Fig  32: Vector to over-express the antisense of 
specific miRNAs. The pmiRZIP lentiviral vector 
express a hairpin interfering RNA that is design to 
generate a full-length antisense miRNA that 
specifically target and antagonize a specific 
endogenous miRNA. These hairpins are transcribed 
from a constitutive H1 promoter. In order to identify 
the transfected/electroporated fibers these vector 
also express a copGFP, under a CMV promoter. 
Fig 33: Vectors to inhibit specific miRNAs efficiently reduce the miRNAs levels in vitro. (a), (b) Transfection of the 
miRZIP over-expressing vectors into C2C12 myoblasts leads to an effective decrease in the activity of the mature 
miRNAs. Luciferase assay for miRNA-206 (b) or for miRNA-21 (c) was performed on C2C12 myoblasts. Cells were 
transfected with the luciferase sensor for the respective miRNAs (0.5 g) in the presence of the empty vector or in the 
presence of the specific miRZIP vector (3.25 g). Renilla (0.25 g) was co-transfected to normalize for transfection 
efficiency. 24h after transfection Luciferase levels were measured. (n=3) Values represent mean ± STD.  ** p<0.01 by T-
Test. 
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or with miRZIP-206 or with miRZIP-21 respectively. Each specific miRZIP successfully increased 
the luciferase activity (Fig 33). These data are consistent with a reduction of the free miRNAs and 
therefore confirm that these vectors can efficiently block the target miRNA.  
In order to test whether these vectors could down-regulate endogenous miRNAs in vivo, we 
transfected innervated and denervated muscles with the sensor for miRNA-206 together with Zip 
Null or with miRZIP-206. As expected, denervated muscles expressing the Zip Null showed a 
decrease in the luciferase activity that is consistent with an increase in the miRNA-206 expression 
level. However the muscles expressing the miRZIP-206 displayed an increase in the Luciferase 
activity both in innervated and denervated muscles confirming that we efficiently blocked free 
miRNA-206 in normal and atrophic muscles (Fig 34). It was not possible to perform the same 
analysis for miRNA-21 since miRZIP-21, per se, affects the expression of the Renilla, the vector 
that was used to normalize the efficiency of transfection.  
Fig 34: Vectors to inhibit specific miRNAs efficiently reduce the miRNAs activity in vivo. 
Expression of pmiRZIP lentiviral vector in vivo, during denervation, efficiently reduce the 
endogenous levels of miRNAs. Adult T.A. muscles were electroporated with the Luciferase 
sensor for miRNA-206 (10 g) together with the empty miRZIP (10 g) or with miRZIP-206 
(10 g). A Renilla vector (5 g) was co-electroporated to normalize for electroporation efficiency. 
Simultaneously, mice were submitted to unilateral transection  of the sciatic nerve. 7 days later 
the Luciferase/Renilla levels were measured. (n=6) Values represent mean ± STE. *p<0.05 and 
** p<0.01 by T-Test. 
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Having demonstrated that 
these miRZIP vectors are able to 
reduce significantly the levels of 
endogenous miRNAs, we then 
monitored whether the inhibition of 
miRNA-206 and miRNA-21 could 
reduce atrophy in denervated 
muscles and promote muscle growth in normal muscles. Thus, we transfected the different miRZIP 
vectors in innervated and denervated TA. The CSA was measure after 7 days of denervation. The 
inhibition of miRNA-206 and miRNA-21 per se was sufficient to induce a 10% hypertrophy in the 
innervated and denervated muscles. However, the simultaneous inhibition of these miRNAs was not 
additive (Fig 35).  
The fact that miRNA over-expression induces atrophy and their inhibition induces 
hypertrophy is consistent and suggests that these miRNAs are modulating the expression of a 
negative regulator of the atrophic process. 
Fig 35: Inhibition of miRNA-206 and 
miRNA-21 partially protects from 
denervation induced atrophy by 
promoting a 10% hypertrophy. (a) 
Inhibition of miRNA-206 during 
denervation increases the C.S.A. of the 
fibers. Adult T.A. muscles were 
electroporated with the empty vector 
(10 g) or with the miRZIP-206 (10 g). 
Simultaneously, the right leg was 
denervated by severing the sciatic nerve. 
Cross-sectional area of transfected fibers, 
identified by the presence of GFP, was 
measured 7 days after electroporation. (n≥3 
muscles) Values represent mean ± STE. ** 
p<0.01, by T-Test. (b) Inhibition of 
miRNA-21 during denervation increases 
the C.S.A. of the fibers. Same conditions as 
in a). (n≥3 muscles) Values represent mean 
± STE. ** p<0.01, by T-Test. (c) Inhibition 
of both miRNA-206 and miRNA-21 during 
denervation increases the C.S.A. of the 
fibers. Adult T.A. muscles were 
electroporated with the empty vector 
(10 g) or with the miRZIP-206 (10 g) 
together with miRZIP-21 (10 g). Same 
conditions as in a). (n≥3 muscles) Values 
represent mean ± STE. *p<0.05 and ** 
p<0.01, by T-Test. 
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We have shown that two miRNAs, miRNA-206 and miRNA-21, were particularly over-
expressed during denervation-induced muscle atrophy. The over-expression of these two miRNAs 
in adult muscle, per se, was sufficient to induce muscle atrophy and their inhibition, always in vivo, 
induced an increase in the fiber size. In order to understand the molecular mechanisms that are 
underneath this regulation, we need to understand which target genes these miRNAs are regulating. 
In the second part of the results of this thesis we describe the approach that we used to identify the 
most probable target genes. We have also validated the most interesting ones as true targets of 
miRNA-206 and miRNA-21. The next step will be to address the biological role of these targets 
during the process of skeletal muscle atrophy. 
 
5.1- Skeletal muscle atrophy is a transcriptionally regulated process 
 
The prediction of the miRNAs targets is one of the most challenging aspects of the miRNA 
biology since each miRNA can have hundreds or thousands of predicted targets. As discussed 
before, one of the mechanisms by which miRNAs post-transcriptionally modulate gene expression 
is by inducing target mRNA degradation. Being supported by several evidences, this mechanism 
facilitates the identification of the miRNAs targets. If this mechanism prevails, one has only to 
consider the mRNAs that show an opposite regulation of the miRNAs. Despite the fact that 
miRNAs can also regulate the translation of the target genes, we decided to focus on the 
identification of the miRNA-induced mRNA degradation. This approach allowed a significant 
reduction of the huge number of predicted targets.  
The first step of this process was to perform the mRNA micro-array on the same samples 
that have been used to characterize the miRNA expression profile. From the 13439 probes present 
in the array, only 8519 had a fluorescence signal above the background in all the 18 samples 
analyzed. In order to update the annotation of the different probes, the Gene ID conversion tool 
from DAVID (http://david.abcc.ncifcrf.govconversion.jsp) was used. At the end of the re-
annotation only 6833 probes were associated to a single GeneSymbol, and these probes were used 
for further analyzes. 
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An hierarchical cluster analyze was performed using the Pearson correlation index that is the 
most robust method to group genes and samples that present similar expression motifs 
independently of the expression levels. As shown in the dendrogram each atrophic condition had a 
particular expression profile that allowed to group them in different clusters. In fact, and as it 
happened for the miRNA expression profile, samples collected 7 and 14 days after denervation 
grouped together when compared to the ones collected 3 days after denervation. Also 24 and 48h of 
starvation gave similar expression profiles that clustered together. Again, diabetes induced by 
streptozotocin is the most divergent condition that seems to be unrelated to any of the previous 
condition.  
 
Performing a SAM one class analysis of all the atrophic samples, a list with 1462 differently 
expressed genes was obtained (false discovery rate of 0.0%). In order to understand which were the 
biological processes mostly implicated in the atrophic process these genes were grouped in 
functional categories taking advantage of the freely available software DAVID, mainly using the 
KEGG pathway (Kanehisa et al, 2002) database. Among the biological processes that are more 
significantly enriched one should highlight the Proteasome and the Ribosome. It is also interesting 
to see that several genes of the Insulin signaling pathway are downregulated. This is the case of Insr 
(insulin receptor) and Igf-1r (Insulin growth factor 1 receptor).  These results are in agreement with 
the findings obtained previously (Lecker et al., 2004). 
Fig 36: Hierarchical cluster analysis obtained from the gene expression profile of several models of skeletal muscle 
atrophy. A color code represents the relative intensity of the expression signal when compared to the control samples, with 
red indicating higher expression levels and green indicating lower expression levels. 
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Fig 37: Significantly enriched pathways 
among the differently expressed genes 
(FDR=0%) in all atrophic conditions. The 
percentage of enrichment represents the 
number of genes present in a pathway over 
the total number of differently over- (579) or 
under-expressed (883) genes. The 
enrichment P-value for each pathway is also 
reported. 
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Fig 38: DAVID analysis on the differently expressed genes revealed the presence of certain enriched pathways or 
cellular compartments. For each gene, green represents under-expression when compared to the normal control and 
red represents over-expressed when compared to the normal control. 
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5.2- Skeletal muscle atrophy is a transcriptionally regulated process fine tuned 
by miRNAs. 
 
Having established that each atrophic condition has a unique mRNA and miRNA signature, 
the obvious question was which mRNAs were regulated by which miRNAs. To address this 
question, Matteo Silvestrin and Cristiano di Pittà, from the CRIBI, developed an algorithm, that 
runs under GenMiR++ (Huang et al 2007), and that integrates these two information. This 
algorithm highlights the interaction miRNA- target mRNA that present opposite expression levels. 
In this way, from the list of possible targets predicted by several algorithms, it was possible to 
identify the most probable interactions.  
 This algorithm to run under GenMiR++ requires three matrixes: the information related to 
the mRNA expression level (X), the information related to the miRNA expression levels (Z), and a 
binary matrix with the information of the predicted interaction mRNA-miRNA (C). There are 
several algorithms that can predict the interaction miRNA-mRNA-target. The most used ones are, 
miRanda, TargetScanS, Pictar and PITA among others. The prediction program miRanda (Enright 
Fig 39: Exel screen with a list of the interactions miRNA-mRNA target obtained with GenMIR++. 
This approach integrates the predicted interactions, that result from miRanda and PITA (two predictive 
algorithms), with the data from the miRNA and mRNA expression profiles. This list contains 9876 
interactions miRNA-mRNA target with a probability score above the 75° percentile. 
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et al., 2003), considers that the most important region of the interaction miRNA-mRNA is the seed 
region, however it also evaluate the 3’ interaction of the miRNA. Furthermore this program also 
considers the thermodynamic stability of the interaction miRNA-mRNA using the Vienna work-
package. The last version of this program (John et al., 2006) also takes into consideration the 
presence of multiple sites of binding in the same 3’UTR for the same miRNA. TargetScanS 
considers the complementarities within the seed region, but it takes also in consideration the 
conservation between species. Pictar (Krek et al., 2005) analyzes the conservation among species of 
the miRNA-binding site as well. After searching for orthologus 3’UTR, this program looks for 
binding within the seed region of the miRNAs allowing some mismatch. Finally this program 
results in a score that considers the free energy of the miRNA/mRNA binding. One of the last 
developed programs is PITA (Probability of Interaction by Target Accessibility) (Kertesz et al 
2007). This algorithm considers a perfect complementarity between the seed-region and the 3’UTR 
of the mRNA, allowing a single mismatch. It also considers the accessibility of the target to the 
miRNA. This program does not take into consideration the conservation between species.  
PITA is the most updated predictive algorithm that takes in consideration not only the 
binding miRNA-mRNA but also the accessibility of the RISC complex to the target mRNA. On the 
other hand miRanda, not only considers the binding of the 3’ of the miRNA, but it is also the most 
sensible (Sethupathy et al, 2006) algorithm considering the predicted targets that were validated. 
For these reasons these two algorithms were chosen to create two different binary matrixes to use in 
the GenMiR++. We then decided to join the lists of miRNA/mRNA-targets resulted by miRanda 
(32789 predictive interactions) and by PITA (8091 predictive interactions). This integrated list was 
loaded into GenMir++ together with the expression levels of the miRNAs and of the mRNAs. Then, 
GenMir++ generates a probabilistic score based on the anti-correlation between miRNA and mRNA 
expression levels. Taken in consideration the probabilistic score given by GenMir++ only 9000 
interaction were considered (>75° percentile). The most significant interactions are displayed in 
Excel format and may be consulted in different ways: select a miRNA to see which are their targets, 
or select a gene to see which miRNAs can regulate it (Fig 39).  
 Since we are studying miRNA-206 and miRNA-21 we have focused on the interaction of 
these two miRNAs and their targets. The analysis with GenMir++ generated 322 possible targets for 
miRNA-206 and 121 possible targets of miRNA-21. All these target genes were down-regulated in 
mRNA array.  
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5.3- PolK, YY1, eIF4E3 and PDCD10 are possible targets of miRNA-206 and 
miRNA-21. 
 
 A closer look on the list of 
predicted targets that came out from 
the GenMir++ analysis revealed the 
presence of some interesting genes. 
At the top of the list of the possible 
targets of miRNA-206 there was 
DNA polymerase Kappa (PolK). In 
the same list there was other two 
DNA polymerases, alpha 1 and 
epsilon 4 (PolA1 and PolE4 
respectively). PolK is a low-fidelity enzyme that is involved in the extension step of lesion bypass 
(Lone et al., 2007). PolA1 is one of the most important DNA polymerase since is the only enzyme 
capable of initiating DNA replication at chromosomal origin sites and at sites of initiation of 
discontinuous synthesis of Okazaki fragments on the lagging side of the replication fork (Srivastava 
et al., 2000). Finally, PolE4 is a histone-fold protein that interacts with other histone-fold proteins to 
bind DNA in a sequence-independent manner. These histone-fold protein dimers combine within 
larger enzymatic complexes for DNA transcription, replication, and packaging. Although their role 
in the adult skeletal muscle, a post-mitotic tissue, is not clear, it is known that PolA1 is regulated by 
miRNA-206 in C2C12 myoblast (Kim et al., 2006). Considering that PolK is the target gene with 
the highest score and that contains 2 binding sites for miRNA-206 we decided to further study 
whether this polymerase was in fact modulated during denervation specifically by miRNA-206.  
Another gene that came out as a target of miRNA-206 was yin-yang 1 (YY1). This is a zinc-
finger transcription factor that has been shown to regulate different functions in skeletal muscle. In 
fact YY1 competes for the binding site of Serum Response Factor (SRF) (Gualberto et al., 1992), a 
known skeletal muscle transcription activator. Similarly, it binds and represses the promoter of the 
Dystrophin gene (Galvagni et al., 1998). Furthermore, NF-kB, one of the most important 
transcription factor during skeletal muscle atrophy, is known to activate YY1 transcription in order 
to inhibit fusion in C2C12 cells (Wang et al., 2007). YY1 is also known to interact directly with 
PGC1a in order to orchestrate mitochondrial biogenesis in a mTOR-dependent way (Cunningham et 
al., 2007). Considering these evidences and the fact that, according to PITA algorithm, YY1 has 2 
Fig 40: Group of genes that were selected from the GenMIR++ list for 
further analysis. Most of the selected genes are, predictably, targets of both 
miRNAs. The energy of the duplex miRNA-mRNA is also shown 
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binding sites for miRNA-206 and 2 binding sites for miRNA-21 we decided to further study the 
role of this transcription factor during skeletal muscle atrophy. 
Also eIF4E3 can be targeted by both miRNA-206 and miRNA-21. This initiation factor is a 
rate limiting component of translation. EIF4E, together with eIF4G and eIF4A forms the eIF4F 
complex that is required for the recruitment of the 60S ribosomal subunit into the 43S pre-initiation 
complex to form a functional 80S initiation complex (Jackson et al., 2010). While eIF4E1 and 
eIF4E2 are ubiquitously expressed, eIF4E3 is expressed mainly in the heart and skeletal muscle. 
The role of this initiation factor in the muscle was never addressed however it is known that the 
over-expression of eIF4E3 in U2OS cells increased cell size and rescues the rapamacyn-induced 
decrease in cell size (Fingar et al., 2002). 
Finally, the last gene we decided to study was Program Cell Death 10 (PDCD10). It is a 
possible target of both miRNA-206 and miRNA-21, containing a binding site for each miRNA. The 
tissues that present the highest expression levels of this gene are the heart, skeletal muscle and 
placenta. Considering that PDCD10 is involved in the cerebral cavernous malformations strongly 
suggests that it is a new player in vascular morphogenesis and/or remodeling (Bergametti et al., 
2005). Again, the role of PDCD10 in the skeletal muscle atrophy is unknown. However this gene 
fulfills the criterion of having at least a binding site for both of the miRNAs under study.  
The initial task was to validate the gene expression profile of microarrays by using 
quantitative RT-PCR. The analyses confirmed that YY1 was significantly down-regulated at 3 and 
7 days but not at 14 days of denervation (Fig 41a). Importantly, eIF4E3, PDCD10 and PolK 
transcripts were down-regulated during early and late stages of denervation (Fig 41b, c, d). These 
results confirmed the data obtained with the micro-array. 
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5.4- The 3’UTR of PolK, YY1, eIF4E3 and PDCD10 are modulated during 
denervation. 
 
To confirm that these genes are true targets of the predicted miRNAs, their 3’UTR was 
cloned into the pMIR vector, at the 3’UTR of the Luciferase gene. These luciferase sensors quantify 
the degree by which the 3’UTR of a gene is modulated by miRNAs. Whenever there is a decrease 
in the luciferase level, it indicates that there is an increase in the miRNAs that regulate the 3’UTR 
of the sensor. In order to analyze whether these genes are under miRNA regulation in denervated 
muscle, we transfected these sensors into control and denervated T.A. muscles. After 15 days of 
denervation, the luciferase activity was measured. Indeed two weeks of denervation induced a 10 
fold reduction of luciferase activity (Fig 42). These findings are consistent with a miRNA 
modulation of these 3’UTRs. 
Fig 41: All predicted targets are down regulated during denervation. Expression levels of (a) YY1, (b) eIF4E3, (c) 
PDCD10 and (d) PolK during different time points of denervation. After 3, 7 or 14 days of denervation, induced by 
unilateral transection  of the sciatic nerve, gastrocnemius muscle was collected, total RNA was extracted and gene 
expression analyzed by Real Time Quantitative PCR. -Actin was used to normalize the expression levels of each gene. 
(n=3) Values represent mean ± STD. * p<0.05, ** p<0.01 by T-Test. 
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Fig 42: Denervation down-modulates the 3’UTR of the selected genes. (a) Schematic representation of the 
Luciferase sensors generated to access the effect of the miRNAs on the 3’UTR of the selected genes. The 3’UTR of 
each target gene was PCR amplified and cloned into the pMIR-LUC vector in the 3’UTR region of the Luciferase gene. 
The binding site for each miRNA are depicted - in blue the binding sites for miRNA-21 and in red the binding sites for 
miRNA-206. Denervation down-modulates the 3’UTR of (b) YY1, (c) eIF4E3, (d) PDCD10 and (e) PolK. The 
luciferase sensors  for the 3’UTR of each gene (10 g) were electroporated into adult T.A. muscles. A Renilla vector 
(5 g) was co-electroporated to normalize for electroporation efficiency. Electroporated animals were simultaneously 
submitted to unilateral transection  of the sciatic nerve. 7 days later the Luciferase/Renilla levels were measured. (n≥3) 
Values represent mean ± STD. *p<0.05 and ** p<0.01 by T-Test. 
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5.5- The 3’UTR of PolK, YY1, eIF4E3 and PDCD10 are modulated by 
miRNA-206 and miRNA-21. 
 
 These results strongly suggest that miRNAs can regulate the expression of these genes. To 
further prove that miRNA-206 and -21 are involved in such control we transfected the 3’UTR 
sensors together with the miRNA over-expressing vectors. After 7 days, muscles were collected and 
luciferase levels measured. Interestingly expression of miRNA 206 did not affect the YY1-3’UTR. 
However, the expression of miRNA-21 was able to reduce to half the luciferase levels of YY1-
3’UTR. No additive effects were observed when miRNA-206 and miRNA-21 were co-expressed 
(Fig 43a). The same analysis was performed on the 3’UTR of eIF4E3 and PDCD10. The 3’UTR of 
these genes were down-regulated by both miRNA-206 and miRNA-21 (Fig 43 b, c). Furthermore, 
the co-expression of miRNA-206 and miRNA-21 led to a further suppression of the 3’UTR of 
eIF4E3 indicating an additive 
effect. To what concerns the 
3’UTR of PolK, there was no 
effect on luciferase activity when 
miRNA-206 (Fig 43 d) was over-
expressed.  
 In conclusion, the data 
obtained with the 3’UTR 
luciferase sensors suggest that 
YY1 is modulated by miRNA-
21, while eIF4E3 and PDCD10 
Fig 43: Over-expression of miRNAs 
modulates the 3’UTR of the selected genes. 
(a) YY1-3’UTR is modulated by miRNA 21 
but not by miRNA-206. The 3’UTRs of 
eIF4E3 (b) and PDCD10 (c) are modulated 
by both miRNA-206 and miRNA-21. (d) The 
3’UTR of PolK is not modulated by miRNA-
206 as it was predicted. The luciferase 
sensors for the 3’UTR of each gene (10 g) 
were electroporated into adult T.A. muscles, 
together in the miRNAs over-expressing 
vectors (20 g). A Renilla vector (5 g) was 
co-electroporated to normalize for 
electroporation efficiency. 7 days later the 
Luciferase/Renilla levels were measured. 
(n≥3) Values represent mean ± STD. 
*p<0.05 and ** p<0.01 by T-Test. 
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are modulated by both miRNA-206 and miRNA-21. PolK is not modulated by miRNA-206.  
To further prove the specificity of these miRNAs, we have mutated the 3’UTR binding sites 
of eIF4E3. Two different approaches were applied: three nucleotides of the seed region of the 
predicted miRNA binding site were either mutated (Mut206 and Mut21) or deleted (Del206 and 
Del21). Theoretically, if these are the only binding sites of these miRNAs, their mutation or 
deletion should rescue the luciferase activity when co-express with miRNA206 or 21. Thus, we co-
transfected C2C12 muscle cells with the mutated 3’UTR and the respective miRNA-expressing 
vector. As expected, the WT eIF4E3 3’UTR is strongly reduced by miRNA-206 and miRNA-21 
(Fig 44a, b). Importantly, the mutated/deleted eIF4E3 3’UTR were significantly less inhibited by 
miRNA 206 or miRNA21. These results confirm that eIF4E is controlled by these microRNAs. 
However, since the rescue was not complete, it may indicate that another non-predicted binding site 
for the miRNA of interest may exist in this region or that other miRNAs can regulate its expression. 
The same approach is currently under study for the 3’UTR of YY1. 
 
Fig 44: Mutations/Deletions on the seed region of the 3’UTR of eIF4E3 partially prevent the miRNA-specific 
regulation. Mutations/Deletions in the binding site for miRNA-206 (a) or miRNA-21 (b) partially prevent the 
regulation of these miRNAs on the 3’UTR of eIF4E3. (a) The luciferase sensors (WT, mutated or deleted) for the 
3’UTR of eIF4E3 (0,64 g) were co-transfected with negative control (0,64 g) or miRNA-206 (0,64 g). A Renilla 
vector (0,32 g) was co-transfected to normalize for transfection efficiency. C2C12 myoblasts were collected 48h after 
transfection and Luciferase/Renilla levels were measured. (n≥3) Values represent mean ± STD 
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5.6- Over-expression of miRNA-206 and miRNA-21 down-regulate eIF4E3, 
PDCD10 and YY1 in C2C12 myoblasts. 
 
 To confirm that these genes are true targets 
of miRNA-206 and miRNA-21 one should 
observe a direct correlation between the over-
expression of the miRNAs and a down-regulation 
of their targets. To achieve this, C2C12 myoblasts 
were transfected with the negative control, 
miRNA-206 or miRNA-21. After 48h total RNA 
was extracted and the expression of these genes 
was analyzed by real time RT-PCR. Interestingly, 
miRNA-206 significantly down-regulated the 
transcript of PDCD10 while miRNA-21 reduced 
mRNAs of eIF4E3 and PDCD10 (Fig 45). There 
is a trend of down-regulation of the eIFE3 
transcript by miRNA206 that did not reach the 
statistical significance that could be achieved by 
additional experiments. Our previous data suggest 
that miRNA-21, but not miRNA-206, controls the 
3’UTR of YY1. However, we couldn’t see this 
regulation at the mRNA level. Thus, we 
hypothesized that, in cells, the regulation could be 
at the protein level. We then performed Western 
blot to detect YY1 protein in miRNA21 
transfected cells. MiRNA-21 was sufficient to 
reduce the protein level of YY1 (Fig 46).  
 
Fig 45: miRNA over-expression alters the expression 
levels of the target genes. Expression levels of (a) eIF4E3, 
(b) PDCD10 and (c) YY1. C2C12 myoblasts were 
transfected with 4 g of miRNA expressing vector. 48h after 
transfection cells were collected and total RNA was extracted 
using Trizol. Gene expression analyzed by Real Time 
Quantitative RT-PCR using GapdH to normalize the 
expression levels of each gene. (n=3) Values represent mean 
± STD. * p<0.05, ** p<0.01 by T-Test. 
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Altogether these results demonstrate for the first time that miRNA-206 regulates eIF4E3 and 
PDCD10, while miRNA-21 controls YY1, eIF4E3 and PDCD10.  
 
 
Fig 46: miRNA-21 over-expression down-regulate YY1 at the protein level. Western 
blot analysis on the YY1 protein levels after transfection of C2C12 myoblasts with 
miRNAs over-expressing vectors (4 g). Cells were harvested 48h after transfection. 
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Skeletal muscle atrophy is a transcriptionally regulated process (Lecker et al., 2004; Sandri 
et al., 2004a; Stitt et al., 2004). FoxOs are key transcription factor that control the expression of 
rate-limiting enzyme of the two most important degradative pathways: the ubiquititn/proteasome 
(Gomes et al., 2001; Sandri et al., 2004a) and the autophagy/lysosome (Mammucari et al., 2007; 
Zhao et al., 2007) pathway. Also NF-kB is involved in the atrophy program (Cai et al., 2004; 
Hunter and Kandarian, 2004). Furthermore, there is a restricted group of genes, called atrogenes, 
which are commonly up- or down-regulated in all the atrophic conditions studied (Lecker et al., 
2004). These findings suggest that basic mechanisms of atrophy are shared among diseases. 
Atrogenes belong to several fundamental biological processes, ranging from ATP production to 
nitrogen metabolism and from transcription/chromatin remodeling to translation control. The 
varieties of processes that are involved in atrophying muscles suggest highly regulated and 
coordinated mechanisms to adapt the myofiber to the catabolic condition. Therefore the level of 
control might not be only at transcriptional stage and might involve additional regulation to fine-
tune the atrophy program. Recently, a new class of regulatory molecules has been discovered. They 
are called miRNAs and are predicted to regulate several genes from the same pathway. Their role in 
the skeletal muscle physiology has just been started to be unraveled. The aim of this thesis was to 
determine their role during muscle atrophy.  
Our data strongly suggest that miRNAs are changing their expression and are contributing to 
the molecular mechanisms implicated in muscle atrophy. We have found several novel and un-
expected findings that contribute to the understanding of muscle loss. Firstly, despite the presence 
of a set of gene, the atrophy-related genes, that are commonly regulated at transcriptional level 
during atrophy, the miRNA expression profile is peculiar for each atrophic condition. Therefore, we 
could not identify any atrophy-related miRNA or AtromiRNA. A second important point was the 
finding that the changes in miRNA expression are delayed when compared to the transcriptional 
regulation. This result suggests that miRNA are involved in fine-tuning the atrophy program that 
was previously activated at transcriptional level.  
Although we were not able to identify a common miRNA to all the atrophic conditions 
studied, we have identified and characterized the two most induced miRNAs of denervated muscles. 
These two miRNAs, miRNA-206 and miRNA-21, are up-regulated both in fast and slow muscles. 
The role of these miRNA in regulation of muscle mass have been studied in vivo by developing 
vectors and techniques that allow the over-expression or the inhibition of these miRNA in adult TA 
muscles. These functional studies revealed that, together, these two miRNAs can account for almost 
half of the reduction in the CSA of the fibers that occurs during denervation-induced atrophy. Gain-
of-function studies have found that miRNA-206, per se, was able of activate Atrogin-1, a key E3-
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ligase involved in protein degradation. Furthermore, loss of function analyses found that the 
inhibition of both miRNA-206 and miRNA-21 promotes muscle growth and partially prevents the 
denervation-induced atrophy. Finally, we have identified some of the targets of these two miRNAs 
and we have started to unravel their biological role in the control of muscle mass and metabolism. 
 
6.1- Different atrophic conditions activate specific miRNA programs. 
 
 To gain insight on the involvement of miRNAs in muscle wasting, miRNA expression 
profiles of atrophic muscles were performed. From the approximately 400 probes present in the 
array, ninety were significantly differentially expressed between controls and atrophic samples. 
However the bioinformatic analyses to reveal miRNAs that were commonly up or down-regulated 
in all the studied atrophic conditions was unsuccessful. This was unexpected since several studies in 
the muscle field indicate that common miRNAs can regulate common mechanisms. In fact, a study 
in cardiac muscle found miRNAs that are commonly induced in different conditions of cardiac 
hypertrophy. These shared miRNAs were also altered in human samples of heart failure (van et al., 
2006). Also analyses on different muscular dystrophies found a group of miRNAs that are 
commonly altered (Eisenberg et al., 2007). Altogether, these results underline the existence of 
common regulatory mechanisms involved in miRNA expression. Although surprising, the lack of a 
common miRNA in our study can be justified by the fact that the atrophic conditions studied are 
quite different from each other. Accordingly, the same genomic study that identified a restrict group 
of genes common to all the atrophic conditions, also showed that the vast majority of differentially 
expressed genes were specific of each condition (Lecker et al., 2004). This is in agreement with the 
fact that the bioinformatic analysis hierarchically clustered the different samples according to their 
atrophic condition. In fact, samples from different time points of denervation clustered together, like 
the samples from different time points of starvation. The miRNA expression profile from diabetic 
samples indicated that this is a completely independent condition.  
 The realization of the miRNA expression profile at different time points revealed that at 
early stages of atrophy there is a general suppression of miRNAs expression. This was particularly 
evident at 3 days of denervation. The samples of 24h and 48h starved muscles were extremely 
difficult to analyze due to variability among samples. However, even in this condition the majority 
of the miRNAs were down-regulated at 24 h of fasting. These findings suggest that miRNA up-
regulation is delayed and occurs in a second time when compared to the transcription of atrophy-
related genes. In fact, 3 days of denervation and 24 h of starvation are the time of the strongest 
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induction of Atrogin-1 and LC3 gene expression while miRNAs induction requires at least 7 days 
of atrophy. It is therefore possible that the changes of miRNAs expression might be under the 
regulation of some atrophy-related genes. Another possibility is that these miRNAs can be involved 
in slowing down the atrophic process or in the metabolic and functional adaptation to the new 
atrophic condition. 
 Considering the absence of common atrophy-related miRNAs or atromiRNA, we decided to 
focus our attention on the two most induced miRNAs, miRNA-206 and miRNA-21, in denervated 
muscles.  
Quantitative RT-PCR analyses and functional assays confirmed that both miRNA-206 and 
miRNA-21 were significantly up-regulated during denervation. This response of both miRNAs was 
independent of the type of muscle analyzed since denervation induced their expression levels both 
in slow and fast muscles. It was interesting to see that the basal levels of miRNA-206 were 10 fold 
higher in slow muscles when compared to fast muscles, as it was previously reported (McCarthy 
and Esser, 2007b). Perhaps, this justifies the fact that the fold increase of this miRNA upon 
denervation was higher in fast muscles (10 fold increase) when compared to slow muscles (4 fold 
increase). Since miRNA-206 expression is higher in slow muscle, it was proposed that its regulation 
is under the control of a transcription factor specific of slow program (McCarthy and Esser, 2007b). 
Other studies indentified MyoD as the critical regulator of miRN-206 expression (Rao et al., 2006; 
Rosenberg et al., 2006), Interestingly, MyoD is more expressed in fast muscles than in slow 
muscles (Voytik et al., 1993), suggesting that at least another transcription factor is responsible for 
the different expression of miRNA-206 between slow and fast muscles. Myogenin is another 
transcription factor that binds to the regulatory region of miRNA-206 (Rao et al., 2006) and it is 
highly expressed in adult slow muscles, being therefore a possible regulator of miRNA-206 in the 
slow muscles. 
Another interesting observation is that miRNA-206 expression levels progressively 
increased during denervation, while miRNA-21 remains constant. It is interesting that both 
transcription factors that we have mentioned before, MyoD and Myogenin, are strongly induced 
during denervation (mainly after 2days of denervation) (Voytik et al., 1993) suggesting that they 
might be involved on the regulation of these miRNAs. However, this does not exclude that another 
atrophy-related transcription factor might be regulating miRNA-206 expression.  
As for miRNA-21, one of the most important transcriptional regulator is AP-1 (Fujita et al., 
2008). Data from our laboratory indicates that during skeletal muscle atrophy, DNA binding 
activity of nuclear extracts to the AP-1 binding sites decreases (Sandri et al., 2004a), suggesting that 
another transcription factor may be involved in the up-regulation of this miRNA. 
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In this thesis we showed that over-expression of c.a.FoxO3 was sufficient to up-regulate 
miRNA-206 and miRNA-21 but it was not required. In fact we have generated a knock-out animal 
in which FoxO1, FoxO3 and FoxO4 (FoxO1,3,4 -/-) were simultaneously deleted specifically in 
skeletal muscle. The findings clearly show that upon denervation miRNA-206 and miRNA-21 are 
still up-regulated in  FoxO1,3,4 null muscles, indicating that their transcription is not FoxO 
dependent. Furthermore, it indicates that the miRNA induction during FoxO3 over-expression may 
be dependent of downstream targets of FoxO3 or products of the atrophy process. These in vivo 
results are in contrast with the ones obtained by Wang et al (Wang and Li, 2010). In this study, 
performed in A549 human lung cancer cells and in human neuroblastoma cell line SH-EP1, FoxO3 
binds one of the two identified binding sites in the promoter region of miRNA-21. In fact over-
expression of c.a.FoxO3a represses miRNA-21 expression while RNAi against FoxO3a increases 
the levels of miRNA-21. It is possible that the cellular context and the binding partners of FoxO3 
can account for these discrepancies. Although, in skeletal muscle, FoxO family members are 
described as transcription factors that induce gene expression, there are reports that they act as 
repressor as well (for example (Karadedou et al., 2011)). 
Similarly, over-expression of Ikk , an activator of the NF-kB pathway, in adult skeletal 
muscle, was sufficient to induce the expression of miRNA-206 and miRNA-21. However, it was 
not possible to discriminate between a direct transcriptional regulation or a indirect activation of an 
atrophic program, since we don’t have available the specific knock-out model for this pathway. 
 As discussed in the introduction, miRNAs can be transcribed from intergenic locus but also 
from introns of coding genes. The transcripts can generate a single miRNA or more than two 
miRNAs when miRNA are poly-cystronic. While miRNA-206 is originated from an intergenic bi-
cystronic locus, miRNA-21 is transcribed from the 10
th
 intron of the TMEM49 gene. Our results 
indicated that their processing was independent of their host genes, suggesting that they have 
independent promoters, as it was already demonstrated for miRNA-21 (Fujita et al., 2008). The fact 
that miRNA-206 is transcribed independently from its bi-cystronic companion is surprising, but the 
increased expression of miRNA-133b was not revealed neither by the array neither by quantitative 
RT-PCR. This is consistent with Chip-on-Chip experiments in which MyoD and Myogenin were 
found to be bound to the promoter region of miRNA-206 but not to the promoter region of miRNA-
133b (Rao et al., 2006), and it may explain why miRNA-133 induces myoblast proliferation (Chen 
et al., 2006a) while miRNA-206 induces myoblast differentiation (Kim et al., 2006; Rosenberg et 
al., 2006). 
We now know that different atrophic conditions activate a peculiar miRNAs signature.  We 
also know that slow and fast muscles respond in similar ways, at least to what concerns miRNA-
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206 and miRNA-21. Finally, the activation of key transcription regulators of the atrophic program, 
although indirectly, are sufficient to alter the miRNA expression levels.  
 
6.2- miRNA-206 induces atrophy in adult skeletal muscle. 
 
The fact that miRNA-206, a skeletal muscle-specific miRNA, was up-regulated during 
denervation was quite interesting. Despite several evidences addressing the role of this miRNA 
during C2C12 differentiation, little is known about the true function of this miRNA in adult muscle. 
It has been shown that miRNA-206 is highly expressed in slow muscles (McCarthy and Esser, 
2007b), suggesting that it is required for the structural or metabolic characteristic of these muscles. 
It was also implicated in muscle regeneration (McCarthy et al., 2007; Nakasa et al., 2010; Yuasa et 
al., 2008c) although the molecular mechanisms were not addressed. Despite the predicted 
importance of this miRNA, no obvious abnormalities in weight, behavior or in the architecture and 
fiber-type distribution of skeletal muscles were found in miRNA 206 knockout mice (Williams et 
al., 2009). Therefore further in vivo studies are required to better understand the biological role of 
this miRNA. 
On the contrary, the role of miRNA-21 in the skeletal muscle is still unknown. There are 
extensive studies on its role in cancer, being considered an onco-miR and its over-expression was 
shown in most cancer types (reviewed in (Kumarswamy et al., 2011). Moreover, it also regulates 
immunological and developmental mechanisms. Importantly, recent studies showed a role of this 
miRNA in cardiovascular biology. miRNA 21 was up-regulated in a variety of models of cardiac 
hypertrophy, a common pathological response to cardiac problems (reviewed in (Cheng and Zhang, 
2010)). However, specific miRNA-21 expression in cardiomyocyte didn’t have any direct effect on 
the regulation of cell size. The major correlation was revealed with cardiac fibrosis which was 
efficiently reversed by miR-21 knockdown in vivo (Thum et al., 2008). Also in this case, more in 
vivo studies are required to understand the role of this miRNA, mainly in muscle wasting. 
To address their biological role in adult muscles, plasmids expressing these miRNAs were 
electroporated in adult muscles, to generate transgenic muscles. This approach avoided the 
adaptation phenomenon’s typical of constitutive transgenic or knock-outs animals. The up-
regulation of these two miRNAs, mainly at late stages of the muscle wasting, can have two 
explanations: it can indicate that they are required for the slowing down of the atrophic program or 
indicate that they are required for the adaptations to the new atrophic condition, and therefore are 
also implicated in the atrophic program. 
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To address the first hypothesis we expressed these miRNAs in denervated muscles. 
According to our data both of these miRNAs do not block the denervation-induced loss of muscle 
mass. Conversely, they further decrease the C.S.A. of the denervated fibers suggesting that these 
miRNAs exacerbate the atrophic program, giving strength to the second hypothesis. To confirm this 
view, we over-expressed these miRNA in control muscles. While miRNA-206 was sufficient to 
induce atrophy, miRNA-21 didn’t alter the C.S.A. of the fibers. Importantly, electroporation of both 
miRNAs induce a more severe atrophy suggesting that miRNA-21, although unable to induce 
atrophy, exacerbates the atrophic effect of miRNA-206. This is the first report presenting functional 
evidences on the involvement of miRNAs in skeletal muscle atrophy.  
  Interestingly, the atrophy observed in the presence of miRNA-206, is followed by an 
increased activation of the atrogin-1 promoter activity. However, the co-expression of these 
miRNAs, although inducing a more severe atrophy, do not activate atrogin-1 promoter. Moreover, 
Murf-1 promoter is repressed by miRNA-206 alone or in the presence of miRNA-21, suggesting 
that this E3-ligase might not be involved in the atrophic process induced by the miRNAs. These two 
E3-ubiquitin ligases were shown to be highly induced during denervation (Bodine et al., 2001b), 
and their transcription was shown to be FoxO dependent (Sandri et al., 2004a). The exact 
mechanism by which miRNA-206 induced an increase of atrogin-1 promoter activity is not known, 
but it is possible that it regulates some transcriptional inhibitor. Although not addressed, it is also 
possible that these miRNAs can also act on the autophagic regulation of muscle mass.  
  The inhibition of miRNA-206 and miRNA-21 during denervation leads to hypertrophy and 
partially prevented the denervation-induced atrophy. This is in agreement with the fact that over-
expression of these miRNAs leads to a decrease CSA of the fibers and may indicate that they are 
regulating key inhibitors of the atrophic process. Since miRNA-1 is able to repress IGF-1 (Elia et 
al., 2009), a well known anabolic signal (Coleman et al., 1995; Musaro et al., 2001), and 
considering that the sequence of miRNA-206 is highly similar to the sequence of miRNA-1, it is 
possible that inhibiting miRNA-206, IGF-1 becomes de-repressed and can induce muscle 
hypertrophy. 
In order to better understand the function of miRNA-206 and miRNA-21, it is important to 
find the other target genes.  
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6.3- Atrophy related miRNAs regulate gene expression mainly by inducing 
degradation of target mRNAs. 
 
 As discussed in the introduction, miRNAs can regulate gene expression by two different 
post-transcriptional mechanisms: blocking the translation or inducing the mRNA degradation. 
Initially, the data supported the translational control as the prevailing mechanism of miRNA 
regulation. However, recent evidence underlines the mRNA degradation as an important 
mechanism of control as well. In order to simplify the definition of the targets, we have developed 
tools to define the transcripts that are reduced by miRNAs. To identify the possible targets a 
genomic approach was used. We started by establish the mRNA expression profile of the same 
samples that were previously analyzed by miRNA micro-array. This approach identified 1462 genes 
that were differentially expressed between atrophic and control conditions. We found a significant 
enrichment of the proteasome and of the ribosome pathway among the up-regulated genes. 
Furthermore, the insulin pathway was down regulated in the atrophic samples. These, confirmed the 
results previously obtained by others (Bodine et al., 2001a; Lecker et al., 2004).  
Crossing the list of the up- or down-regulates mRNAs in each atrophic condition, with the 
list of the predicted targets of the altered miRNAs and looking for the inversely correlation between 
miRNA and mRNA we significantly reduced the list of predicted targets. Since we are focusing on 
miRNA-206 and miRNA-21, we found 322 and 121 possible targets, respectively. Considering the 
fact that target mRNA can be regulated simultaneously by more than one miRNA, and that both of 
these miRNAs are up-regulated during denervation, it was decided to focus mainly on targets that 
were commonly regulated by miRNA-206 and miRNA-21. Therefore, the number of potential 
target was reduced to 4: PolK, YY1, eIF4E3 and PDCD10. 
In C2C12 myoblasts it was shown that DNA polymerase alpha1 (PolA1) is down- regulated 
by miRNA-206 (Kim et al., 2006). The author proposed that down-regulation was required for the 
exit from the cell cycle, and for the activation of a differentiation program. Although the role of 
DNA polymerases in adult skeletal muscle is not known, it is interesting to note that the list of the 
down-regulated predicted targets include three DNA polymerases (PolK, PolA1 and PolE4), being 
Polk the gene with the highest predictive scores. The reasons for this suppression is unknown, but 
our data has indicated that during denervation the 3’UTR of this genes is down-regulated, 
Chapter 6 – General Discussion and Conclusions 
 118 
suggesting the involvement of miRNAs in this regulation. However the two binding site for 
miRNA-206 were not sufficient to modulate the 3’UTR of this gene suggesting that another 
miRNA is responsible for the modulation of PolK. 
Another predicted target down-regulated during denervation is YY1. This is a transcription 
factor which has been already described to modulate different function in the skeletal muscle. In 
fact, it has been shown to block several myogenic processes (Cunningham et al., 2007; Galvagni et 
al., 1998; Gualberto et al., 1992). Importantly, in adult muscles YY1 is involved in mitochondrial 
biogenesis (Cunningham et al., 2007) and in dystrophin expression (Galvagni et al., 1998). 
Considering that during atrophy there are metabolic and structural adaptations, this gene becomes of 
interest for further study. According to our data, the 3’UTR of this gene is modulated during 
denervation. Furthermore, miRNA-21 was shown to directly modulate the 3’UTR of YY1, while 
miRNA-206 doesn’t have any effect. This data suggests that miRNA-21, by repressing YY1, might 
activate metabolic changes in adult muscle. Interestingly, YY1 might be also involved in the 
regulation of miRNA-206 and miRNA-21. In fact, it is known that YY1 binds to AP1, and repress 
the AP1-dependent transcription of miRNA-206 (Song and Wang, 2009). This is possibly a 
mechanism that may contribute for the up-regulation of miRNA-206 during denervation. On the 
other hand, YY1 repress the binding of SRF to some of muscle specific promoters (Gualberto et al., 
1992). Considering that the regulatory region of miRNA-21 has a functional SRF binding site 
(Zhang et al., 2011) it is possible that the induction of miRNA-21 leads to a reduction of YY1, 
liberating SRF from its repressive effect and inducing the expression of miRNA-21. 
During denervation, protein synthesis is altered, shifting the metabolic and structural 
properties of the fibers. Although requiring further confirmation, data from our laboratory, indicate 
that the rate of proteins synthesis might be decreased. In fact, Eukaryotic translation initiation factor 
4E-binding protein 1 (eIF4E-BP1 or simply 4EBP1), a repressor of protein synthesis, is an atrophy-
related gene (Lecker et al., 2004) that is up-regulated in atrophying muscles. Furthermore at the 
protein level it is highly up-regulated and hyper-phosphorylated during denervation suggesting a 
block of the pathways that activates proteins synthesis. 4EBP1 binds and repress eIF4E, the most 
critical initiation factor for the beginning of translation. Interestingly, in the list of the down-
regulated predicted target genes, an isoform of eIF4E, eIF4E3, is one of the most repressed genes 
possibly by miRNA-206 and miRNA-21. Although there are no studies on the role of this gene in 
skeletal muscle, we have found that its 3’UTR is suppressed by miRNA-206 and miRNA-21. It is 
therefore possible that these two miRNAs act together and synergistically to slow down the rate of 
protein synthesis during denervation.  
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Also PDCD10 fulfill the standard to be a target of both miRNA-206 and miRNA-21. 
Although the role in skeletal muscle is not known, it is involved in the cerebral cavernous 
malformation for its role in vascular morphogenesis (Bergametti et al., 2005). This gene is highly 
expressed in skeletal muscle and during denervation is strongly down-regulated. According to our 
data, this down-regulation results from a down-modulation of its 3’UTR that occurs under the 
control of both miRNA-206 and miRNA-21. The function of this gene and the reason for this down-
regulation during denervation requires further studies. 
To confirm that these genes were real targets two approaches were taken. The first approach 
analyzed the expression levels of these genes in C2C12 myoblasts after transfection with miRNAs. 
This would indicate whether there was a direct regulation of target genes by the miRNAs. While 
miRNA-206 expression significantly decreased the mRNA level of PDCD10, miRNA-21 decreased 
the transcripts of eIF4E3 and PDCD10. Surprisingly, mRNA level of YY1 was not affected but a 
significant reduction of the protein was found. The regulation of eIF4E3 at the protein level still 
requires further studies. These results confirm that YY1 is a target of miRNA-21 and that PDCD10 
is a target of both miRNA-206 and miRNA-21. To further confirm the miRNA-dependent 
regulation of eIF4E3, we mutagenize the miRNAs sites at 3’UTR. In fact, the mutagenesis of the 
miRNA-206 and miRNA-21 binding sites partially prevented the action of these miRNAs on the 
3’UTR. The same approach is now being taken for the 3’UTR of the YY1 gene, in order to further 
confirm the previous results. 
Altogether, these results indicate that the bioinformatic approach used to identify target 
genes of miRNAs was valid. Since the role of the majority of these target is not known in adult 
skeletal muscle or during the atrophic process, further studies are required to elucidate their 
function. 
 
One of the most interesting results from this thesis concerns the inhibition of both miRNAs 
in vivo. In fact, this inhibition leads to an hypertrophic phenotype and partially prevents the 
denervation-induced loss of CSA. In a period in which miRNAs are gaining strength as therapeutic 
agents these results are quite promising. Several studies demonstrated that miRNAs can be inhibited 
in vivo. Recently, it was shown that systemic delivery, by subcutaneous injection, of antisense 
oligonucleotides was able to block specific miRNAs in the heart. For example, the inhibition of 
miRNA-208a, was sufficient to prevent cardiac remodeling and to improve cardiac function and 
serviva (Montgomery et al., 2011). This is an example of the therapeutic potential of the miRNAs. 
Using a sponge vector to block miRNA 206, we were able to partially prevent muscle atrophy 
induced by denervation, suggesting that it may be a useful treatment for spare muscle mass during 
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catabolic conditions or aging. Considering the tissue specificity of miRNA-206 no major side 
effects are expected. However a better understanding of the targets and of the molecular 
mechanisms that miRNAs are regulating is necessary. 
 
In conclusion, the results presented in this thesis show that miRNA expression is 
deregulated during atrophic conditions. Focusing on muscle denervation we show that two 
miRNAs, miRNA-206 and miRNA-21 are strongly up-regulated. Although the exact mechanisms 
implicated were not fully elucidated we showed that FoxO3 and NF-kB, the two most important 
transcriptional regulators of muscle wasting, are sufficient to up-regulate these two miRNAs. The 
role of these miRNAs was also addressed in vivo. We showed, for the first time, that these miRNAs 
regulate muscle mass. Most importantly we have shown that inhibition of these two miRNAs 
induced muscle growth and prevent atrophy-induced muscle loss. Some targets of these miRNAs 
were also identified. We found that miRNA-206 regulates the expression of eIF4E3, an important 
regulator of muscle growth, while miRNA-21 could regulate the expression of eIF4E3 and YY1, an 
important regulator of mitochondria biogenesis. Altogether, these results indicate that increasing the 
knowledge on miRNA biology, specifically in the skeletal muscle, may help the understanding the 
molecular mechanisms that govern the atrophic conditions and may contribute for the developing of 
miRNA-based therapies. 
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The work present in this thesis clearly demonstrated that each atrophic condition has a 
specific miRNA expression signature. As usual, from micro-arrays a huge number of information 
was retrieved. For practical reasons, and also because they were appealing, only two miRNAs were 
studied. Other studies are required to elucidate the role that the other deregulated miRNAs play 
during each specific atrophic condition. This will bring a better understanding on the complex 
regulatory role of miRNAs. 
 As it was shown in the results of this thesis, the role of the target genes is still unclear. 
Several approaches are currently being taken in order to address this point. We need to address 
whether the over-expression of this two genes induces a phenotype in the skeletal muscle. It was 
also shown that miRNA-21 requires an atrophic stimulus in order to develop an atrophic phenotype. 
Since, YY1 and eIF4E3 are targets of miRNA-21, and since they are down-regulated during 
denervation-induced atrophy, it is possible that their inhibition is a required event for the activation 
or commitment of an atrophic program. Therefore we are currently analyzing denervated muscles in 
which YY1 and eIF4E3 were over-expressed. The main question is whether these two proteins are 
capable of preventing muscle atrophy.  
As it was already discussed, miRNAs can target hundreds of mRNAs and therefore block 
their translation or induce the degradation of the mRNAs. In this thesis we have shown that 
degradation of the target mRNA is an important mechanism. For practical reasons only a limited 
number of targets were studied. However, a broader knowledge of the miRNA target is required. In 
order to identify the mRNAs that are targeted by the miRNA machinery, we are currently 
optimizing an immunoprecipitation technique that allows the immunoprecipitation of the mRNAs 
bound to the Ago2 protein, a key protein in the recognition miRNA/target mRNA. Briefly, Ago2 
Protein is immunoprecipitated under specific conditions allowing the maintenance of the biding 
mRNA/protein. In this way, all the mRNAs bound to Ago2 will then be purified and analyzed either 
by RT-PCR either by micro-array. By performing this experiment in innervated Vs denervated 
muscle, we will obtain a list of mRNAs regulated by the miRNA pathway during denervation. 
Crossing this list with the list of the possible targets of each deregulated miRNA, will allow the 
identification of hundreds of targets, and it will allow to understand which metabolic pathways are 
being post-transcriptionally regulated by miRNAs. 
It was demonstrated that over-expression of the two miRNAs under study, miRNA-206 and 
miRNA-21, induces hypertrophy and partially prevent denervation-induced atrophy. Therefore, it 
will be important to address the effect of systemic delivery of these miRNAs on the atrophic 
program. A condition that deserves considerably study is the atrophy induced by ageing. This 
approach may contribute for the development of specific therapies in the following years.
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